doc_id sent_index relation_id relation trigger trigger_offset arg_num arg_base_np arg_protein arg_domain arg_site arg_sugar PSource SiteSource NProtein NID SiteName sent_text 26295743 1 4 gly Arabinogalactan 83:97 arg1 heavily glycosylated proteoglycans Arabinogalactan heavily glycosylated proteoglycans Cterm Arabinogalactan Arabinogalactan proteins are heavily glycosylated proteoglycans in plants. 25416425 4 14 gly carrying 538:545 arg1 Kv1.4 proteins AND N-glycans Kv1.4 proteins N-glycans PUBTATOR Kv1.4 proteins 3739 Kv1.4 proteins carrying N-glycans with different compositions were generated by adding glycosidase inhibitors or using N-glycosylation-deficient mutant cell lines. 25759508 0 41 gly O-Glycosylation 13:27 arg1 Human Immunoglobulin G3 Human Immunoglobulin G3 PUBTATOR Human Immunoglobulin G3 3502 Hinge-Region O-Glycosylation of Human Immunoglobulin G3 (IgG3). 25759508 0 41 gly O-Glycosylation 13:27 arg1 IgG3 IgG3 PUBTATOR IgG3 P01860 Hinge-Region O-Glycosylation of Human Immunoglobulin G3 (IgG3). 28446609 8 57 gly glycosylated 1706:1717 arg1 fully glycosylated Env fully glycosylated Env PUBTATOR Env 30816 Glycan-deficient Env derivatives can be used as priming immunogens because they should engage and activate a more divergent set of germlines than fully glycosylated Env. 25496419 0 6 gly 3-deoxy-D-manno-oct-2-ulosonic 73:102 arg1 Kdo oct-2 Kdo OGER oct-2 P09086 First and stereoselective synthesis of an α-(2→5)-linked disaccharide of 3-deoxy-D-manno-oct-2-ulosonic acid (Kdo). 25142936 5 43 gly s-eNPP6 825:831 arg1 the site-specific glycan structures eNPP6 the site-specific glycan structures PUBTATOR eNPP6 537431 Here we completed characterization of the site-specific glycan structures of bovine brain s-eNPP6, and determined the endo H-sensitivity glycan profiles of s-eNPP6 from bovine liver and kidney. 25142936 5 45 gly s-eNPP6 891:897 arg1 the endo H-sensitivity glycan profiles eNPP6 the endo H-sensitivity glycan profiles PUBTATOR eNPP6 537431 Here we completed characterization of the site-specific glycan structures of bovine brain s-eNPP6, and determined the endo H-sensitivity glycan profiles of s-eNPP6 from bovine liver and kidney. 24308486 2 47 gly glycosylation 364:376 arg1 IgE IgE PUBTATOR IgE P01854 Here, we present site-specific glycosylation analysis of IgE from three different sources: IgE from the serum of a hyperimmune donor, from the pooled serum of multiple nondiseased donors, and from the pooled serum of 2 patients with IgE myeloma. 25092234 3 78 gly glycosylation 462:474 arg1 hFXI hFXI PUBTATOR hFXI 2160 This study reports the first in-depth glycosylation analysis of hFXI based on advanced MS approaches. 25251695 5 53 gly glycoprotein 861:872 arg1 an ER-retained glycoprotein ER-retained glycoprotein three N-glycans Cterm ER-retained glycoprotein 6400 SUBEX-C57Y is an ER-retained glycoprotein with three N-glycans that is stabilized in the presence of kifunensine, a potent inhibitor of α-mannosidases. 25658763 3 86 gly glycosylation 570:582 arg1 EMMPRIN EMMPRIN PUBTATOR EMMPRIN 682 METHODS The glycosylation patterns of EMMPRIN expressed by monocytes/macrophages (THP-1 cells) in response to different extracellular stimuli were observed, and the structures of different glycosylation forms were identified. 25209049 3 5 gly glycosylated 496:507 arg1 THP THP PUBTATOR THP 7369 This may make glycan analysis of uEVs difficult since THP is heavily glycosylated. 26747427 2 27 gly has 295:297 arg1 Human AT AND biantennary complex-type oligosaccharides Human AT biantennary complex-type oligosaccharides PUBTATOR Human AT 462 Human AT has biantennary complex-type oligosaccharides with the unique feature of lacking a core fucose, which affects its biological activities by changing its heparin-binding affinity. 28749929 5 65 gly glycoforms 1056:1065 arg1 native IgG native IgG Cterm IgG Compared with in vivo glycoengineering technologies and the glycosyltransferase-enabled in vitro engineering method, the current approach is robust and features quantitative yield, homogeneous glycoforms of produced antibodies and ADCs, compatibility with diverse natural and non-natural glycan structures, convenient exploitation of native IgG as the starting material, and a well-defined conjugation site for antibody modifications. 29279989 6 66 gly deglycosylated 861:874 arg1 IgA IgA PUBTATOR IgA 973 Human immunoglobulin A (IgA) and bovine submaxillary mucin (BSM) were then deglycosylated through hydrazinolysis and the removed glycans were tagged under optimum conditions. 29279989 6 66 gly deglycosylated 861:874 arg1 Human immunoglobulin A Human immunoglobulin A PUBTATOR Human immunoglobulin A 973 Human immunoglobulin A (IgA) and bovine submaxillary mucin (BSM) were then deglycosylated through hydrazinolysis and the removed glycans were tagged under optimum conditions. 29279989 6 66 gly deglycosylated 861:874 arg1 BSM BSM PUBTATOR BSM 100140959 Human immunoglobulin A (IgA) and bovine submaxillary mucin (BSM) were then deglycosylated through hydrazinolysis and the removed glycans were tagged under optimum conditions. 25164811 10 50 gly HjCel3A 1325:1331 arg1 a single N-acetylglucosamine HjCel3A a single N-acetylglucosamine Cterm HjCel3A In H. jecorina-produced HjCel3A, a single N-acetylglucosamine is present at both sites, whereas in Pp-HjCel3A, the P. pastoris-produced HjCel3A enzyme, the glycan chains consist of 8 or 4 saccharides. 25164811 10 80 gly present 1366:1372 arg1 H. jecorina-produced HjCel3A AND a single N-acetylglucosamine HjCel3A a single N-acetylglucosamine Cterm HjCel3A In H. jecorina-produced HjCel3A, a single N-acetylglucosamine is present at both sites, whereas in Pp-HjCel3A, the P. pastoris-produced HjCel3A enzyme, the glycan chains consist of 8 or 4 saccharides. 24910992 9 27 gly non-glycosylated 1272:1287 arg1 a non-glycosylated SHH variant a non-glycosylated SHH variant PUBTATOR SHH variant 6469 Robust interaction of both EDEM2 and OS-9 with a non-glycosylated SHH variant indicates that the misfolded polypeptide backbone, rather than a glycan signature, functions as the predominant signal for recognition for ERAD. 25004930 3 9 gly glycosylation 512:524 arg1 polyclonal IgG polyclonal IgG Cterm IgG Here we present a high-throughput workflow to analyze Fab and Fc glycosylation of polyclonal IgG purified from 5 μl of serum. 28630087 2 108 gly N-glycosylation 445:459 arg1 HNE HNE PUBTATOR HNE 1991 Herein, LC-MS/MS-based glycan, glycopeptide and glycoprotein profiling were utilized to first determine the heterogeneous N-glycosylation of HNE purified from neutrophil lysates and then from isolated neutrophil granules of healthy individuals. 25824821 7 38 part_of N394 938:941 arg1 human IgE IgE N394 PUBTATOR SpecificSite IgE P01854 N394 The obligatory glycan was mapped to a single N-linked oligomannose structure in the constant domain 3 (Cε3) of IgE, at asparagine-394 (N394) in human IgE and N384 in mouse. 26538210 6 40 gly fut-1 1065:1069 arg1 N-glycans fut-1;fut-8 N-glycans PUBTATOR fut-1;fut-8 174400 In contrast, maximally two fucoses were found on N-glycans of the fut-1;fut-8 and fut-6;fut-8 strains. 25458834 1 35 gly O-glycoprotein 149:162 arg1 Podoplanin Podoplanin PUBTATOR Podoplanin 10630 Podoplanin is a transmembrane O-glycoprotein that binds to C-type lectin-like receptor 2 (CLEC-2). 28887379 11 29 gly glycosylation 1751:1763 arg1 HCD CID, HCD OGER CID, HCD Q9NR71 GlycoPAT is used to catalogue site-specific glycosylation on simple glycoproteins, standard protein mixtures and human plasma cryoprecipitate samples in three common MS/MS fragmentation modes: CID, HCD and ETD. 28887379 11 108 gly glycoproteins 1775:1787 arg1 CID CID, HCD OGER CID, HCD Q9NR71 GlycoPAT is used to catalogue site-specific glycosylation on simple glycoproteins, standard protein mixtures and human plasma cryoprecipitate samples in three common MS/MS fragmentation modes: CID, HCD and ETD. 28336547 0 24 gly Glycans 0:6 arg1 the intestinal peptide transporter PEPT1 PEPT1 Glycans PUBTATOR PEPT1 56643 Glycans in the intestinal peptide transporter PEPT1 contribute to function and protect from proteolysis. 25551295 0 43 gly G1 165:166 arg1 [(13)C,(15)N]-N-acetylglucosamine labeling immunoglobulin G1 [(13)C,(15)N]-N-acetylglucosamine labeling Cterm immunoglobulin G1 Intramolecular N-glycan/polypeptide interactions observed at multiple N-glycan remodeling steps through [(13)C,(15)N]-N-acetylglucosamine labeling of immunoglobulin G1. 25551295 0 43 gly G1 165:166 arg1 15 immunoglobulin G1 15 Cterm immunoglobulin G1 Intramolecular N-glycan/polypeptide interactions observed at multiple N-glycan remodeling steps through [(13)C,(15)N]-N-acetylglucosamine labeling of immunoglobulin G1. 26840264 10 29 gly glycosylation 1694:1706 arg1 IgGs IgGs Cterm IgGs 5) Although the glycosylation of IgGs was not correlated with the level of the two plasmatic glycosyltransferases, it showed progressive age-associated changes consistent with a shift toward a pro-inflammatory glycotype. 25305020 3 72 gly glycosylated 660:671 arg1 calcium-sensing receptor calcium-sensing receptor PUBTATOR calcium-sensing receptor 846 In the present study, we purified the glycosylated extracellular domain of calcium-sensing receptor (CaSR) (ECD) (residues 20-612), containing either complex or high mannose N-glycan structures depending on the host cell line employed for recombinant expression. 29274340 3 27 gly glycosylation 708:720 arg1 rhGAA rhGAA OGER rhGAA Q6P7A9 This study investigated M6P glycosylation on rhGAA using liquid chromatography (LC)-electrospray ionization (ESI)-high-energy collisional dissociation (HCD) tandem mass spectrometry (MS/MS). 26956389 10 32 gly released 1480:1487 arg2 gp120 AND N-glycans gp120 N-glycans PUBTATOR gp120 3700 Examples of isomer separations are shown for N-glycans released from the well-characterized glycoproteins chicken ovalbumin, porcine thyroglobulin and gp120 from the human immunodeficiency virus. 26956389 10 32 gly released 1480:1487 arg2 chicken ovalbumin AND N-glycans chicken ovalbumin N-glycans PUBTATOR ovalbumin 396058 Examples of isomer separations are shown for N-glycans released from the well-characterized glycoproteins chicken ovalbumin, porcine thyroglobulin and gp120 from the human immunodeficiency virus. 26956389 10 32 gly released 1480:1487 arg2 porcine thyroglobulin AND N-glycans porcine thyroglobulin N-glycans PUBTATOR thyroglobulin P01266 Examples of isomer separations are shown for N-glycans released from the well-characterized glycoproteins chicken ovalbumin, porcine thyroglobulin and gp120 from the human immunodeficiency virus. 26956389 10 42 gly glycoproteins 1517:1529 arg1 gp120 gp120 PUBTATOR gp120 3700 Examples of isomer separations are shown for N-glycans released from the well-characterized glycoproteins chicken ovalbumin, porcine thyroglobulin and gp120 from the human immunodeficiency virus. 26956389 10 42 gly glycoproteins 1517:1529 arg1 chicken ovalbumin chicken ovalbumin PUBTATOR ovalbumin 396058 Examples of isomer separations are shown for N-glycans released from the well-characterized glycoproteins chicken ovalbumin, porcine thyroglobulin and gp120 from the human immunodeficiency virus. 26956389 10 42 gly glycoproteins 1517:1529 arg1 porcine thyroglobulin porcine thyroglobulin PUBTATOR thyroglobulin P01266 Examples of isomer separations are shown for N-glycans released from the well-characterized glycoproteins chicken ovalbumin, porcine thyroglobulin and gp120 from the human immunodeficiency virus. 28375048 6 70 gly IgGs 1413:1416 arg1 high mannose glycans IgGs high mannose glycans Cterm IgGs Arabinosylated recombinant IgGs and the accompanying reduction in high mannose glycans, facilitated a reduction in dendritic cell uptake, increased FcγRIIIa signaling, and significantly increased the levels of ADCC. 26567221 8 50 gly N-glycosylated 1336:1349 arg1 HMGB1 HMGB1 PUBTATOR HMGB1 3146 Taken together, we propose that HMGB1 is N-glycosylated, and that this is important for its DNA interaction and is a prerequisite for its nucleocytoplasmic transport and extracellular secretion. 29273683 11 13 gly glycosylation 1634:1646 arg1 the RCL the RCL OGER RCL O43598 Moreover, while glycosylation of N347 in the RCL limits these activities, N-glycans at other sites also appear to protect CBG from neutrophil elastase or chymotrypsin. 25361541 0 89 gly glycans 112:118 arg1 phosphacan/RPTPβ phosphacan glycans PUBTATOR phosphacan 19283 Major glycan structure underlying expression of the Lewis X epitope in the developing brain is O-mannose-linked glycans on phosphacan/RPTPβ. 28803068 4 24 gly present 780:786 arg2 HEK293-expressed hIFNγ AND N-linked glycans HEK293-expressed hIFNγ N-linked glycans PUBTATOR hIFNγ 3458 Hydrophilic Interaction Liquid Chromatography determined the structure of N-linked glycans present in HEK293-expressed hIFNγ (hIFNγ-HEK). 28803068 4 24 gly present 780:786 arg1 hIFNγ-HEK AND N-linked glycans hIFNγ-HEK N-linked glycans OGER HEK P29320 Hydrophilic Interaction Liquid Chromatography determined the structure of N-linked glycans present in HEK293-expressed hIFNγ (hIFNγ-HEK). 27793989 5 15 gly glycosylated 1458:1469 arg1 an N25Q mutant form an N25Q mutant form PUBTATOR form of PECAM-1 5175 To verify the contribution of the Asn-25 glycan to endothelial barrier function, we generated an N25Q mutant form of PECAM-1 that is not glycosylated at this position and examined its ability to contribute to vascular integrity in endothelial cell-like REN cells. 29042829 2 44 gly glycosylation 299:311 arg1 IgGs IgGs Cterm IgGs A standard approach to analyze glycosylation of IgGs involves the release of the N-glycans by the enzyme peptide N-glycosidase F, which cleaves the linkage between the asparagine residue and innermost N-acetylglucosamine (GlcNAc) of all N-glycans except those containing a 3-linked fucose attached to the reducing terminal GlcNAc residue. 24910992 10 41 gly nonglycosylated 1478:1492 arg1 SHH-N278A SHH-N278A PUBTATOR Notably, SHH 6469 Notably, SHH-N278A is the first nonglycosylated substrate to require EDEM2 for recognition and targeting for ERAD. 27333379 7 51 gly detected 1166:1173 arg1 IgA1 AND galactose-deficient and α2,6-sialylated O-glycans IgA1 galactose-deficient and α2,6-sialylated O-glycans PUBTATOR IgA1 P01876 Here, we expand our engineering repertoire by in planta generation of galactose-deficient and α2,6-sialylated O-glycans which are the prevailing glycans detected on IgA1 from patients with IgAN. 27333379 7 51 gly detected 1166:1173 arg2 IgA1 AND the prevailing glycans IgA1 the prevailing glycans PUBTATOR IgA1 P01876 Here, we expand our engineering repertoire by in planta generation of galactose-deficient and α2,6-sialylated O-glycans which are the prevailing glycans detected on IgA1 from patients with IgAN. 25016576 0 63 gly epitope 70:76 arg1 the HIV-1 envelope protein envelope protein epitope PUBTATOR envelope protein 100616444 Characterization of a monoclonal antibody to a novel glycan-dependent epitope in the V1/V2 domain of the HIV-1 envelope protein, gp120. 26240146 1 45 gly glycosylation 119:131 arg1 hCG hCG OGER hCG The glycosylation of human chorionic gonadotropin (hCG) plays an important role in reproductive tumors. 26240146 1 45 gly glycosylation 119:131 arg1 human chorionic gonadotropin human chorionic gonadotropin OGER chorionic gonadotropin The glycosylation of human chorionic gonadotropin (hCG) plays an important role in reproductive tumors. 29190644 1 0 gly glycoprotein 185:196 arg1 Human butyrylcholinesterase Human butyrylcholinesterase PUBTATOR Human butyrylcholinesterase 590 Human butyrylcholinesterase (BChE) is a glycoprotein capable of bioscavenging toxic compounds such as organophosphorus (OP) nerve agents. 25038691 5 47 gly present 838:844 arg2 bLF AND more diverse complex-type oligosaccharide structures bLF more diverse complex-type oligosaccharide structures Cterm bLF 280846 Overall, the data suggested that more diverse complex-type oligosaccharide structures were present on bLF during early lactation with an abundance of oligomannose type glycans in later lactation. 26972002 0 4 gly Glycoprotein 90:101 arg1 Individual Glycan Sites Envelope Glycoprotein Individual Glycan Sites Cterm Envelope Glycoprotein 155971 Composition and Antigenic Effects of Individual Glycan Sites of a Trimeric HIV-1 Envelope Glycoprotein. 25326312 7 58 gly galactokinase 1396:1408 arg1 Dietary galactose galactokinase Dietary galactose PUBTATOR galactokinase 2584 Dietary galactose and mutation of galactokinase (dGALK) or UDP-glucose dehydrogenase (sugarless) genes are identified, respectively, as critical environmental and genetic modifiers of behavioral and cellular defects. 28994289 0 29 gly L 97:97 arg1 Polysaccharides rapa L Polysaccharides OGER rapa L Q96PN7 Structural Characterization and Immunostimulatory Activity of Polysaccharides from Brassica rapa L. . 25629924 1 52 gly glycoprotein 125:136 arg1 Secretory immunoglobulin A Secretory immunoglobulin A Cterm Secretory immunoglobulin A Secretory immunoglobulin A (sIgA) is a major glycoprotein in milk and plays a key role in mediating immune protection of the gut mucosa. 28445724 4 51 gly CD4-supersite 643:655 arg1 titers 1: >1,000,000 against four-glycan-deleted autologous viruses with over 90% breadth against four-glycan-deleted heterologous strains exhibiting tier 2 neutralization character CD4 titers 1: >1,000,000 against four-glycan-deleted autologous viruses with over 90% breadth against four-glycan-deleted heterologous strains exhibiting tier 2 neutralization character PUBTATOR CD4 P01730 Immunizations yielded little neutralization against wild-type viruses but potent CD4-supersite neutralization (titers 1: >1,000,000 against four-glycan-deleted autologous viruses with over 90% breadth against four-glycan-deleted heterologous strains exhibiting tier 2 neutralization character). 27773703 15 2 gly megalin 1480:1486 arg1 Fut8-/- mouse kidneys RBP Fut8-/- mouse kidneys PUBTATOR RBP P02753 RBP-binding analysis of megalin lacking core fucose, in Fut8-/- mouse kidneys, had significantly decreased binding activity. 27773703 15 27 gly Fut8-/- 1512:1518 arg1 Fut8-/- mouse kidneys megalin Fut8-/- mouse kidneys PUBTATOR megalin P98164 RBP-binding analysis of megalin lacking core fucose, in Fut8-/- mouse kidneys, had significantly decreased binding activity. 24889612 3 7 gly sialylated 374:383 arg1 sTn sTn OGER sTn Q05639 Here we show that sialylated O-linked sugar T antigen (sTn) and its attached peptide region are both required for ligand recognition by PILRα. 27529638 4 6 gly GLP-1 525:529 arg1 O-linked N-glycan GLP-1 O-linked N-glycan OGER GLP-1 Q9H9B1 It was shown that the GLP-1 with O-linked N-glycan maintained an unchanged secondary structure after glycosylation, suggesting the potential application of this approach for peptide/protein drug production. 26869352 11 29 gly fucosylated 1824:1834 arg1 fucosylated haptoglobin fucosylated haptoglobin PUBTATOR haptoglobin 3240 These data suggest that the original tissue/cell producing fucosylated haptoglobin is different in each cancer type and linkage of fucosylation might be a clue of primary lesion, thereby enabling a differential diagnosis between gastroenterological cancers and non-gastroenterological cancers. 28672164 2 5 gly β-HlH 367:371 arg1 N-glycans HlH N-glycans OGER HlH For the first time, we investigated N-glycans of the structural subunit β-HlH of hemocyanin isolated from Helix lucorum. 25641685 7 31 gly glycoforms 1238:1247 arg1 apoC-III glycoforms apoC-III glycoforms PUBTATOR apoC-III 345 CONCLUSIONS AND CLINICAL RELEVANCE MALDI-TOF MS appears as a powerful technique for the analysis of apoC-III glycoforms for potential routine screening of COG- and ATP6V0A2-CDGs. 28880909 5 73 gly glycosylation 1050:1062 arg1 FSHR FSHR PUBTATOR FSHR 2492 The focus of this analysis was the site-specific glycosylation at asparagine (Asn) 52 of the α-subunit of FSH, owing to the pivotal role of Asn52 glycosylation in FSH receptor (FSHR) activation/signalling. 28880909 5 73 gly glycosylation 1050:1062 arg1 FSH receptor FSH receptor PUBTATOR FSH receptor 2492 The focus of this analysis was the site-specific glycosylation at asparagine (Asn) 52 of the α-subunit of FSH, owing to the pivotal role of Asn52 glycosylation in FSH receptor (FSHR) activation/signalling. 26507102 12 121 gly glycosylation 1845:1857 arg1 lubricin lubricin OGER lubricin Q92954 CONCLUSIONS This is the first demonstration of a change in the glycosylation profile of lubricin in synovial fluid from diseased equine joints compared with that from normal joints. 28482115 7 26 gly glycoprotein 1386:1397 arg1 FLA4 FLA4 PUBTATOR FLA4 823808 FLA4 functions as a soluble glycoprotein via its carboxy-proximal Fas1 domain and its normal cellular trafficking depends on N- and O-glycosylation. 27333379 2 57 gly carries 326:332 arg1 The IgA1 AND aberrantly glycosylated O-glycans The IgA1 aberrantly glycosylated O-glycans PUBTATOR IgA1 P01876 The IgA1 in these immune complexes carries aberrantly glycosylated O-glycans. 24511137 4 19 gly O-glycosylated 953:966 arg1 poorly O-glycosylated 6-19 IgA glycovariants poorly O-glycosylated 6-19 IgA glycovariants OGER IgA glycovariants P11912 Wild-type 6-19 IgA secreted by implanted cells induced significant formation of glomerular lesions, whereas poorly O-glycosylated 6-19 IgA glycovariants or a 6-19 IgA hinge mutant lacking O-linked glycans did not. 29062024 4 0 gly fucosylation 784:795 arg1 IgG1-Fc IgG1-Fc OGER IgG1 P01857 Our simulation highlights increased conformational fluctuation of the N-glycan at Asn162 of sFcγRIIIa upon fucosylation of IgG1-Fc, consistent with crystallographic data giving no interpretable electron density for this N-glycan, except for the innermost part. 29062024 4 6 gly IgG1-Fc 800:806 arg1 fucosylation IgG1 fucosylation OGER IgG1 P01857 Our simulation highlights increased conformational fluctuation of the N-glycan at Asn162 of sFcγRIIIa upon fucosylation of IgG1-Fc, consistent with crystallographic data giving no interpretable electron density for this N-glycan, except for the innermost part. 29062024 4 15 gly sFcγRIIIa 769:777 arg1 the N-glycan at Asn162 FcγRIIIa the N-glycan at Asn162 PUBTATOR FcγRIIIa 2214 Our simulation highlights increased conformational fluctuation of the N-glycan at Asn162 of sFcγRIIIa upon fucosylation of IgG1-Fc, consistent with crystallographic data giving no interpretable electron density for this N-glycan, except for the innermost part. 25658763 2 95 gly glycosylation 414:426 arg1 EMMPRIN EMMPRIN PUBTATOR EMMPRIN 682 We have hypothesized that high-level heterogeneousness of protein glycosylation of EMMPRIN may have functional relevance to its biological effects and affect the inflammatory activity of monocytes/macrophages. 25527317 5 69 gly BNC 910:912 arg1 the glycans Okapi BNC the glycans OGER Okapi BNC Q01954 Significant differences were found in the glycans of Giraffe and Okapi BNC compared with those from the bovine, with little or no expression of terminal αN-acetylgalactosamine bound by Dolichos biflorus and Vicia villosa agglutinins which instead bound to placental blood vessels. 28109443 1 63 gly O-glycoprotein 273:286 arg1 Human immunoglobulin A1 Human immunoglobulin A1 PUBTATOR Human immunoglobulin A1 3493 Human immunoglobulin A1 (IgA1), which carries four to six mucin-type O-glycans (O-glycans) on its hinge region (HR), is the most abundant O-glycoprotein in plasma or serum. 28109443 1 109 gly carries 173:179 arg1 Human immunoglobulin A1 AND O-glycans Human immunoglobulin A1 O-glycans PUBTATOR Human immunoglobulin A1 3493 Human immunoglobulin A1 (IgA1), which carries four to six mucin-type O-glycans (O-glycans) on its hinge region (HR), is the most abundant O-glycoprotein in plasma or serum. 28109443 1 109 gly carries 173:179 arg1 Human immunoglobulin A1 AND four to six mucin-type O-glycans Human immunoglobulin A1 four to six mucin-type O-glycans PUBTATOR Human immunoglobulin A1 3493 Human immunoglobulin A1 (IgA1), which carries four to six mucin-type O-glycans (O-glycans) on its hinge region (HR), is the most abundant O-glycoprotein in plasma or serum. 28109443 1 109 gly carries 173:179 arg1 IgA1 AND O-glycans IgA1 O-glycans PUBTATOR IgA1 P01876 Human immunoglobulin A1 (IgA1), which carries four to six mucin-type O-glycans (O-glycans) on its hinge region (HR), is the most abundant O-glycoprotein in plasma or serum. 28109443 1 109 gly carries 173:179 arg1 IgA1 AND four to six mucin-type O-glycans IgA1 four to six mucin-type O-glycans PUBTATOR IgA1 P01876 Human immunoglobulin A1 (IgA1), which carries four to six mucin-type O-glycans (O-glycans) on its hinge region (HR), is the most abundant O-glycoprotein in plasma or serum. 24644239 8 26 gly glycosylation 1155:1167 arg1 the chemokine (Ser-)CCL1 the chemokine (Ser-)CCL1 PUBTATOR CCL1 6346 To the best of our knowledge, these are the first investigations of the effect of glycosylation on the chemotactic activity of the chemokine (Ser-)CCL1 using homogeneous N-glycosylated protein molecules of defined covalent structure. 26908049 3 31 gly ART 553:555 arg1 the N-linked glycan ART the N-linked glycan PUBTATOR ART 9048 METHODS Modification of the N-linked glycan of ART was performed by incubation with various enzymes. 24970053 10 36 gly N-glycosylation 1449:1463 arg1 CD147 CD147 PUBTATOR CD147 682 In conclusion, we found that β3GnT8 regulated the level of N-glycans on CD147 and that N-glycosylation of CD147 has an important effect on MMP-2 expression. 26138399 4 75 gly glycoproteins 572:584 arg1 milk glycoproteins milk glycoproteins PUBTATOR milk glycoproteins 100532204 The broad specificity of EndoBI-1 suggests the enzyme may be useful for many applications, particularly for deglycosylating milk glycoproteins in dairy processing. 26301455 1 42 part_of has 195:197 arg1 Cellobiohydrolase I AND Asn388 Cellobiohydrolase I Asn45, Asn194, Asn388, and Asn430 Cterm AminoAcid Cellobiohydrolase I Asn45, Asn194, Asn388, and Asn430 Cellobiohydrolase I from Penicillium verruculosum (PvCel7A) has four potential N-glycosylation sites at its catalytic module: Asn45, Asn194, Asn388, and Asn430. 26301455 1 42 part_of has 195:197 arg1 Cellobiohydrolase I AND Asn430 Cellobiohydrolase I Asn45, Asn194, Asn388, and Asn430 Cterm AminoAcid Cellobiohydrolase I Asn45, Asn194, Asn388, and Asn430 Cellobiohydrolase I from Penicillium verruculosum (PvCel7A) has four potential N-glycosylation sites at its catalytic module: Asn45, Asn194, Asn388, and Asn430. 26301455 1 42 part_of has 195:197 arg1 Cellobiohydrolase I AND Asn45 Cellobiohydrolase I Asn45, Asn194, Asn388, and Asn430 Cterm AminoAcid Cellobiohydrolase I Asn45, Asn194, Asn388, and Asn430 Cellobiohydrolase I from Penicillium verruculosum (PvCel7A) has four potential N-glycosylation sites at its catalytic module: Asn45, Asn194, Asn388, and Asn430. 26301455 1 42 part_of has 195:197 arg1 Cellobiohydrolase I AND Asn430 Cellobiohydrolase I Asn45, Asn194, Asn388, and Asn430 Cterm AminoAcid Cellobiohydrolase I Asn45, Asn194, Asn388, and Asn430 Cellobiohydrolase I from Penicillium verruculosum (PvCel7A) has four potential N-glycosylation sites at its catalytic module: Asn45, Asn194, Asn388, and Asn430. 26301455 1 42 part_of has 195:197 arg1 Cellobiohydrolase I AND Asn45 Cellobiohydrolase I Asn45, Asn194, Asn388, and Asn430 Cterm AminoAcid Cellobiohydrolase I Asn45, Asn194, Asn388, and Asn430 Cellobiohydrolase I from Penicillium verruculosum (PvCel7A) has four potential N-glycosylation sites at its catalytic module: Asn45, Asn194, Asn388, and Asn430. 26301455 1 42 part_of has 195:197 arg1 Cellobiohydrolase I AND Asn45 Cellobiohydrolase I Asn45, Asn194, Asn388, and Asn430 Cterm AminoAcid Cellobiohydrolase I Asn45, Asn194, Asn388, and Asn430 Cellobiohydrolase I from Penicillium verruculosum (PvCel7A) has four potential N-glycosylation sites at its catalytic module: Asn45, Asn194, Asn388, and Asn430. 24352591 4 11 gly epitope 905:911 arg1 phosphacan phosphacan epitope PUBTATOR phosphacan 19283 The O-linked HNK-1 epitope on phosphacan almost disappeared due to the knockout of protein O-mannose β1,2-N-acetylglucosaminyltransferase 1, an N-acetylglucosaminyltransferase essential for O-mannose-linked glycan synthesis, indicating that the reducing terminal of the O-linked HNK-1 is mannose. 28170415 5 62 gly N-glycans 520:528 arg1 bLF bLF N-glycans Cterm bLF 280846 This study investigated and compared N-glycans in recombinant human lactoferrin (rhLF), bovine lactoferrin (bLF) and human lactoferrin by Nano-LC-Chip-Q-TOF Mass Spectrometry. 28170415 5 62 gly N-glycans 520:528 arg1 rhLF rhLF N-glycans OGER rhLF P02788 This study investigated and compared N-glycans in recombinant human lactoferrin (rhLF), bovine lactoferrin (bLF) and human lactoferrin by Nano-LC-Chip-Q-TOF Mass Spectrometry. 28170415 5 62 gly N-glycans 520:528 arg1 human lactoferrin lactoferrin N-glycans PUBTATOR lactoferrin This study investigated and compared N-glycans in recombinant human lactoferrin (rhLF), bovine lactoferrin (bLF) and human lactoferrin by Nano-LC-Chip-Q-TOF Mass Spectrometry. 28170415 5 62 gly N-glycans 520:528 arg1 recombinant human lactoferrin lactoferrin N-glycans PUBTATOR lactoferrin This study investigated and compared N-glycans in recombinant human lactoferrin (rhLF), bovine lactoferrin (bLF) and human lactoferrin by Nano-LC-Chip-Q-TOF Mass Spectrometry. 28170415 5 62 gly N-glycans 520:528 arg1 recombinant human lactoferrin lactoferrin N-glycans PUBTATOR lactoferrin 100861194 This study investigated and compared N-glycans in recombinant human lactoferrin (rhLF), bovine lactoferrin (bLF) and human lactoferrin by Nano-LC-Chip-Q-TOF Mass Spectrometry. 26563299 3 32 gly glycosylation 531:543 arg1 hetIL-15 hetIL-15 OGER IL-15 P40933 Favorable pharmacokinetic properties are associated with the heterodimeric formation and the glycosylation of hetIL-15, which, however, remains largely uncharacterized. 24806200 0 62 gly glycoprotein 96:107 arg1 glycoprotein hormones glycoprotein hormones PUBTATOR chorionic gonadotropin (hCG) glycoprotein 93659 Chemical synthesis of the β-subunit of human luteinizing (hLH) and chorionic gonadotropin (hCG) glycoprotein hormones. 26869352 3 80 gly fucosylated 524:534 arg1 fucosylated haptoglobin fucosylated haptoglobin PUBTATOR haptoglobin 3240 However, an increase in fucosylated haptoglobin has been reported in various types of cancer. 24798328 7 23 gly man 1159:1161 arg1 LDLR LDLR man PUBTATOR LDLR 373644 The glycosites in linker regions of LDLR class A repeats are conserved in LDLR from man to Xenopus and found in other homologous receptors. 26328495 5 0 gly modified 758:765 arg1 POMGNT1 AND a sialylated core-1 O-glycan POMGNT1 a sialylated core-1 O-glycan PUBTATOR POMGNT1 55624 These results suggest that POMGNT1 is modified by a sialylated core-1 O-glycan. 24352591 3 44 gly phosphacan 874:883 arg1 the terminal HNK-1 epitope phosphacan the terminal HNK-1 epitope PUBTATOR phosphacan 19283 Here, using mass spectrometric analyses, we identified the major carrier glycoprotein of the O-linked HNK-1 as phosphacan in developing mouse brains and determined the major O-glycan structures having the terminal HNK-1 epitope from partially purified phosphacan. 24130173 6 83 gly non-sialylated 1107:1120 arg1 non-sialylated plant-derived rBChE non-sialylated plant-derived rBChE Cterm rBChE P06276 Sialylated and non-sialylated plant-derived rBChE exhibited functional in vitro activity comparable to that of its commercially available equine-derived counterpart. 26956484 8 68 gly Orai1 1205:1209 arg1 the N-glycan Orai1 the N-glycan PUBTATOR Orai1 84876 In human mast cells, inhibition of sialyl sulfation altered the N-glycan of Orai1 (and other proteins) and increased SOCE. 26488311 2 71 gly glycosylation 194:206 arg1 clusterin clusterin OGER clusterin P10909 The glycosylation of clusterin from human plasma was comprehensively analyzed and characterized using mass spectrometry (MS)-based glycoproteomics analysis. 26208004 8 51 gly DC-SIGN 1373:1379 arg1 the carbohydrate recognition domain DC-SIGN the carbohydrate recognition domain OGER DC-SIGN Q9NNX6 Furthermore, a complex between a glycan on DENV and the carbohydrate recognition domain (CRD) of DC-SIGN was mimicked with computational docking experiments. 26208004 8 84 gly glycan 1309:1314 arg1 DC-SIGN DC-SIGN glycan OGER DC-SIGN Q9NNX6 Furthermore, a complex between a glycan on DENV and the carbohydrate recognition domain (CRD) of DC-SIGN was mimicked with computational docking experiments. 28581490 12 69 gly changes 1802:1808 arg1 MUC1 MUC1 changes PUBTATOR MUC1 4582 These glycan changes on MUC1 were detected with high sensitivity owing to the cluster effect of immobilized lectins on a tandem repeat peptide antigen covered with highly dense glycosylation such as mucin. 27873468 3 37 gly mucin-1 605:611 arg1 a peptide repeat sequence motif mucin-1 a peptide repeat sequence motif PUBTATOR mucin-1 4582 Using a peptide repeat sequence motif of the glycoprotein mucin-1, the principle of introducing synthetic (glyco)peptides with distinct variations in these three parameters to an array-based screening of tissue lectins is illustrated. 28109443 2 95 gly carries 480:486 arg1 the IgA1 AND undergalactosylated or truncated O-glycans the IgA1 undergalactosylated or truncated O-glycans PUBTATOR IgA1 P01876 While normal O-glycans from hematopoietic-originated cells are core 1-based complex structures, many reports showed that the IgA1 from patients with IgA nephropathy (IgAN) carries undergalactosylated or truncated O-glycans such as the Tn antigen and its sialylated version the SialylTn (STn) antigen on the HR. 27550041 0 44 gly glycosylation 14:26 arg1 donkey milk lactoferrin donkey milk lactoferrin PUBTATOR lactoferrin 280846 Site-specific glycosylation of donkey milk lactoferrin investigated by high-resolution mass spectrometry. 28672164 7 55 gly chains 1016:1021 arg1 β-HlH HlH chains OGER HlH Several carbohydrate chains in β-HlH are core-fucosylated without Xyl and also possess a high degree of methylation. 28714086 12 42 gly carry 2193:2197 arg1 native KARs AND the complex capping oligosaccharide human natural killer-1 native KARs the complex capping oligosaccharide human natural killer-1 OGER KARs Q15046 We also report that native KARs carry the complex capping oligosaccharide human natural killer-1. 27984785 3 18 gly glycoprotein 279:290 arg1 GP1,2 GP1,2 PUBTATOR GP1 9567 The ebolavirus envelope glycoprotein (GP1,2) is heavily glycosylated, but the precise glycosylation patterns of ebolaviruses are largely unknown. 27984785 3 18 gly glycoprotein 279:290 arg1 The ebolavirus envelope glycoprotein The ebolavirus envelope glycoprotein PUBTATOR envelope glycoprotein 100616444 The ebolavirus envelope glycoprotein (GP1,2) is heavily glycosylated, but the precise glycosylation patterns of ebolaviruses are largely unknown. 27984785 3 52 gly glycosylated 311:322 arg1 GP1,2 GP1,2 PUBTATOR GP1 9567 The ebolavirus envelope glycoprotein (GP1,2) is heavily glycosylated, but the precise glycosylation patterns of ebolaviruses are largely unknown. 27984785 3 52 gly glycosylated 311:322 arg1 The ebolavirus envelope glycoprotein The ebolavirus envelope glycoprotein PUBTATOR envelope glycoprotein 100616444 The ebolavirus envelope glycoprotein (GP1,2) is heavily glycosylated, but the precise glycosylation patterns of ebolaviruses are largely unknown. 27114034 2 40 gly glycosylated 379:390 arg1 fully glycosylated Env trimers fully glycosylated Env trimers PUBTATOR Env trimers 100616444 To understand how antibodies can overcome the barriers imposed by the glycan shield, we crystallized fully glycosylated Env trimers from clades A, B, and G, visualizing the shield at 3.4-3.7 Å resolution. 27649061 8 60 gly glycoforms 1436:1445 arg1 IgG glycoforms IgG glycoforms Cterm IgG The SWATH data independent quantification of IgG glycoforms in pooled plasma samples of patients with liver cirrhosis detects reliably the expected changes in the quantity of major glycoforms compared to healthy controls. 26105115 3 10 gly density 372:378 arg1 the gp120 subunit gp120 subunit density PUBTATOR gp120 subunit 3700 The unusually high glycan density on the gp120 subunit limits processing during biosynthesis, leaving a region of under-processed oligomannose-type structures, which is a primary target of these bnAbs. 26383616 4 19 gly released 791:798 arg1 human IgG AND N-glycans human IgG N-glycans Cterm IgG The database comprises CE GUs and suggested structures of N-glycans released from human IgG. 25040827 1 1 gly N-glycan 154:161 arg1 the prothoracicotropic hormone prothoracicotropic hormone N-glycan PUBTATOR prothoracicotropic hormone 692767 The predominant structure of the N-glycan on the prothoracicotropic hormone (PTTH) isolated from 1.8 million adult heads of silkmoths was determined to be Manα1-6Manβ1-4GlcNAcβ1-4(Fucα1-6)GlcNAc-OH, which is identical to that of the baculovirus-expressed recombinant PTTH. 25040827 1 1 gly N-glycan 154:161 arg1 PTTH PTTH N-glycan PUBTATOR PTTH 692767 The predominant structure of the N-glycan on the prothoracicotropic hormone (PTTH) isolated from 1.8 million adult heads of silkmoths was determined to be Manα1-6Manβ1-4GlcNAcβ1-4(Fucα1-6)GlcNAc-OH, which is identical to that of the baculovirus-expressed recombinant PTTH. 25040827 1 24 gly hormone 189:195 arg1 Manα1-6Manβ1-4GlcNAcβ1-4(Fucα1-6)GlcNAc-OH prothoracicotropic hormone Manα1-6Manβ1-4GlcNAcβ1-4(Fucα1-6)GlcNAc-OH PUBTATOR prothoracicotropic hormone 692767 The predominant structure of the N-glycan on the prothoracicotropic hormone (PTTH) isolated from 1.8 million adult heads of silkmoths was determined to be Manα1-6Manβ1-4GlcNAcβ1-4(Fucα1-6)GlcNAc-OH, which is identical to that of the baculovirus-expressed recombinant PTTH. 26154505 7 79 gly rEPO 1343:1346 arg1 sialic acid content rEPO sialic acid content PUBTATOR rEPO 24335 Furthermore, sialic acid content of rEPO from these engineered cells was increased ∼45% higher with tetra-sialylation accounting for ∼10% of total sugar chains compared to ∼3% for the wild-type parental CHO-K1. 25369125 3 20 gly Galectin-3 360:369 arg1 its carbohydrate binding properties structure of Galectin-3 its carbohydrate binding properties PUBTATOR structure of Galectin-3 3958 There are still uncertainties about the relationship between the quaternary structure of Galectin-3 and its carbohydrate binding properties. 27732771 9 77 gly glycoforms 1153:1162 arg1 different plasma-derived VWF (pd-VWF) glycoforms VWF PUBTATOR VWF 22371 Methods By use of a series of exoglycosidases, different plasma-derived VWF (pd-VWF) glycoforms were generated. 28958711 9 19 gly N- 1437:1438 arg1 SAs SAs N- OGER SAs Q12999 Collectively, our results identified novel N-glycans enriched in SAs on the rhiBSP and demonstrated that SAs at both N- and O-glycans are important for BSP regulation of osteoblast differentiation and mineralization in vitro. 28958711 9 26 gly O-glycans 1444:1452 arg1 SAs SAs O-glycans OGER SAs Q12999 Collectively, our results identified novel N-glycans enriched in SAs on the rhiBSP and demonstrated that SAs at both N- and O-glycans are important for BSP regulation of osteoblast differentiation and mineralization in vitro. 26482295 7 60 gly glycosylate 1332:1342 arg1 human immunoglobulin G human immunoglobulin G Cterm human immunoglobulin G One notable example is D. gigas PglB, which was the only bacterial OST to glycosylate the Fc domain of human immunoglobulin G at its native 'QYNST' sequon. 28052259 1 14 gly glycoprotein 186:197 arg1 LDL-receptor-related protein 6 LDL-receptor-related protein 6 PUBTATOR LDL-receptor-related protein 6 4040 LDL-receptor-related protein 6 (LRP6) is a single-pass membrane glycoprotein with a large modular ectodomain and forms a higher order signaling platform upon binding Wnt ligands on the cell surface. 26110648 1 28 gly N-glycosylation 111:125 arg1 HIV Clade B gp120 HIV Clade B gp120 PUBTATOR gp120 3700 The co-evolution of the potential N-glycosylation sites of HIV Clade B gp120 was mapped onto the coevolution network of the protein structure using mean field direct coupling analysis (mfDCA). 26372017 0 33 gly transglycosylation 10:27 arg1 ginsenoside Rg1 ginsenoside Rg1 OGER Rg1 Q16821 Enzymatic transglycosylation of ginsenoside Rg1 by rice seed α-glucosidase. 28400175 13 39 gly other 1724:1728 arg1 other targeted N-glycans IgE other targeted N-glycans OGER IgE P01854 With the ability to glyco-engineer recombinant IgE, we provide an important step towards the generation of IgE with other targeted N-glycans. 28400175 13 93 gly targeted 1730:1737 arg1 other targeted N-glycans IgE other targeted N-glycans OGER IgE P01854 With the ability to glyco-engineer recombinant IgE, we provide an important step towards the generation of IgE with other targeted N-glycans. 27439567 2 41 gly glycoprotein 272:283 arg1 A1AT A1AT Cterm A1AT P01009 This procedure is applied to the glycoprotein alpha-1-antitrypsin (A1AT), which contains both core- and antennary-fucosylated glycosites. 25094044 0 41 gly ER-resident 50:60 arg1 uridine 5'-diphosphate-glucose ER-resident uridine 5'-diphosphate-glucose Cterm ER-resident Glycan structure and site of glycosylation in the ER-resident glycoprotein, uridine 5'-diphosphate-glucose: glycoprotein glucosyltransferases 1 from rat, porcine, bovine, and human. 24726881 3 24 gly alpha-1,6-mannosylglycoprotein 442:471 arg1 alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A PUBTATOR alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A 4249 Two structures are formed by Golgi beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase (EC = 2.4.1.144, GnT-III) and alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A (EC = 2.4.1.155, GnT-V) respectively. 24726881 3 40 gly beta-1,4-mannosyl-glycoprotein 342:371 arg1 Golgi beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase Golgi beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase PUBTATOR beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase 4248 Two structures are formed by Golgi beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase (EC = 2.4.1.144, GnT-III) and alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A (EC = 2.4.1.155, GnT-V) respectively. 26301455 0 39 gly glycosylation 9:21 arg1 Cel7A Cel7A Cterm Cel7A N-linked glycosylation of recombinant cellobiohydrolase I (Cel7A) from Penicillium verruculosum and its effect on the enzyme activity. 26657071 2 19 gly aglycosylated 373:385 arg1 authentically glycosylated and aglycosylated hCES1 authentically glycosylated and aglycosylated hCES1 PUBTATOR hCES1 1066 To analyse the role of the single N-linked glycan on the structure and activity of the enzyme, authentically glycosylated and aglycosylated hCES1, generated by mutating asparagine 79 to glutamine, were produced in human embryonic kidney cells. 26657071 2 26 gly glycosylated 356:367 arg1 authentically glycosylated and aglycosylated hCES1 authentically glycosylated and aglycosylated hCES1 PUBTATOR hCES1 1066 To analyse the role of the single N-linked glycan on the structure and activity of the enzyme, authentically glycosylated and aglycosylated hCES1, generated by mutating asparagine 79 to glutamine, were produced in human embryonic kidney cells. 24644239 3 10 gly glycosylation 489:501 arg1 CCL1 CCL1 PUBTATOR AminoAcid CCL1 6346 There are no systematic studies of the effect of glycosylation on the biological activities of either CCL1 or Ser-CCL1. 28104755 0 80 gly N-glycosylation 0:14 arg1 human sphingomyelin phosphodiesterase acid-like 3A (SMPDL3A) human sphingomyelin phosphodiesterase acid-like 3A (SMPDL3A) PUBTATOR sphingomyelin phosphodiesterase acid-like 3A 10924 N-glycosylation of human sphingomyelin phosphodiesterase acid-like 3A (SMPDL3A) is essential for stability, secretion and activity. 25361541 9 57 gly glycans 1642:1648 arg1 phosphacan/RPTPβ phosphacan glycans PUBTATOR phosphacan 5803 Since O-mannosylated glycans on phosphacan/RPTPβ could also present human natural killer-1, another glycan epitope specifically expressed in the nervous system, our results revealed the importance of O-mannosylated glycan chains in the presentation of functional glycan epitopes in the brain. 27604319 5 62 gly glycosylation 949:961 arg1 gp120 gp120 PUBTATOR gp120 Q14624 While most prior studies have focused on glycan analysis of recombinant forms of gp120, here we report the first systematic glycosylation site analysis of gp120 derived from virions produced by infected T lymphoid cells and show that a single site is exclusively substituted with complex glycans. 26563299 9 15 gly hexasaccharides 1452:1466 arg1 Thr81 Thr81 Thr81 AminoAcid Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160 IL-15 contained no O-glycans, whereas sIL-15Rα was heavily O-glycosylated with partially sialylated core 1 and 2-type mono- to hexasaccharides on Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160. 26563299 9 15 gly hexasaccharides 1452:1466 arg1 Ser158 Ser158 Ser158 AminoAcid Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160 IL-15 contained no O-glycans, whereas sIL-15Rα was heavily O-glycosylated with partially sialylated core 1 and 2-type mono- to hexasaccharides on Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160. 26563299 9 15 gly hexasaccharides 1452:1466 arg1 Ser160 Ser160 Ser160 AminoAcid Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160 IL-15 contained no O-glycans, whereas sIL-15Rα was heavily O-glycosylated with partially sialylated core 1 and 2-type mono- to hexasaccharides on Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160. 26563299 9 15 gly hexasaccharides 1452:1466 arg1 Thr86 Thr86 Thr86 AminoAcid Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160 IL-15 contained no O-glycans, whereas sIL-15Rα was heavily O-glycosylated with partially sialylated core 1 and 2-type mono- to hexasaccharides on Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160. 26563299 9 15 gly hexasaccharides 1452:1466 arg1 Thr156 Thr156 Thr156 AminoAcid Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160 IL-15 contained no O-glycans, whereas sIL-15Rα was heavily O-glycosylated with partially sialylated core 1 and 2-type mono- to hexasaccharides on Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160. 26563299 9 15 gly hexasaccharides 1452:1466 arg1 Thr2 Thr2 Thr2 AminoAcid Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160 IL-15 contained no O-glycans, whereas sIL-15Rα was heavily O-glycosylated with partially sialylated core 1 and 2-type mono- to hexasaccharides on Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160. 26563299 9 58 gly O-glycosylated 1384:1397 arg1 sIL-15Rα sIL-15Rα OGER sIL Q15468 IL-15 contained no O-glycans, whereas sIL-15Rα was heavily O-glycosylated with partially sialylated core 1 and 2-type mono- to hexasaccharides on Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160. 26563299 9 97 gly contained 1331:1339 arg1 IL-15 AND no O-glycans IL-15 no O-glycans PUBTATOR IL-15 P40933 IL-15 contained no O-glycans, whereas sIL-15Rα was heavily O-glycosylated with partially sialylated core 1 and 2-type mono- to hexasaccharides on Thr2, Thr81, Thr86, Thr156, Ser158, and Ser160. 24352591 8 6 gly HNK-1 1951:1955 arg1 phosphacan phosphacan HNK-1 PUBTATOR phosphacan 19283 The reactivity of the 6B4 mAb almost completely disappeared in GlcAT-P-deficient mice, and exogenously expressed phosphacan was selectively recognized by the 6B4 mAb when co-expressed with GlcAT-P, suggesting that the 6B4 mAb preferentially recognizes O-mannose-linked HNK-1 on phosphacan. 29048990 0 43 gly glycosylation 14:26 arg1 H1N1 H1N1 Cterm H1N1 Site-specific glycosylation profile of influenza A (H1N1) hemagglutinin through tandem mass spectrometry. 26784534 1 25 gly O-glycosylation 77:91 arg1 von Willebrand factor von Willebrand factor PUBTATOR von Willebrand factor 7450 BACKGROUND: O-glycosylation of von Willebrand factor (VWF) affects many of its functions; however, there is currently no information on the occupancy of the 10 putative O-glycosylation sites. 26784534 1 25 gly O-glycosylation 77:91 arg1 VWF VWF PUBTATOR VWF 7450 BACKGROUND: O-glycosylation of von Willebrand factor (VWF) affects many of its functions; however, there is currently no information on the occupancy of the 10 putative O-glycosylation sites. 24085030 10 57 gly glycoproteins 1476:1488 arg1 transferrin transferrin PUBTATOR transferrin 7018 Some of salivary glycoproteins, such as α-amylase, clusterin, haptoglobin, heavy and light chains of immunoglobulins, and transferrin, seem to be worthy of detailed glycosylation analysis in the detection of alcohol dependence. 24085030 10 57 gly glycoproteins 1476:1488 arg1 clusterin clusterin PUBTATOR clusterin 1191 Some of salivary glycoproteins, such as α-amylase, clusterin, haptoglobin, heavy and light chains of immunoglobulins, and transferrin, seem to be worthy of detailed glycosylation analysis in the detection of alcohol dependence. 24085030 10 57 gly glycoproteins 1476:1488 arg1 heavy and light chains heavy and light chains OGER chains 1191 Some of salivary glycoproteins, such as α-amylase, clusterin, haptoglobin, heavy and light chains of immunoglobulins, and transferrin, seem to be worthy of detailed glycosylation analysis in the detection of alcohol dependence. 24085030 10 57 gly glycoproteins 1476:1488 arg1 haptoglobin haptoglobin PUBTATOR haptoglobin 3240 Some of salivary glycoproteins, such as α-amylase, clusterin, haptoglobin, heavy and light chains of immunoglobulins, and transferrin, seem to be worthy of detailed glycosylation analysis in the detection of alcohol dependence. 27506355 12 66 gly N-glycosylation 1610:1624 arg1 recombinant human acetylcholinesterase recombinant human acetylcholinesterase PUBTATOR acetylcholinesterase 43 In addition, we further applied our method to reveal, for the first time, the site-specific N-glycosylation profile of recombinant human acetylcholinesterase expressed in HEK293 cells. 26231935 2 56 gly N-glycosylation 335:349 arg1 AChE AChE PUBTATOR AChE 43 Several lines of evidence demonstrated that N-glycosylation of AChE affected the enzymatic activity, as well as its biosynthesis. 25458834 8 59 gly residue 924:930 arg1 podoplanin podoplanin residue PUBTATOR podoplanin 10630 Carboxyl groups from the sialic acid residue on podoplanin and from the C terminus of the rhodocytin α subunit interact differently at this "second" binding site on CLEC-2. 28230186 4 27 gly glycosylation 479:491 arg1 IgM binding IgM binding PUBTATOR IgM P01871 In contrast, little is known about the effect of glycosylation on IgM binding to the human Fcμ receptor (hFCMR). 25799047 10 52 gly glycosylation 2057:2069 arg1 CelA itself CelA itself PUBTATOR CelA 2693958 It will also allow the study of glycosylation of CelA itself and its role in the structure and function of this important enzyme in biomass deconstruction. 24327294 4 59 gly glycosylated 720:731 arg1 glycosylated BChE glycosylated BChE PUBTATOR BChE 590 However, the asparagine-linked glycans on the surface of glycosylated BChE may interfere with the PEGylation modification. 25658763 9 58 gly Glycosylation 1931:1943 arg1 EMMPRIN EMMPRIN PUBTATOR EMMPRIN 682 Glycosylation of EMMPRIN may serve as a potential target for regulating the inflammatory activities of monocytes/macrophages. 24820161 3 25 gly has 530:532 arg1 Hyaluronidase 1 AND two predicted C-mannosylation sites Hyaluronidase 1 two predicted C-mannosylation sites PUBTATOR Hyaluronidase 1 3373 Hyaluronidase 1 (HYAL1), degrading hyaluronic acid (HA), has two predicted C-mannosylation sites at Trp¹³⁰ and Trp³²¹. 24820161 3 25 gly has 530:532 arg1 HYAL1 AND two predicted C-mannosylation sites HYAL1 two predicted C-mannosylation sites PUBTATOR HYAL1 3373 Hyaluronidase 1 (HYAL1), degrading hyaluronic acid (HA), has two predicted C-mannosylation sites at Trp¹³⁰ and Trp³²¹. 25927005 11 136 gly glycosylation 1931:1943 arg1 HCV E2 HCV E2 Cterm HCV E2 In addition, elimination of single glycosylation sites of HCV E2 had no impact on the RNA synthesis of structural proteins and formation of virus-like particles in insect and mammalian cells. 25355867 0 45 gly α1-antitrypsin 45:58 arg1 Proteolytic and N-glycan processing 1-antitrypsin Proteolytic and N-glycan processing PUBTATOR 1-antitrypsin 5265 Proteolytic and N-glycan processing of human α1-antitrypsin expressed in Nicotiana benthamiana. 29233911 4 62 gly O-glycosylation 509:523 arg1 C1-Inh C1-Inh PUBTATOR C1-Inh 710 Here, we performed for the first time an in-depth site-specific N- and O-glycosylation analysis of C1-Inh combining various mass spectrometric approaches, including C18-porous graphitized carbon (PGC)-LC-ESI-QTOF-MS/MS applying stepping-energy collision-induced dissociation (CID) and electron-transfer dissociation (ETD). 28109443 4 57 gly O-glycans 846:854 arg1 the two HRs HRs O-glycans OGER HRs P12081 An additional question is whether the O-glycans at all sites on the two HRs of one IgA1 molecule are homogeneous (either all normal or all Tn/STn) or heterogeneous (both normal and Tn/STn O-glycans). 27235585 7 55 gly glycosylation 1072:1084 arg1 the transferrin structure the transferrin structure PUBTATOR transferrin 7018 Here, we explore the effect of glycosylation on the transferrin structure. 27638310 3 5 gly O-glycosylation 520:534 arg1 rhGM-CSF rhGM-CSF OGER CSF However, there are no previous reports of the O-glycosylation of rhGM-CSF from plant cells, and so this study investigated O-glycans, O-glycosylation sites, and their structural role in rrhGM-CSF. 27638310 3 12 gly O-glycans 597:605 arg1 rrhGM-CSF CSF O-glycans OGER CSF However, there are no previous reports of the O-glycosylation of rhGM-CSF from plant cells, and so this study investigated O-glycans, O-glycosylation sites, and their structural role in rrhGM-CSF. 24910992 7 33 gly non-glycosylated 1034:1049 arg1 both glycosylated and non-glycosylated SHHs both glycosylated and non-glycosylated SHHs PUBTATOR SHHs, EDEM3 80267 While EDEM2 was required for ERAD of both glycosylated and non-glycosylated SHHs, EDEM3 was only necessary for glycosylated SHH and EDEM1 was dispensable for both. 24910992 7 57 gly glycosylated 1086:1097 arg1 glycosylated SHH glycosylated SHH PUBTATOR SHH 6469 While EDEM2 was required for ERAD of both glycosylated and non-glycosylated SHHs, EDEM3 was only necessary for glycosylated SHH and EDEM1 was dispensable for both. 24910992 7 75 gly glycosylated 1017:1028 arg1 both glycosylated and non-glycosylated SHHs both glycosylated and non-glycosylated SHHs PUBTATOR SHHs, EDEM3 80267 While EDEM2 was required for ERAD of both glycosylated and non-glycosylated SHHs, EDEM3 was only necessary for glycosylated SHH and EDEM1 was dispensable for both. 25117693 6 66 gly B 1331:1331 arg1 the glycan RNase B the glycan OGER RNase B P07998 The NMR spectra revealed that the secreted proteins from A. niger contain both N-linked glycans with a high-mannose core similar to the structure of the glycan from RNase B, and O-linked glycans bearing mannose and glucose with 1→3 and 1→6 linkages. 26171609 3 71 gly N-glycan 491:498 arg1 25-kDa HAI-2 HAI-2 N-glycan PUBTATOR HAI-2 10653 The N-glycan on 25-kDa HAI-2 appears to be of the oligomannose type and that on 30-40-kDa HAI-2 to be of complex type with extensive terminal N-acetylglucosamine branching. 27506355 11 60 gly glycoprotein 1365:1376 arg1 human transferrin human transferrin PUBTATOR transferrin 7018 We validated our method using a standard glycoprotein, human transferrin, and evaluated its potential to be used in site-specific glycosylation profiling of glycoprotein datasets from LC-MS/MS. 25124036 6 50 gly glycoform 995:1003 arg1 TFF2 TFF2 PUBTATOR TFF2 7032 We show here that the gastric glycoform of TFF2 is a calcium-independent lectin, which binds with high specificity to O-linked α1,4-GlcNAc-capped hexasaccharides on human and porcine stomach mucin. 25124036 6 91 gly hexasaccharides 1111:1125 arg1 porcine stomach mucin mucin hexasaccharides PUBTATOR mucin 100508689 We show here that the gastric glycoform of TFF2 is a calcium-independent lectin, which binds with high specificity to O-linked α1,4-GlcNAc-capped hexasaccharides on human and porcine stomach mucin. 28880909 0 104 gly glycosylation 32:44 arg1 a biosimilar recombinant human follicle-stimulating hormone product a biosimilar recombinant human follicle-stimulating hormone product Cterm follicle-stimulating hormone product In-vivo biological activity and glycosylation analysis of a biosimilar recombinant human follicle-stimulating hormone product (Bemfola) compared with its reference medicinal product (GONAL-f). 28880909 0 104 gly glycosylation 32:44 arg1 Bemfola Bemfola Cterm Bemfola In-vivo biological activity and glycosylation analysis of a biosimilar recombinant human follicle-stimulating hormone product (Bemfola) compared with its reference medicinal product (GONAL-f). 26492619 3 0 gly O-glycan 389:396 arg1 Thr52 Thr52 Thr52 AminoAcid Thr52 Among the three PLAG domains, O-glycan on Thr52 of PLAG3 is critical for binding with C-type lectin-like receptor-2 (CLEC-2) and is essential for platelet-aggregating activity of PDPN. 25824821 0 0 gly glycan 9:14 arg1 IgE IgE glycan PUBTATOR IgE P01854 A single glycan on IgE is indispensable for initiation of anaphylaxis. 27124023 6 39 gly N-glycosylation 1353:1367 arg1 IgG IgG Cterm IgG These findings suggest that the individual variation in N-glycosylation of IgG contributes to pathogenesis of hypertension, presumably via its effect on pro- and/or anti-inflammatory pathways. 28749929 4 2 gly IgG 700:702 arg1 GlcNAc IgG GlcNAc Cterm IgG Next, a homogeneous N-glycan substrate, presynthesized as described here, is attached to the remaining N-acetylglucosamine (GlcNAc) of IgG, using a mutant endoglycosidase (also called endoglycosynthase) that lacks hydrolytic activity but possesses transglycosylation activity for glycoengineering. 28749929 4 2 gly IgG 700:702 arg1 the remaining N-acetylglucosamine IgG the remaining N-acetylglucosamine Cterm IgG Next, a homogeneous N-glycan substrate, presynthesized as described here, is attached to the remaining N-acetylglucosamine (GlcNAc) of IgG, using a mutant endoglycosidase (also called endoglycosynthase) that lacks hydrolytic activity but possesses transglycosylation activity for glycoengineering. 28434712 1 31 gly IgG1 303:306 arg1 enzymatically released N-linked glycans IgG1 enzymatically released N-linked glycans OGER IgG1 P01857 Herein is reported the separation and identification of a previously unknown imidazoline by-product originating from the fluorescent labeling procedure when applied to enzymatically released N-linked glycans of a human IgG1. 26067753 1 58 gly G1 137:138 arg1 N-glycan processing immunoglobulin G1 N-glycan processing Cterm immunoglobulin G1 We investigated N-glycan processing of immunoglobulin G1 using the monoclonal antibody cetuximab (CxMab), which has a glycosite in the Fab domain in addition to the conserved Fc glycosylation, as a reporter. 25210040 8 35 gly determinant 1760:1770 arg1 human TFF2 TFF2 determinant PUBTATOR TFF2 7032 The structural features of the LacdiNAc-inducing determinant on human TFF2 are discussed on the basis of crystal structures of porcine TFF2, and a series of extracellular matrix-related LacdiNAc-positive glycoproteins detected as novel candidate proteins in the secretome of HEK-293 cells. 28956227 5 10 gly NTPDase3/CD39L3 1088:1102 arg1 four different glycan modifications NTPDase3 four different glycan modifications PUBTATOR NTPDase3 956 To understand the mechanism of the ecto-NTPDase activity and substrate specificity, potentially impacted by N-glycans, we have generated soluble enzymatic domains of NTPDase3/CD39L3 in human embryotic kidney cells with four different glycan modifications. 24719303 2 44 gly non-glycosylated 368:383 arg1 RNase A RNase A PUBTATOR RNase A 6035 Spectral data of the intact glycan moiety of RNase B is obtained by subtracting high-quality spectral data of RNase A, the non-glycosylated form of the RNase, from the spectra of the glycoprotein. 24719303 2 44 gly non-glycosylated 368:383 arg1 the RNase form of the RNase OGER form of the RNase P07998 Spectral data of the intact glycan moiety of RNase B is obtained by subtracting high-quality spectral data of RNase A, the non-glycosylated form of the RNase, from the spectra of the glycoprotein. 26240167 3 31 gly Pdi1p 498:502 arg1 site-specific N-glycan remodeling Pdi1p site-specific N-glycan remodeling PUBTATOR Pdi1p 29943 We applied newly developed mass spectrometry-based analytics to quantify site-specific N-glycan remodeling of the model protein Pdi1p expressed in insect cells. 29268168 3 15 gly afucosylated 468:479 arg1 afucosylated IgG afucosylated IgG PUBTATOR IgG 16059 The increase in affinity for afucosylated IgG has previously been shown to depend on direct carbohydrate-carbohydrate interactions between the IgG-Fc glycan with an N-linked glycan at position 162 unique to hFcγRIIIa and hFcγRIIIb. 24799124 7 17 gly ceruloplasmin 1559:1571 arg1 core-fucosylation ceruloplasmin core-fucosylation PUBTATOR ceruloplasmin 1356 However, in HBV- or HCV-related liver diseases, no significant site-specific change in core-fucosylation of ceruloplasmin was observed between HCC and cirrhosis. 24799124 7 20 gly core-fucosylation 1538:1554 arg1 ceruloplasmin ceruloplasmin PUBTATOR ceruloplasmin 1356 However, in HBV- or HCV-related liver diseases, no significant site-specific change in core-fucosylation of ceruloplasmin was observed between HCC and cirrhosis. 24575722 5 58 gly fucosylated 966:976 arg1 increased fucosylated haptoglobin increased fucosylated haptoglobin PUBTATOR haptoglobin 3240 Using our reverse lectin-based ELISA assay, increased fucosylated haptoglobin was observed in sera of patients with ovarian cancer, while the protein level of haptoglobin remained the same between cancers and noncases. 24970053 4 7 gly glycoform 630:638 arg1 HG-CD147 HG-CD147 PUBTATOR HG-CD147 682 CD147 is a major carrier of β1-6-branched polylactosamine sugars on tumor cells, and the high glycoform of CD147 (HG-CD147) induces matrix metalloproteinase (MMP) production. 24970053 4 7 gly glycoform 630:638 arg1 CD147 CD147 PUBTATOR CD147 682 CD147 is a major carrier of β1-6-branched polylactosamine sugars on tumor cells, and the high glycoform of CD147 (HG-CD147) induces matrix metalloproteinase (MMP) production. 26457763 3 13 gly glycosylated 380:391 arg1 a heavily glycosylated receptor aminopeptidase N a heavily glycosylated receptor aminopeptidase N OGER aminopeptidase N P15144 For virus transmission, PEMV binds to a heavily glycosylated receptor aminopeptidase N in the pea aphid gut and is transcytosed across the gut epithelium into the aphid body cavity prior to release in saliva as the aphid feeds. 25326312 8 49 gly fucosylated 1768:1778 arg1 HRP HRP Cterm HRP 2768671 Assaying the NMJ extracellular synaptomatrix with a broad panel of lectin probes reveals profound alterations in dGALT mutants, including depletion of galactosyl, N-acetylgalactosamine and fucosylated horseradish peroxidase (HRP) moieties, which are differentially corrected by dGALK co-removal and sugarless overexpression. 25326312 8 49 gly fucosylated 1768:1778 arg1 fucosylated horseradish peroxidase fucosylated horseradish peroxidase PUBTATOR peroxidase 2768671 Assaying the NMJ extracellular synaptomatrix with a broad panel of lectin probes reveals profound alterations in dGALT mutants, including depletion of galactosyl, N-acetylgalactosamine and fucosylated horseradish peroxidase (HRP) moieties, which are differentially corrected by dGALK co-removal and sugarless overexpression. 26563299 7 30 part_of IL-15 1085:1089 arg1 Asn112 IL-15 Asn71 and Asn112 PUBTATOR AminoAcid IL-15 P40933 Asn71 and Asn112 The two potential IL-15 N-glycosylation sites (Asn71 and Asn112) located at the IL-2 receptor interface were unoccupied. 24941220 12 37 gly glycosylation 1870:1882 arg1 virion-derived gp120 virion-derived gp120 PUBTATOR gp120 3700 This direct observation of site-specific glycosylation of virion-derived gp120 has implications in HIV glycobiology and vaccine design. 26088564 0 66 gly glycoprotein 41:52 arg1 human α1-acid glycoprotein human α1-acid glycoprotein Cterm α1-acid Structural glycobiology of human α1-acid glycoprotein and its implications for pharmacokinetics and inflammation. 28230186 3 8 gly Glycosylation 347:359 arg1 IgG IgG Cterm IgG Glycosylation of IgG is known to modulate the effector functions of Fcγ receptors. 26189796 2 32 gly glycosylation 383:395 arg1 E-cadherin E-cadherin PUBTATOR E-cadherin 999 However, the role that site-specific glycosylation of E-cadherin has in its defective function in gastric cancer cells needs to be determined. 26240146 5 17 gly Hyperglycosylated 680:696 arg1 Hyperglycosylated hCG Hyperglycosylated hCG OGER hCG Hyperglycosylated hCG was purified from the urine of invasive mole patients, and the structure of its N-linked oligosaccharides was confirmed to be more branched by MS. The binding kinetics of the anti-hCG antibodies MCA329 and MCA1024 against hCG and hyperglycosylated hCG were compared using biolayer interferometry. 26240146 5 29 gly hyperglycosylated 932:948 arg1 hyperglycosylated hCG hyperglycosylated hCG OGER hCG Hyperglycosylated hCG was purified from the urine of invasive mole patients, and the structure of its N-linked oligosaccharides was confirmed to be more branched by MS. The binding kinetics of the anti-hCG antibodies MCA329 and MCA1024 against hCG and hyperglycosylated hCG were compared using biolayer interferometry. 29029079 4 5 gly structures 553:562 arg1 native EC-SOD EC-SOD structures PUBTATOR EC-SOD 6649 Here we analyzed glycan structures on native EC-SOD purified from human sera, and identified sialylated biantennary structures. 26631508 8 83 gly released 1541:1548 arg1 MUC7 AND O-glycans MUC7 O-glycans PUBTATOR MUC7 4589 LC-MS/MS analysis of O-glycans released from MUC7 by β-elimination revealed that although patients had an increase in core 1 sulfation, the even larger reduction in sialylation resulted in a global decline of charged glycans. 24820161 2 1 gly C-mannosylation 284:298 arg1 ribonuclease 2 ribonuclease 2 PUBTATOR ribonuclease 2 6036 In the protein glycosylation, C-mannosylation was first identified in ribonuclease 2, and some proteins have been reported to be C-mannosylated; however, effects of its modifications for target proteins remain unclear. 24509848 5 54 part_of residue 680:686 arg1 N-glycosylation t N-glycosylation residue PUBTATOR SpecificSite t N-glycosylation 780 Asn(211) residue Here, we report that N-glycosylation at the Asn(211) residue plays a unique role in the control of DDR1 dimerization and autophosphorylation. 26657071 0 12 gly Aglycosylated 61:73 arg1 Aglycosylated Human Carboxylesterase 1 Aglycosylated Human Carboxylesterase 1 OGER Carboxylesterase 1 P23141 Comparison of the Structure and Activity of Glycosylated and Aglycosylated Human Carboxylesterase 1. 27493216 1 63 gly glycoprotein 121:132 arg1 The dystrophin glycoprotein complex The dystrophin glycoprotein complex OGER dystrophin glycoprotein P11532 The dystrophin glycoprotein complex, which connects the cell membrane to the basement membrane, is essential for a variety of biological events, including maintenance of muscle integrity. 26038399 1 4 gly glycoproteins 163:175 arg1 GPs GPs OGER GPs BACKGROUND: N-linked glycosylation is a common posttranslational modification found on viral glycoproteins (GPs) and involved in promoting expression, cellular attachment, protection from proteases, and antibody evasion. 28575723 1 11 gly glycosylated 137:148 arg1 Cha o 3 Cha o 3 OGER Cha o 3 Q9UL49 Cha o 3 is a newly found glycosylated allergen from Chamaecyparis obtusa (Japanese cypress) pollen. 26239923 7 14 gly oligosaccharides 1052:1067 arg1 buffalo colostrum IgG IgG oligosaccharides Cterm IgG The high non-fucosyl and sialyl oligosaccharides in buffalo colostrum IgG provide ample scope for its utilization in targeted therapies to elicit effective ADCC and anti-inflammatory responses. 26239923 7 30 gly non-fucosyl 1029:1039 arg1 buffalo colostrum IgG IgG non-fucosyl Cterm IgG The high non-fucosyl and sialyl oligosaccharides in buffalo colostrum IgG provide ample scope for its utilization in targeted therapies to elicit effective ADCC and anti-inflammatory responses. 28417175 3 43 gly glycoproteins 714:726 arg1 ovalbumin ovalbumin PUBTATOR ovalbumin 522479 After further validation with other two standard glycoproteins (ovalbumin and bovine fetuin), the proposed strategy was applied to human serum for preliminary pathological analysis of N-glycans between healthy and lung cancer individuals. 28692416 2 96 gly N-glycosylation 448:462 arg1 IgG IgG Cterm IgG Our previous work has shown an association between hypertension and immunoglobulin G (IgG) glycome composition, suggesting that individual variation in N-glycosylation of IgG might contribute to hypertension pathogenesis. 26812091 3 18 gly glycosylation 395:407 arg1 uhFSH uhFSH OGER hFSH Using a glycoproteomic strategy, this study compared the glycosylation of a putative highly purified FSH (uhFSH) obtained from human urine with that of a recombinant human FSH (rhFSH) obtained from Chinese hamster ovary (CHO) cells. 26812091 3 18 gly glycosylation 395:407 arg1 a putative highly purified FSH a putative highly purified FSH OGER FSH Using a glycoproteomic strategy, this study compared the glycosylation of a putative highly purified FSH (uhFSH) obtained from human urine with that of a recombinant human FSH (rhFSH) obtained from Chinese hamster ovary (CHO) cells. 28486782 0 81 gly N-glycosylation 8:22 arg1 EGFR ectodomain ligand binding EGFR ectodomain ligand binding PUBTATOR EGFR 1956 Role of N-glycosylation in EGFR ectodomain ligand binding. 24651839 6 4 gly IgA1 925:928 arg1 Glycan profiling IgA1 Glycan profiling PUBTATOR IgA1 P01876 Glycan profiling of IgA1 by the lectin microarray revealed an intense signal for Wisteria floribunda agglutinin (WFA). 24931470 3 41 gly CD4-bound 468:476 arg1 their glycan composition CD4 their glycan composition PUBTATOR CD4 920 Here, we use hydrogen-deuterium exchange and oxidative labeling to gain a more precise understanding of the unliganded and CD4-bound forms of soluble Env trimers (SOSIP.664), including their glycan composition. 24931470 3 43 gly trimers 499:505 arg1 their glycan composition Env trimers their glycan composition PUBTATOR Env trimers 100616444 Here, we use hydrogen-deuterium exchange and oxidative labeling to gain a more precise understanding of the unliganded and CD4-bound forms of soluble Env trimers (SOSIP.664), including their glycan composition. 24820161 4 42 gly C-mannosylated 636:649 arg1 HYAL1 HYAL1 PUBTATOR HYAL1 3373 In this study, we examined whether HYAL1 is C-mannosylated or not, and the effect of C-mannosylation on HYAL1. 28902916 1 64 gly glycoproteins 209:221 arg1 Env Env PUBTATOR Env 100616444 Extensive shielding by N-glycans on the surface of the HIV envelope glycoproteins (Env) restricts B cell recognition of conserved neutralizing determinants. 24644239 1 70 gly glycosylated 151:162 arg1 CCL1 CCL1 PUBTATOR CCL1 6346 CCL1 is a naturally glycosylated chemokine protein that is secreted by activated T-cells and acts as a chemoattractant for monocytes. 28661444 2 15 gly glycosylation 586:598 arg1 two recombinant MTB proteins two recombinant MTB proteins Cterm MTB In this work, we investigated the effect of the chemical glycosylation on two recombinant MTB proteins produced in E. coli with an additional seven-amino acid tag (recombinant Ag85B and TB10.4). 29274340 4 84 gly released 883:890 arg1 rhGAA AND The glycans rhGAA The glycans OGER rhGAA Q6P7A9 The glycans released from rhGAA were labeled with procainamide to improve mass ionization efficiency and the sensitivity of MS/MS. 24575722 6 73 gly fucosylated 1150:1160 arg1 fucosylated haptoglobin fucosylated haptoglobin PUBTATOR haptoglobin 3240 The combination of fucosylated haptoglobin and CA125 (AUC = 0.88) showed improved performance for distinguishing stage-III ovarian cancer from noncases compared with CA125 alone (AUC = 0.86). 24130173 5 71 gly rBChE 856:860 arg1 that sialylation content rBChE that sialylation content Cterm rBChE P06276 Attempts to increase that sialylation content of rBChE by the over-expression of an additional glycosylation enzyme that generates branched N-glycans (i.e. β1,4-N-acetylglucosaminyl-transferase IV), allowed the production of rBChE decorated with tri-sialylated structures (up to 70%). 26328495 2 14 gly modified 392:399 arg3 POMGNT1 AND O-glycans POMGNT1 O-glycans PUBTATOR POMGNT1 55624 POMGNT1 is not modified by N-glycans because there are no potential N-glycosylation sites; however, it is not clear whether POMGNT1 is modified by O-glycans. 26328495 2 62 gly modified 272:279 arg1 POMGNT1 AND N-glycans POMGNT1 N-glycans PUBTATOR POMGNT1 55624 POMGNT1 is not modified by N-glycans because there are no potential N-glycosylation sites; however, it is not clear whether POMGNT1 is modified by O-glycans. 26189796 4 12 gly N-glycosylation 772:786 arg1 E-cadherin E-cadherin PUBTATOR E-cadherin 999 In vitro models further indicated that, among the four potential N-glycosylation sites of E-cadherin, Asn-554 is the key site that is selectively modified with β1,6 GlcNAc-branched N-glycans catalyzed by GnT-V. 25416425 7 13 gly carried 1039:1045 arg1 Kv1.4 AND a unique oligomannose-type N-glycan Kv1.4 a unique oligomannose-type N-glycan PUBTATOR Kv1.4 3739 Kv1.4 in CSTP-treated cells carried a unique oligomannose-type N-glycan that contains three glucose residues. 28446609 1 28 gly glycosylated 201:212 arg1 The gp120 subunit The gp120 subunit PUBTATOR gp120 subunit 3700 The gp120 subunit of the HIV-1 envelope (Env) protein is heavily glycosylated at ∼25 glycosylation sites, of which ∼7-8 are located in the V1/V2 and V3 variable loops and the others in the remaining core gp120 region. 26189796 5 37 gly E-cadherin 988:997 arg1 This aberrant glycan modification E-cadherin This aberrant glycan modification PUBTATOR E-cadherin 999 This aberrant glycan modification on this specific asparagine site of E-cadherin was demonstrated to affect its critical functions in gastric cancer cells by affecting E-cadherin cellular localization, cis-dimer formation, molecular assembly and stability of the adherens junctions and cell-cell aggregation, which was further observed in human gastric carcinomas. 28109443 7 90 gly IgA1 1888:1891 arg1 the O-glycans IgA1 the O-glycans PUBTATOR IgA1 P01876 These results raised a serious question about the role of Tn/STn antigens on IgA1 in pathogenesis of IgAN, and there is a demand for a practical methodology that any laboratory can utilize to analyze the O-glycans of IgA1. 28397166 4 62 gly N-glycosylation 728:742 arg1 IgG IgG Cterm IgG In the present study, N-glycosylation of IgG in RA patients and in healthy people was characterized through identification of the released glycans using multistage matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-MSn), and quantitation by CE. 24820161 7 29 gly HYAL1 1021:1025 arg1 C-mannosylation HYAL1 C-mannosylation PUBTATOR HYAL1 3373 Computer simulation demonstrated that C-mannosylation of HYAL1 at Trp¹³⁰ changed conformation of the catalytic active site, and faced Glu¹³¹ in the opposite direction toward its substrate, HA, indicating that C-mannosylation will negatively regulate its secretion, and will attenuate its enzymatic activity. 24820161 7 40 gly C-mannosylation 1002:1016 arg1 HYAL1 HYAL1 PUBTATOR HYAL1 3373 Computer simulation demonstrated that C-mannosylation of HYAL1 at Trp¹³⁰ changed conformation of the catalytic active site, and faced Glu¹³¹ in the opposite direction toward its substrate, HA, indicating that C-mannosylation will negatively regulate its secretion, and will attenuate its enzymatic activity. 25450502 3 37 gly OPN 595:597 arg1 the overall glycan pattern OPN the overall glycan pattern PUBTATOR OPN 6696 In this work, we profiled the overall glycan pattern of human recombinant OPN using a lectin array and completed detailed structural analysis of O-glycopeptides by mass spectrometry (MS). 24854630 10 76 gly O-sLe 1650:1654 arg1 PSA PSA O-sLe PUBTATOR PSA P07288 CONCLUSIONS GCNT1 is over-expressed in prostate cancer and is associated with higher levels of core 2 O-sLe(x) in PSA, PAP and MUC1 proteins. 24854630 10 76 gly O-sLe 1650:1654 arg1 PAP PAP O-sLe PUBTATOR PAP 55 CONCLUSIONS GCNT1 is over-expressed in prostate cancer and is associated with higher levels of core 2 O-sLe(x) in PSA, PAP and MUC1 proteins. 24854630 10 76 gly O-sLe 1650:1654 arg1 MUC1 proteins MUC1 proteins O-sLe PUBTATOR MUC1 proteins 4582 CONCLUSIONS GCNT1 is over-expressed in prostate cancer and is associated with higher levels of core 2 O-sLe(x) in PSA, PAP and MUC1 proteins. 28104755 5 5 gly N-glycosylation 698:712 arg1 human SMPDL3A human SMPDL3A PUBTATOR SMPDL3A 10924 Here, we investigate the roles of N-glycosylation in the expression, secretion and activity of human SMPDL3A, using inhibitors of N-glycosylation and site-directed mutagenesis, with either THP-1 macrophages or CHO cells expressing human SMPDL3A. 26051934 1 7 gly glycosylated 87:98 arg1 Env Env PUBTATOR Env 155971 A highly glycosylated, trimeric envelope glycoprotein (Env) mediates HIV-1 cell entry. 26051934 1 7 gly glycosylated 87:98 arg1 A highly glycosylated, trimeric envelope glycoprotein A highly glycosylated, trimeric envelope glycoprotein PUBTATOR envelope glycoprotein 155971 A highly glycosylated, trimeric envelope glycoprotein (Env) mediates HIV-1 cell entry. 26051934 1 27 gly glycoprotein 119:130 arg1 Env Env PUBTATOR Env 155971 A highly glycosylated, trimeric envelope glycoprotein (Env) mediates HIV-1 cell entry. 26051934 1 27 gly glycoprotein 119:130 arg1 A highly glycosylated, trimeric envelope glycoprotein A highly glycosylated, trimeric envelope glycoprotein PUBTATOR envelope glycoprotein 155971 A highly glycosylated, trimeric envelope glycoprotein (Env) mediates HIV-1 cell entry. 28672164 6 44 gly β-HlH 885:889 arg1 The glycans HlH The glycans OGER HlH The glycans of β-HlH mainly contain a terminal MeHex residue; in some cases even two, three or four of these residues occur. 25793407 7 82 gly NG1 1139:1141 arg1 α(1,6)-linked arm monogalactosylated, core-fucosylated diantennary N-glycans NG1 α(1,6)-linked arm monogalactosylated, core-fucosylated diantennary N-glycans OGER NG1 Q9UHD0 In particular, α(1,6)-linked arm monogalactosylated, core-fucosylated diantennary N-glycans (NG1(6)A2F) were significantly reduced in T2DM compared with CTR subjects. 27503803 1 13 gly attached 155:162 arg2 human vitamin D binding protein AND the O-glycan structure human vitamin D binding protein the O-glycan structure PUBTATOR vitamin D binding protein 2638 Disagreement exists regarding the O-glycan structure attached to human vitamin D binding protein (DBP). 27503803 1 13 gly attached 155:162 arg1 DBP AND the O-glycan structure DBP the O-glycan structure PUBTATOR DBP 1628 Disagreement exists regarding the O-glycan structure attached to human vitamin D binding protein (DBP). 26576925 5 26 gly monoglycosylated 764:779 arg1 C C Cterm C 19122 In support of this hypothesis, here we show that diglycosylated PrP(C) molecules that have more sialic groups per molecule than monoglycosylated PrP(C) were preferentially excluded from conversion. 26576925 5 26 gly monoglycosylated 764:779 arg1 monoglycosylated PrP monoglycosylated PrP PUBTATOR PrP 19122 In support of this hypothesis, here we show that diglycosylated PrP(C) molecules that have more sialic groups per molecule than monoglycosylated PrP(C) were preferentially excluded from conversion. 26576925 5 71 gly diglycosylated 685:698 arg1 C C Cterm C 19122 In support of this hypothesis, here we show that diglycosylated PrP(C) molecules that have more sialic groups per molecule than monoglycosylated PrP(C) were preferentially excluded from conversion. 26576925 5 71 gly diglycosylated 685:698 arg1 diglycosylated PrP diglycosylated PrP PUBTATOR PrP 19122 In support of this hypothesis, here we show that diglycosylated PrP(C) molecules that have more sialic groups per molecule than monoglycosylated PrP(C) were preferentially excluded from conversion. 28336547 8 104 gly glycosylation 1567:1579 arg1 PEPT1 PEPT1 PUBTATOR PEPT1 56643 In addition, our experiments provide strong evidence that glycosylation of PEPT1 confers resistance against proteolytic cleavage by proteinase K, whereas a remarkable intrinsic stability against trypsin, even in the absence of N-linked glycans, was detected.NEW & NOTEWORTHY This study highlights the role of N50-linked glycans in modulating the bidirectional transport activity of the murine peptide transporter PEPT1. 24644239 4 4 gly non-glycosylated 631:646 arg1 (Ser-)CCL1 (Ser-)CCL1 PUBTATOR CCL1 6346 Here we report the total chemical syntheses of both N-glycosylated and non-glycosylated forms of (Ser-)CCL1, by convergent native chemical ligation. 24644239 4 33 gly N-glycosylated 612:625 arg1 (Ser-)CCL1 (Ser-)CCL1 PUBTATOR CCL1 6346 Here we report the total chemical syntheses of both N-glycosylated and non-glycosylated forms of (Ser-)CCL1, by convergent native chemical ligation. 25479762 1 7 gly N-glycosylated 190:203 arg1 BACKGROUND γ-Glutamyl transpeptidase 1 BACKGROUND γ-Glutamyl transpeptidase 1 PUBTATOR -Glutamyl transpeptidase 1 2678 BACKGROUND γ-Glutamyl transpeptidase 1 (GGT1) is an N-glycosylated membrane protein that catabolizes extracellular glutathione and other γ-glutamyl-containing substrates. 25071157 2 65 gly contains 405:412 arg1 serum IgA1 AND aberrant, undergalactosylated O-glycans serum IgA1 aberrant, undergalactosylated O-glycans PUBTATOR IgA1 P01876 Prior studies suggested that serum IgA1 from IgAN patients contains aberrant, undergalactosylated O-glycans, for example, Tn antigen and its sialylated version, SialylTn (STn), but the mechanisms underlying aberrant O-glycosylation are not well understood. 28437635 4 24 gly glycosylation 597:609 arg1 SLC52A1 SLC52A1 PUBTATOR SLC52A1 55065 In addition, we showed that glycosylation of SLC52A1 is not necessary for PERV-A receptor function. 24651839 9 89 gly glycosylated 1448:1459 arg1 highly polymerized and glycosylated IgA1 highly polymerized and glycosylated IgA1 PUBTATOR IgA1 P01876 WFA specifically recognized highly polymerized and glycosylated IgA1. 27489265 1 32 gly glycoprotein 144:155 arg1 The envelope glycoprotein envelope glycoprotein PUBTATOR envelope glycoprotein 100616444 The envelope glycoprotein (Env) is the major target for HIV-1 broadly neutralizing antibodies (bNAbs). 26231935 1 30 gly glycoprotein 138:149 arg1 Acetylcholinesterase Acetylcholinesterase PUBTATOR Acetylcholinesterase 43 Acetylcholinesterase (AChE; EC 3.1.1.7) is a glycoprotein possessing three conserved N-linked glycosylation sites in mammalian species, locating at 296, 381, and 495 residues of the human sequence. 25016576 2 75 gly glycans 413:419 arg1 gp120 gp120 glycans PUBTATOR gp120 Q14624 These were recovered from HIV-1 infected subjects, and several (e.g., PG9, PG16, CH01, CH03) target glycans in the first and second variable (V1/V2) domain of gp120. 26382581 0 84 gly N-glycosylation 15:29 arg1 recombinant human coagulation factor VII recombinant human coagulation factor VII PUBTATOR coagulation factor VII 2155 Differences in N-glycosylation of recombinant human coagulation factor VII derived from BHK, CHO, and HEK293 cells. 27842516 2 30 gly glycosylation 295:307 arg1 flagellin flagellin PUBTATOR flagellin 29236998 Post-translational glycosylation of flagellin, the main structural protein of the flagellum, is a common characteristic among many Gram-negative bacteria and Archaea. 26239923 1 45 gly glycoprotein 121:132 arg1 Immunoglobulin G Immunoglobulin G Cterm Immunoglobulin G Immunoglobulin G (IgG) is a major glycoprotein in ruminant colostrum. 27693835 6 52 gly contained 816:824 arg1 CPE-II AND an AceA-containing nonasaccharide CPE-II an AceA-containing nonasaccharide OGER CPE P16870 Sequential degradation using partial acid hydrolysis indicated that CPE-II contained Rhap-(1→5)-Kdo, Araf-(1→5)-Dha, an AceA-containing nonasaccharide, and an uronic acid-rich oligosaccharide in addition to an α-(1→4)-galacturono-oligosaccharide main chain. 27693835 6 52 gly contained 816:824 arg1 CPE-II AND Rhap-(1→5)-Kdo CPE-II Rhap-(1→5)-Kdo OGER CPE P16870 Sequential degradation using partial acid hydrolysis indicated that CPE-II contained Rhap-(1→5)-Kdo, Araf-(1→5)-Dha, an AceA-containing nonasaccharide, and an uronic acid-rich oligosaccharide in addition to an α-(1→4)-galacturono-oligosaccharide main chain. 27693835 6 52 gly contained 816:824 arg1 CPE-II AND Araf-(1→5)-Dha CPE-II Araf-(1→5)-Dha OGER CPE P16870 Sequential degradation using partial acid hydrolysis indicated that CPE-II contained Rhap-(1→5)-Kdo, Araf-(1→5)-Dha, an AceA-containing nonasaccharide, and an uronic acid-rich oligosaccharide in addition to an α-(1→4)-galacturono-oligosaccharide main chain. 27693835 6 52 gly contained 816:824 arg1 CPE-II AND an uronic acid-rich oligosaccharide CPE-II an uronic acid-rich oligosaccharide OGER CPE P16870 Sequential degradation using partial acid hydrolysis indicated that CPE-II contained Rhap-(1→5)-Kdo, Araf-(1→5)-Dha, an AceA-containing nonasaccharide, and an uronic acid-rich oligosaccharide in addition to an α-(1→4)-galacturono-oligosaccharide main chain. 26112419 0 22 gly deglycosylation 81:95 arg1 IgG IgG Cterm structure of IgG Single molecule Förster resonance energy transfer studies of the effect of EndoS deglycosylation on the structure of IgG. 25824821 7 11 gly structure 870:878 arg1 IgE IgE structure PUBTATOR IgE P01854 The obligatory glycan was mapped to a single N-linked oligomannose structure in the constant domain 3 (Cε3) of IgE, at asparagine-394 (N394) in human IgE and N384 in mouse. 26956484 0 86 gly glycosylation 19:31 arg1 Orai1 Orai1 PUBTATOR Orai1 84876 Cell type-specific glycosylation of Orai1 modulates store-operated Ca2+ entry. 27957769 12 15 gly structures 2334:2343 arg1 MUC1 MUC1 structures PUBTATOR MUC1 4582 All antibody sera show high reactivity to the tumor-associated saccharide structures on MUC1. 27638310 10 21 gly O-glycosylation 1527:1541 arg1 rhGM-CSF rhGM-CSF OGER CSF This is the first report on the O-glycosylation of rhGM-CSF derived from plant cells. 28947169 3 25 gly glycans 385:391 arg1 the protein protein can glycans OGER protein can P35658 The results clearly indicated that glycans on the protein can be identified by their selective binding activity to various lectins. 24947385 4 8 gly sialylated 556:565 arg1 GFP-tagged GLUT4 GFP-tagged GLUT4 PUBTATOR GFP-tagged GLUT4 6517 We found that sialylated glycoforms of GFP-tagged GLUT4 appear to be internalized more slowly than non-sialylated GLUT4 upon insulin removal. 24947385 4 13 gly non-sialylated 641:654 arg1 non-sialylated GLUT4 non-sialylated GLUT4 PUBTATOR GLUT4 6517 We found that sialylated glycoforms of GFP-tagged GLUT4 appear to be internalized more slowly than non-sialylated GLUT4 upon insulin removal. 24947385 4 27 gly GLUT4 592:596 arg1 sialylated glycoforms GFP-tagged GLUT4 sialylated glycoforms PUBTATOR GFP-tagged GLUT4 6517 We found that sialylated glycoforms of GFP-tagged GLUT4 appear to be internalized more slowly than non-sialylated GLUT4 upon insulin removal. 24947385 4 32 gly glycoforms 567:576 arg1 GFP-tagged GLUT4 GFP-tagged GLUT4 PUBTATOR GFP-tagged GLUT4 6517 We found that sialylated glycoforms of GFP-tagged GLUT4 appear to be internalized more slowly than non-sialylated GLUT4 upon insulin removal. 24965454 0 83 gly glycosylated 57:68 arg1 soluble and fully glycosylated HIV-1 Env soluble and fully glycosylated HIV-1 Env PUBTATOR HIV-1 Env 100616444 Structure of 2G12 Fab2 in complex with soluble and fully glycosylated HIV-1 Env by negative-stain single-particle electron microscopy. 26328495 8 46 gly non-glycosylated 1192:1207 arg1 recombinant sPOMGNT1 recombinant sPOMGNT1 PUBTATOR POMGNT1 55624 To examine whether the O-glycans affect the functions and properties of POMGNT1, we compared glycosylated and non-glycosylated forms of recombinant sPOMGNT1 for their activity and surface hydrophobicity using the hydrophobic probe 1-anilino-8-naphthalene sulfonate (ANS). 26503433 1 6 gly haptoglobin 159:169 arg1 fucosylated glycans haptoglobin fucosylated glycans PUBTATOR haptoglobin 3240 A method for the detection of fucosylated glycans from haptoglobin in patient serum has been developed that provides enhanced sensitivity. 26869421 7 2 gly glycoforms 1323:1332 arg1 the 4 IgG1-Fc glycoforms the 4 IgG1-Fc glycoforms OGER 4 IgG1 P01857 Thus, the overall physical stability profiles of the 4 IgG1-Fc glycoforms also show a correlation with oligosaccharide structure. 25016576 1 86 gly epitopes 259:266 arg1 the HIV-1 envelope protein, gp120 gp120 epitopes PUBTATOR gp120 Q14624 Recent studies have described several broadly neutralizing monoclonal antibodies (bN-mAbs) that recognize glycan-dependent epitopes (GDEs) in the HIV-1 envelope protein, gp120. 24519758 5 60 gly glycosylation 716:728 arg1 goat milk lactoferrin goat milk lactoferrin OGER lactoferrin P02788 After the protein was isolated from milk by affinity chromatography, N-glycans were enzymatically released and a complete characterization of glycan composition was carried out by advanced MS. The glycosylation of goat milk lactoferrin was compared with that of human and bovine milk glycoproteins. 24533768 4 54 gly glycans 569:575 arg1 Asn-297 Asn-297 Asn-297 SpecificSite Asn-297 The native glycans on Asn-297 of antibodies were enzymatically remodeled in vitro using galactosyl and sialyltransferases to introduce terminal sialic acids. 24644239 2 8 gly non-glycosylated 382:397 arg1 Ser-CCL1 Ser-CCL1 PUBTATOR AminoAcid CCL1 6346 Originally, CCL1 was identified as a 73 amino acid protein having one N-glycosylation site, and a variant 74 residue non-glycosylated form, Ser-CCL1, has also been described. 28509333 1 56 gly glycosylation 174:186 arg1 native immunoglobulin (Ig)G native immunoglobulin (Ig)G Cterm (Ig)G The goal of this study was to investigate the glycosylation profile of native immunoglobulin (Ig)G present in serum immune complexes in patients with rheumatoid arthritis (RA). 27956708 7 47 gly present 1111:1117 arg1 ACPA-IgG AND Fab-glycans ACPA Fab-glycans PUBTATOR ACPA 5657 Importantly, Fab-glycans were estimated to be present on over 90% of ACPA-IgG, which is five times higher than in control IgG isolated from the same patients. 26492619 8 2 part_of PLAG1 970:974 arg1 The Thr34 PLAG1 The Thr34 PUBTATOR AminoAcid PLAG1 5324 Thr34 The Thr34 of PLAG1 is critical for LpMab-10 recognition, and O-glycan is not included in LpMab-10 epitope, indicating that Thr34 of PLAG1 is not O-glycosylated. 26492619 8 53 part_of PLAG1 1089:1093 arg1 Thr34 PLAG1 Thr34 PUBTATOR AminoAcid PLAG1 5324 Thr34 The Thr34 of PLAG1 is critical for LpMab-10 recognition, and O-glycan is not included in LpMab-10 epitope, indicating that Thr34 of PLAG1 is not O-glycosylated. 27503803 5 11 gly GcMAF 1109:1113 arg1 the glycan structure GcMAF the glycan structure OGER GcMAF P02774 In addition, the putative anti-cancer derivative of DBP known as Gc Protein-derived Macrophage Activating Factor (GcMAF, which is formed by the combined action of β-galactosidase and neuraminidase upon DBP) was analyzed intact by ESI-MS, revealing that the activating E. coli β-galactosidase cleaves nothing from the protein-leaving the glycan structure of active GcMAF as a Gal-GalNAc-Thr disaccharide, regardless of the order in which β-galactosidase and neuraminidase are applied. 28486782 2 51 gly glycosylated 223:234 arg1 EGFR EGFR PUBTATOR EGFR 1956 The extracellular domain of EGFR is known to be heavily glycosylated. 25479762 4 14 gly N-glycans 622:630 arg1 hGGT1 hGGT1 N-glycans PUBTATOR hGGT1 2678 Tumor-specific changes in the glycans have also been observed, suggesting that the N-glycans on hGGT1 would be an important biomarker for detecting tumors and monitoring their progression during treatment. 27818199 8 79 gly underglycosylated 1136:1152 arg1 an underglycosylated form form of ACE PUBTATOR form of ACE 1636 More importantly, it affected the processing of the protein to the membrane, resulting in expression of an underglycosylated form of ACE. 24467287 2 55 gly glycoproteins 334:346 arg1 the Semliki Forest virus E1 and E2 glycoproteins the Semliki Forest virus E1 and E2 glycoproteins PUBTATOR E1 and E2 glycoproteins 6080 Alphavirus biogenesis has been extensively studied, and the Semliki Forest virus E1 and E2 glycoproteins have been shown to exhibit differing degrees of processing of N-linked glycans. 28955811 1 60 gly glycoprotein 125:136 arg1 Human carboxylesterase 2 Human carboxylesterase 2 PUBTATOR Human carboxylesterase 2 8824 Human carboxylesterase 2 (hCES2) is a glycoprotein involved in the metabolism of drugs and several environmental xenobiotics, whose crystallization has been proved to be a challenging task. 29187599 4 80 part_of Asn-110 551:557 arg1 native hDAO hDAO Asn-110 PUBTATOR SpecificSite hDAO 1610 Asn-110 Here, we show that Asn-110 in native hDAO from amniotic fluid and Caco-2 cells, DAO from porcine kidneys, and rhDAO produced in two different HEK293 cell lines is also consistently occupied by oligomannosidic glycans. 29187599 4 80 part_of Asn-110 551:557 arg1 rhDAO rhDAO Asn-110 OGER SpecificSite rhDAO O35078 Asn-110 Here, we show that Asn-110 in native hDAO from amniotic fluid and Caco-2 cells, DAO from porcine kidneys, and rhDAO produced in two different HEK293 cell lines is also consistently occupied by oligomannosidic glycans. 29187599 4 80 part_of Asn-110 551:557 arg1 DAO DAO Asn-110 PUBTATOR SpecificSite DAO 1610 Asn-110 Here, we show that Asn-110 in native hDAO from amniotic fluid and Caco-2 cells, DAO from porcine kidneys, and rhDAO produced in two different HEK293 cell lines is also consistently occupied by oligomannosidic glycans. 26797772 5 8 gly TNSALP 847:852 arg1 individual single N-glycan deletion mutants TNSALP individual single N-glycan deletion mutants PUBTATOR TNSALP 249 Using site-directed mutagenesis, we demonstrated that TNSALP has five N-glycans in transfected COS-1 cells and that individual single N-glycan deletion mutants of TNSALP retain the dimeric structure required for ALP activity, excluding the possibility that any single N-glycan plays a vital role in the structure and function of TNSALP. 26797772 5 44 gly has 745:747 arg1 TNSALP AND five N-glycans TNSALP five N-glycans PUBTATOR TNSALP 249 Using site-directed mutagenesis, we demonstrated that TNSALP has five N-glycans in transfected COS-1 cells and that individual single N-glycan deletion mutants of TNSALP retain the dimeric structure required for ALP activity, excluding the possibility that any single N-glycan plays a vital role in the structure and function of TNSALP. 27194760 4 31 gly mannosylated 702:713 arg1 The glycoprotein GC The glycoprotein GC Cterm GC The glycoprotein GC was mainly highly mannosylated on tick cell-derived viral progeny. 25498018 2 59 gly glycosylation 508:520 arg1 CLEC-2 CLEC-2 PUBTATOR CLEC-2 51266 The two forms appear to have different ligand-binding abilities, indicating that the differential glycosylation of CLEC-2 possibly produces functionally distinct glycoforms. 26507102 3 136 gly glycosylation 337:349 arg1 lubricin lubricin OGER lubricin Q92954 OBJECTIVES To characterise the glycosylation profile of lubricin in synovial fluid from horses with osteoarthritis and study secretion and degradation of lubricin in an in vitro inflammation cartilage model. 26170448 10 28 gly Glcα-1,4-Gal 1261:1272 arg1 the O-glycan Gal the O-glycan OGER Gal P22466 Besides, the O-glycan was characterized as a Glcα-1,4-Gal disaccharide by mass spectrometry combined with monosaccharide composition analysis and glycosidase treatment. 26154505 6 65 gly EPO 1272:1274 arg1 the total N-glycans EPO the total N-glycans PUBTATOR EPO P01588 Tri- and tetraantennary N-glycans represented approximately 92% of the total N-glycans on the resulting EPO as measured using MS analysis. 26154505 6 71 gly N-glycans 1245:1253 arg1 the resulting EPO EPO N-glycans PUBTATOR EPO P01588 Tri- and tetraantennary N-glycans represented approximately 92% of the total N-glycans on the resulting EPO as measured using MS analysis. 27020775 0 42 gly glycosylation 30:42 arg1 donkey milk lactoferrin donkey milk lactoferrin PUBTATOR lactoferrin P02788 Sequence characterization and glycosylation sites identification of donkey milk lactoferrin by multiple enzyme digestions and mass spectrometry. 26082235 6 22 gly glycoform 1199:1207 arg1 IgG IgG Cterm IgG Then the deglycosylated IgG serves as an acceptor for an endoglycosidase-catalyzed transglycosylation to add a desired N-glycan to the GlcNAc acceptor to reconstitute a defined, homogeneous natural glycoform of IgG, using a glycosynthase mutant as the enzyme and activated glycan oxazoline as the donor substrate. 26082235 6 59 gly deglycosylated 1010:1023 arg1 Then the deglycosylated IgG Then the deglycosylated IgG Cterm IgG Then the deglycosylated IgG serves as an acceptor for an endoglycosidase-catalyzed transglycosylation to add a desired N-glycan to the GlcNAc acceptor to reconstitute a defined, homogeneous natural glycoform of IgG, using a glycosynthase mutant as the enzyme and activated glycan oxazoline as the donor substrate. 29145098 7 2 gly B 1650:1650 arg1 MPDPZ-Boc-Asn-GlcNAc-labeled glycans ribonuclease B MPDPZ-Boc-Asn-GlcNAc-labeled glycans Cterm ribonuclease B Moreover, the QMERSIL using LC-MS/MS was evaluated with various molar ratios (1:1, 1:5, 5:1) of d0(d8)- MPDPZ-Boc-Asn-GlcNAc-labeled glycans from ribonuclease B, bovine fetuin, and ovalbumin. 29145098 7 12 gly ovalbumin 1672:1680 arg1 MPDPZ-Boc-Asn-GlcNAc-labeled glycans ovalbumin MPDPZ-Boc-Asn-GlcNAc-labeled glycans PUBTATOR ovalbumin 522479 Moreover, the QMERSIL using LC-MS/MS was evaluated with various molar ratios (1:1, 1:5, 5:1) of d0(d8)- MPDPZ-Boc-Asn-GlcNAc-labeled glycans from ribonuclease B, bovine fetuin, and ovalbumin. 29119347 0 81 gly alpha-L-iduronidase 86:104 arg1 N-glycan structures alpha-L-iduronidase N-glycan structures PUBTATOR alpha-L-iduronidase 3425 N-glycan structures and downstream mannose-phosphorylation of plant recombinant human alpha-L-iduronidase: toward development of enzyme replacement therapy for mucopolysaccharidosis I. KEY MESSAGE: Arabidopsis N-glycan processing mutants provide the basis for tailoring recombinant enzymes for use as replacement therapeutics to treat lysosomal storage diseases, including N-glycan mannose phosphorylation to ensure lysosomal trafficking and efficacy. 29119347 0 81 gly alpha-L-iduronidase 86:104 arg1 downstream mannose-phosphorylation alpha-L-iduronidase downstream mannose-phosphorylation PUBTATOR alpha-L-iduronidase 3425 N-glycan structures and downstream mannose-phosphorylation of plant recombinant human alpha-L-iduronidase: toward development of enzyme replacement therapy for mucopolysaccharidosis I. KEY MESSAGE: Arabidopsis N-glycan processing mutants provide the basis for tailoring recombinant enzymes for use as replacement therapeutics to treat lysosomal storage diseases, including N-glycan mannose phosphorylation to ensure lysosomal trafficking and efficacy. 28729420 5 18 gly FUT8 1094:1097 arg1 free N-glycans FUT8 free N-glycans PUBTATOR FUT8 2530 Consistent with previous studies, we found that free N-glycans lacking an unmasked α1,3-arm GlcNAc moiety are not FUT8 substrates. 26699903 1 2 gly glycoprotein 174:185 arg1 SCUBE1 SCUBE1 PUBTATOR SCUBE1 (S1) Q8IWY4 SCUBE1 (S1), a secreted and membrane-bound glycoprotein, has a modular protein structure composed of an N-terminal signal peptide sequence followed by nine epidermal growth factor (EGF)-like repeats, a spacer region and three cysteine-rich (CR) motifs with multiple potential N-linked glycosylation sites, and one CUB domain at the C-terminus. 25629924 3 89 gly glycosylation 408:420 arg1 sIgA sIgA Cterm IgA P11912 In this study, the site-specific glycosylation of sIgA isolated from human colostrum (n = 3) was analyzed using a combination of LC-MS and LC-MS/MS and in-house software (Glycopeptide Finder). 28322444 0 63 gly N-glycosylation 53:67 arg1 the potassium channel Kv3.1b the potassium channel Kv3.1b Cterm Kv3.1b Identification and characterization of site-specific N-glycosylation in the potassium channel Kv3.1b. 27867113 3 36 gly hyperglycosylated 508:524 arg1 a hyperglycosylated IFN-α2b mutein a hyperglycosylated IFN-α2b mutein Cterm IFN-α2b mutein 3440 In this work, a hyperglycosylated IFN-α2b mutein (IFN4N) was produced in CHO and HEK cell lines and an extensive characterization of their properties was performed. 27333379 6 40 gly O-glycans 982:990 arg1 recombinant IgA1 IgA1 O-glycans PUBTATOR IgA1 P01876 Recently, we demonstrated that Nicotiana benthamiana are suitable for the generation of distinct O-glycans on recombinant IgA1. 25499076 0 79 gly glycosylated 105:116 arg1 recombinant and pituitary glycosylated human prolactin recombinant and pituitary glycosylated human prolactin PUBTATOR prolactin 5617 N-glycoprofiling analysis in a simple glycoprotein model: a comparison between recombinant and pituitary glycosylated human prolactin. 26492619 10 35 gly O-glycosylated 1386:1399 arg1 PDPN PDPN PUBTATOR PDPN 10630 By using monoclonal antibodies against different Ser/Thr, including epitopes of PDPN, it becomes possible to determine whether Ser/Thr residues of PDPN are O-glycosylated. 25187161 7 47 gly TCRδ 1205:1208 arg1 the sialylated Tn antigen TCRδ( the sialylated Tn antigen PUBTATOR TCRδ( 110066 There were significant differences in the sialylated species between the TCRδ(-/-) and WT mice with the sialylated Tn antigen found exclusively in the TCRδ(-/-)small intestine, whereas the sulfation pattern remained mostly unchanged. 27550041 1 2 gly lactoferrin 181:191 arg1 the N-glycans lactoferrin the N-glycans PUBTATOR lactoferrin 280846 A comprehensive monosaccharide composition of the N-glycans of donkey milk lactoferrin, isolated by ion exchange chromatography from an individual milk sample, was obtained by means of chymotryptic digestion, TiO2 and HILIC enrichment, reversed-phase high-performance liquid chromatography, electrospray mass spectrometry, and high collision dissociation fragmentation. 26701617 9 21 gly glycosylated 1463:1474 arg1 glycosylated PDGF-BB glycosylated PDGF-BB OGER PDGF Furthermore, antiserum against PDGF-BBΔGly also recognized glycosylated PDGF-BB, indicating that protein immunogenicity was unaltered by glycosylation. 27124023 3 30 gly IgG 766:768 arg1 digalactosylated glycans IgG digalactosylated glycans Cterm IgG A hydrophilic interaction chromatography of fluorescently labeled glycans was used to analyze N-glycans attached to IgG in plasma samples from a total of 4757 individuals of Chinese Han, Croatian, and Scottish ethnicity.Five glycans (IgG with digalactosylated glycans) significantly differed in participants with prehypertension or hypertension compared to those with normal blood pressure, while additional 17 glycan traits were only significantly differed in participants with hypertension compared to those of normal blood pressure. 27124023 3 60 gly attached 636:643 arg1 IgG AND N-glycans IgG N-glycans Cterm IgG A hydrophilic interaction chromatography of fluorescently labeled glycans was used to analyze N-glycans attached to IgG in plasma samples from a total of 4757 individuals of Chinese Han, Croatian, and Scottish ethnicity.Five glycans (IgG with digalactosylated glycans) significantly differed in participants with prehypertension or hypertension compared to those with normal blood pressure, while additional 17 glycan traits were only significantly differed in participants with hypertension compared to those of normal blood pressure. 26916835 4 46 gly contained 551:559 arg1 RESULTS GC-SPI AND glucosamine RESULTS GC-SPI glucosamine OGER SPI P10645 RESULTS GC-SPI contained glucosamine of 13.6 g kg-1 protein, but less reactable &bond;NH2 than SPI (0.42 vs. 0.50 mol kg-1 protein). 28880909 10 13 gly observed 1779:1786 arg1 Bemfola AND A different glycan profile Bemfola A different glycan profile Cterm Bemfola A different glycan profile was observed at Asn52 in Bemfola compared with GONAL-f (a lower proportion of bi-antennary structures [~53% vs ~77%], and a higher proportion of tri-antennary [~41% vs ~23%] and tetra-antennary structures [~5% vs <1%]). 26240146 4 12 gly glycoforms 668:677 arg1 different hCG glycoforms different hCG glycoforms OGER hCG Here, we report a hydrogen/deuterium exchange and MS approach to investigate the effect of N-glycosylation on the binding of antibodies against different hCG glycoforms. 24799124 1 18 gly ceruloplasmin 212:224 arg1 core-fucosylation ceruloplasmin core-fucosylation PUBTATOR ceruloplasmin 1356 A mass spectrometry-based methodology has been developed to study changes in core-fucosylation of serum ceruloplasmin that are site-specific between cirrhosis and hepatocellular carcinoma (HCC). 24799124 1 48 gly core-fucosylation 185:201 arg1 serum ceruloplasmin serum ceruloplasmin PUBTATOR ceruloplasmin 1356 A mass spectrometry-based methodology has been developed to study changes in core-fucosylation of serum ceruloplasmin that are site-specific between cirrhosis and hepatocellular carcinoma (HCC). 24130173 4 3 gly BChE 637:640 arg1 Site-specific sugar profiling BChE Site-specific sugar profiling OGER BChE P06276 Site-specific sugar profiling of secreted recombinant BChE (rBChE) collected from the intercellular fluid revealed the presence of mono- and di-sialylated N-glycans, which largely resembles to the plasma-derived orthologue. 26701617 10 80 gly glycosylation 1595:1607 arg1 PDGF-BB structure PDGF-BB structure OGER PDGF These findings elucidate the effect of glycosylation on PDGF-BB structure and biological activity, and can potentially contribute to the design and production of homogeneously expressed unglycosylated or human-type glycosylated PDGF-BB in P. pastoris for pharmaceutical applications. 28680094 5 47 gly interface 709:717 arg1 β3-N320 3 interface PUBTATOR 3 1934 We found that the N-glycan site, β3-N320 at the headpiece and leg domain interface positively regulates αIIbβ3 but not αVβ3 activation. 28680094 5 73 gly headpiece 684:692 arg1 β3-N320 3 headpiece PUBTATOR 3 1934 We found that the N-glycan site, β3-N320 at the headpiece and leg domain interface positively regulates αIIbβ3 but not αVβ3 activation. 27020775 6 29 gly glycans 1109:1115 arg1 donkey lactoferrin lactoferrin glycans PUBTATOR lactoferrin P02788 Analysis of the glycosylated protein showed that glycans in donkey lactoferrin are linked to the protein backbone via an amide bond to asparagine residues located at the positions 137, 281 and 476. 29212317 6 32 gly glycoproteins 959:971 arg1 alpha 1 antitrypsin alpha 1 antitrypsin PUBTATOR alpha 1 antitrypsin 5265 Apolipoprotein CIII, fetuin A, and alpha 1 antitrypsin are glycoproteins associated with lipoproteins and are implicated in many cardiovascular and other disease conditions. 29212317 6 32 gly glycoproteins 959:971 arg1 Apolipoprotein CIII Apolipoprotein CIII PUBTATOR Apolipoprotein CIII 345 Apolipoprotein CIII, fetuin A, and alpha 1 antitrypsin are glycoproteins associated with lipoproteins and are implicated in many cardiovascular and other disease conditions. 29212317 6 32 gly glycoproteins 959:971 arg1 fetuin A fetuin A PUBTATOR fetuin A 197 Apolipoprotein CIII, fetuin A, and alpha 1 antitrypsin are glycoproteins associated with lipoproteins and are implicated in many cardiovascular and other disease conditions. 25040827 2 30 gly N-glycosylated 441:454 arg1 N-glycosylated PTTH N-glycosylated PTTH PUBTATOR N-glycosylated PTTH 692767 An ecdysis progression assay demonstrated that N-glycosylated PTTH exhibited a slightly higher activity than the recombinant PTTH without N-glycosylation produced by an Escherichia coli expression system. 26567221 4 46 gly N-glycosylated 645:658 arg1 HMGB1 HMGB1 PUBTATOR HMGB1 3146 We found two consensus (N37 and N134) and one non-consensus (N135) residues that were N-glycosylated in HMGB1 by performing liquid chromatography tandem mass spectrometry (LC-MS/MS) and analyzing for N-glycan composition and structure. 25253346 1 27 gly glycoprotein 175:186 arg1 HIV-1 surface envelope glycoprotein envelope glycoprotein PUBTATOR envelope glycoprotein 100616444 The HIV-1 surface envelope glycoprotein (Env) trimer mediates entry into CD4(+) CCR5(+) host cells. 25629924 0 30 gly glycosylation 14:26 arg1 secretory immunoglobulin A secretory immunoglobulin A Cterm secretory immunoglobulin A Site-specific glycosylation of secretory immunoglobulin A from human colostrum. 26993603 0 54 part_of Asn144 24:29 arg1 GP73 N-glycosylation GP73 N-glycosylation Asn144 PUBTATOR AminoAcid GP73 N-glycosylation 51280 Asn144 GP73 N-glycosylation at Asn144 reduces hepatocellular carcinoma cell motility and invasiveness. 27867113 0 45 gly hyperglycosylated 48:64 arg1 hyperglycosylated IFN-α2 hyperglycosylated IFN-α2 PUBTATOR IFN-α2 3440 Glycosylation and antiproliferative activity of hyperglycosylated IFN-α2 potentiate HEK293 cells as biofactories. 27867113 0 79 gly Glycosylation 0:12 arg1 hyperglycosylated IFN-α2 hyperglycosylated IFN-α2 PUBTATOR IFN-α2 3440 Glycosylation and antiproliferative activity of hyperglycosylated IFN-α2 potentiate HEK293 cells as biofactories. 26908049 9 12 gly glycosylation 1397:1409 arg1 ART ART PUBTATOR ART 9048 In contrast, differences in thermal and colloidal stability clearly revealed a role of glycosylation in increasing the solubility and stability of ART. 28509333 3 20 gly fucosylated 512:522 arg1 LCA LCA OGER LCA P08575 Lectins capturing fucosyl residues (AAL), fucosylated tri-mannose N-glycan core sites (LCA), terminal sialic acid residues (SNA) and O-glycosidically linked galactose/N-acetylgalactosamine (GalNac-L) were used. 29273683 7 31 gly glycosylated 723:734 arg1 human CBG human CBG PUBTATOR CBG 866 Deglycosylation of fully glycosylated human CBG or human CBG with only one N-glycan at N238 with Endo H-reduced steroid-binding affinity, while PNGase F-mediated deglycosylation does not, indicating that steroid binding is preserved by deamidation of N238 when its N-glycan is removed. 29273683 7 51 gly Deglycosylation 698:712 arg1 human CBG CBG PUBTATOR CBG 866 Deglycosylation of fully glycosylated human CBG or human CBG with only one N-glycan at N238 with Endo H-reduced steroid-binding affinity, while PNGase F-mediated deglycosylation does not, indicating that steroid binding is preserved by deamidation of N238 when its N-glycan is removed. 24575722 7 27 gly fucosylated 1384:1394 arg1 fucosylated haptoglobin fucosylated haptoglobin PUBTATOR haptoglobin 3240 In differentiating early-stage ovarian cancer from noncases, fucosylated haptoglobin showed comparable performance to CA125. 28920453 1 35 gly Glycosylation 139:151 arg1 rhEPOs rhEPOs Cterm rhEPOs AIM: Glycosylation of recombinant human erythropoietins (rhEPOs) is significantly associated with drug's quality and potency. 28920453 1 35 gly Glycosylation 139:151 arg1 recombinant human erythropoietins recombinant human erythropoietins Cterm erythropoietins AIM: Glycosylation of recombinant human erythropoietins (rhEPOs) is significantly associated with drug's quality and potency. 25142936 4 21 gly structures 664:673 arg1 brain s-eNPP6 eNPP6 structures PUBTATOR eNPP6 537431 In brain s-eNPP6 the N-glycans are mainly hybrid and high mannose type structures, reminiscent of processed mannose-6-phosphorylated glycans. 26382581 5 91 gly found 1213:1217 arg1 rFVII AND Most N-glycans rFVII Most N-glycans Cterm rFVII P08709 Most N-glycans found on rFVII produced in HEK293 cells were not detected on rFVII from CHO and BHK cells, or, somewhat unexpectedly, on pdFVII; all other protein features were similar. 27235585 5 16 gly glycoprotein 857:868 arg1 native human transferrin native human transferrin PUBTATOR transferrin 7018 In addition, native human transferrin is a glycoprotein that two N-linked complex glycan chains located in the C-lobe. 26869352 8 88 gly released 1379:1386 arg1 haptoglobin AND N-glycan alditols haptoglobin N-glycan alditols PUBTATOR haptoglobin 3240 We next analyzed N-glycan alditols released from haptoglobin using graphitized carbon column LC-ESI MS to identify the linkage of fucosylation. 24941220 4 92 gly glycopeptides 621:633 arg1 virion-associated gp120 virion-associated gp120 PUBTATOR gp120 3700 This challenge promoted us to employ a Q-Exactive mass spectrometer to identify low abundant glycopeptides from virion-associated gp120. 28400175 8 89 gly IgE 1100:1102 arg1 the glycan diversity IgE the glycan diversity OGER IgE P01854 This contrasts with the glycan diversity of HEK cell-derived IgE, carrying at least 20 different glycoforms. 28444691 3 27 gly undersialylated 384:398 arg1 apoC-III apoC-III PUBTATOR apoC-III 345 In COG-CDG, isoelectric focusing separation of undersialylated glycoforms of serum transferrin and apolipoprotein C-III (apoC-III) allows to detect N-glycosylation and O-glycosylation defects, respectively. 28444691 3 27 gly undersialylated 384:398 arg1 serum transferrin serum transferrin OGER transferrin P02787 In COG-CDG, isoelectric focusing separation of undersialylated glycoforms of serum transferrin and apolipoprotein C-III (apoC-III) allows to detect N-glycosylation and O-glycosylation defects, respectively. 28444691 3 27 gly undersialylated 384:398 arg1 apolipoprotein C-III apolipoprotein C-III PUBTATOR apolipoprotein C-III 345 In COG-CDG, isoelectric focusing separation of undersialylated glycoforms of serum transferrin and apolipoprotein C-III (apoC-III) allows to detect N-glycosylation and O-glycosylation defects, respectively. 28444691 3 32 gly transferrin 420:430 arg1 undersialylated glycoforms transferrin undersialylated glycoforms OGER transferrin P02787 In COG-CDG, isoelectric focusing separation of undersialylated glycoforms of serum transferrin and apolipoprotein C-III (apoC-III) allows to detect N-glycosylation and O-glycosylation defects, respectively. 28444691 3 77 gly glycoforms 400:409 arg1 apoC-III apoC-III PUBTATOR apoC-III 345 In COG-CDG, isoelectric focusing separation of undersialylated glycoforms of serum transferrin and apolipoprotein C-III (apoC-III) allows to detect N-glycosylation and O-glycosylation defects, respectively. 28444691 3 77 gly glycoforms 400:409 arg1 serum transferrin serum transferrin OGER transferrin P02787 In COG-CDG, isoelectric focusing separation of undersialylated glycoforms of serum transferrin and apolipoprotein C-III (apoC-III) allows to detect N-glycosylation and O-glycosylation defects, respectively. 28444691 3 77 gly glycoforms 400:409 arg1 apolipoprotein C-III apolipoprotein C-III PUBTATOR apolipoprotein C-III 345 In COG-CDG, isoelectric focusing separation of undersialylated glycoforms of serum transferrin and apolipoprotein C-III (apoC-III) allows to detect N-glycosylation and O-glycosylation defects, respectively. 28444691 3 84 gly C-III 451:455 arg1 undersialylated glycoforms apolipoprotein C-III undersialylated glycoforms PUBTATOR apolipoprotein C-III 345 In COG-CDG, isoelectric focusing separation of undersialylated glycoforms of serum transferrin and apolipoprotein C-III (apoC-III) allows to detect N-glycosylation and O-glycosylation defects, respectively. 28104755 8 50 gly deglycosylation 1210:1224 arg1 purified recombinant SMPDL3A purified recombinant SMPDL3A PUBTATOR SMPDL3A 10924 Enzymatic deglycosylation of purified recombinant SMPDL3A also resulted in significant loss of phosphodiesterase activity. 27574189 2 17 gly ADAMTS13 254:261 arg1 the glycan composition ADAMTS13 the glycan composition PUBTATOR ADAMTS13 11093 Here, we studied the glycan composition of plasma-derived ADAMTS13. 24233973 7 12 gly sialylated 1369:1378 arg1 clone C-P55 clone C-P55 OGER P55 P19438 The H5 hemagglutinin binds with similar strength to PSGL-1/mIgG(2b) carrying mostly sialylated core 1 (clone C-P55), a mix of sialylated core 1 and sialylated lactosamine (clone 293-P) or mainly sialylated lactosamine (clone C-PSLex) O-glycans, indicating that this hemagglutinin is unable to discriminate between these structures.The potential use of the large, flexible PSGL-1/mIgG(2b) mucin-type fusion protein carrying Siaα2-3Gal as a multivalent inhibitor of influenza virus is discussed. 24233973 7 23 gly carrying 1353:1360 arg1 PSGL-1/mIgG AND mostly sialylated core 1 PSGL-1/mIgG mostly sialylated core 1 PUBTATOR PSGL-1 6404 The H5 hemagglutinin binds with similar strength to PSGL-1/mIgG(2b) carrying mostly sialylated core 1 (clone C-P55), a mix of sialylated core 1 and sialylated lactosamine (clone 293-P) or mainly sialylated lactosamine (clone C-PSLex) O-glycans, indicating that this hemagglutinin is unable to discriminate between these structures.The potential use of the large, flexible PSGL-1/mIgG(2b) mucin-type fusion protein carrying Siaα2-3Gal as a multivalent inhibitor of influenza virus is discussed. 24233973 7 23 gly carrying 1353:1360 arg1 PSGL-1/mIgG AND sialylated lactosamine (clone 293-P) or mainly sialylated lactosamine (clone C-PSLex) O-glycans PSGL-1/mIgG sialylated lactosamine (clone 293-P) or mainly sialylated lactosamine (clone C-PSLex) O-glycans PUBTATOR PSGL-1 6404 The H5 hemagglutinin binds with similar strength to PSGL-1/mIgG(2b) carrying mostly sialylated core 1 (clone C-P55), a mix of sialylated core 1 and sialylated lactosamine (clone 293-P) or mainly sialylated lactosamine (clone C-PSLex) O-glycans, indicating that this hemagglutinin is unable to discriminate between these structures.The potential use of the large, flexible PSGL-1/mIgG(2b) mucin-type fusion protein carrying Siaα2-3Gal as a multivalent inhibitor of influenza virus is discussed. 28301166 10 86 gly glycosylation 1802:1814 arg1 pigs pigs OGER pigs Q96S52 Therefore, we conclude that B. hyodysenteriae plays a major role in regulating colonic mucin glycosylation in pigs during SD. 24403418 10 82 gly glycosylation 1535:1547 arg1 hERG channel hERG channel PUBTATOR hERG channel 2078 In addition, the patterns of derived electrocardiogram show that reduced glycosylation of hERG channel shortens the QT interval and decreases the re-entry rate of spiral waves. 28104755 1 34 gly glycoprotein 260:271 arg1 Sphingomyelin phosphodiesterase acid-like 3A Sphingomyelin phosphodiesterase acid-like 3A PUBTATOR Sphingomyelin phosphodiesterase acid-like 3A 10924 Sphingomyelin phosphodiesterase acid-like 3A (SMPDL3A) is a recently identified phosphodiesterase, which is a secreted N-linked glycoprotein. 26850169 5 62 gly fucosylated 878:888 arg1 fucosylated Fc fucosylated Fc Cterm Fc For example, Fc regions with afucosylated glycans bind more tightly to FcγRIIIa than fucosylated Fc, and afucosylated Fcs exhibit enhanced ADCC activity in vivo and in vitro. 24820161 6 52 gly C-mannosylated 948:961 arg1 secreted HYAL1 secreted HYAL1 PUBTATOR HYAL1 3373 Surprisingly, although HYAL1 was secreted into conditioned medium and it possessed enzymatic activity, secreted HYAL1 was not C-mannosylated. 26956484 10 22 gly glycosylation 1429:1441 arg1 Orai1 Orai1 PUBTATOR Orai1 84876 In summary, the glycosylation state of Orai1 influences SOCE-mediated Ca(2+) signaling and, thus, may contribute to pathophysiological Ca(2+) signaling observed in immune disease and cancer. 26657071 4 10 gly glycosylated 662:673 arg1 glycosylated hCES1 glycosylated hCES1 PUBTATOR hCES1 1066 The purified aglycosylated enzyme was found to be more active than glycosylated hCES1 and analysis of enzyme kinetics revealed that both enzymes exhibit positive cooperativity. 24692304 3 23 gly glycosylated 349:360 arg1 glycosylated Ser-CCL1 glycosylated Ser-CCL1 PUBTATOR AminoAcid CCL1 6346 We used glycosylated Ser-CCL1 that had been prepared by total chemical synthesis as a homogeneous compound containing an N-linked asialo biantennary nonasaccharide glycan moiety of defined covalent structure. 28482115 3 13 gly N-glycosylated 559:572 arg1 FLA4 FLA4 PUBTATOR FLA4 823808 FLA4 is likely to be GPI-anchored, is highly N-glycosylated and carries two O-glycan epitopes previously associated with arabinogalactan proteins. 28482115 3 17 gly carries 578:584 arg1 FLA4 AND two O-glycan epitopes FLA4 two O-glycan epitopes PUBTATOR FLA4 823808 FLA4 is likely to be GPI-anchored, is highly N-glycosylated and carries two O-glycan epitopes previously associated with arabinogalactan proteins. 28230186 2 7 gly glycosylated 257:268 arg1 Human IgM Human IgM PUBTATOR Human IgM P01871 Human IgM is heavily glycosylated, featuring five N-linked glycan sites on the μ chain and one on the J-chain. 26154505 3 11 gly content 692:698 arg1 EPO EPO content PUBTATOR EPO P01588 Sialylation increased on both EPO and CHO cellular proteins as observed by SNA lectin analysis, and HPLC profiling revealed that the sialic acid content of total glycans on EPO increased by 26%. 26154505 3 51 gly glycans 709:715 arg1 EPO EPO glycans PUBTATOR EPO P01588 Sialylation increased on both EPO and CHO cellular proteins as observed by SNA lectin analysis, and HPLC profiling revealed that the sialic acid content of total glycans on EPO increased by 26%. 26154505 3 73 gly EPO 720:722 arg1 the sialic acid content EPO the sialic acid content PUBTATOR EPO P01588 Sialylation increased on both EPO and CHO cellular proteins as observed by SNA lectin analysis, and HPLC profiling revealed that the sialic acid content of total glycans on EPO increased by 26%. 28322444 3 20 gly unglycosylated 495:508 arg1 N220-glycosylated and unglycosylated Kv3.1b N220-glycosylated and unglycosylated Kv3.1b Cterm Kv3.1b Large quantities of asparagine 229 (N229)-glycosylated Kv3.1b reached the plasma membrane, whereas N220-glycosylated and unglycosylated Kv3.1b were mainly retained in the endoplasmic reticulum (ER). 28322444 3 33 gly N220-glycosylated 473:489 arg1 N220-glycosylated and unglycosylated Kv3.1b N220-glycosylated and unglycosylated Kv3.1b Cterm Kv3.1b Large quantities of asparagine 229 (N229)-glycosylated Kv3.1b reached the plasma membrane, whereas N220-glycosylated and unglycosylated Kv3.1b were mainly retained in the endoplasmic reticulum (ER). 28322444 3 51 gly -glycosylated 415:427 arg1 asparagine 229 (N229)-glycosylated Kv3.1b asparagine 229 (N229)-glycosylated Kv3.1b Cterm Kv3.1b Large quantities of asparagine 229 (N229)-glycosylated Kv3.1b reached the plasma membrane, whereas N220-glycosylated and unglycosylated Kv3.1b were mainly retained in the endoplasmic reticulum (ER). 28576848 6 84 gly FcγRI 1302:1306 arg1 The glycan profiles FcγRI The glycan profiles PUBTATOR FcγRI 14129 The glycan profiles of CHO expressed FcγRI and FcγRIIIaPhe158/Val158 were compared with the glycan profiles of the receptors expressed in NS0 and HEK293 cells and we show that the glycan type and abundance differs significantly between the receptors and that these glycan differences lead to the observed differences in the respective FcγR binding patterns with rituximab. 24632142 5 32 gly glycosylated 913:924 arg1 recombinantly-expressed human aspartoacylase recombinantly-expressed human aspartoacylase OGER aspartoacylase P45381 A more extensive study specifically designed to resolve this discrepancy has now shown that recombinantly-expressed human aspartoacylase is not glycosylated, but is still fully functional and stable even when produced from a bacterial expression system. 25458834 0 11 gly O-glycosylated 61:74 arg1 O-glycosylated podoplanin O-glycosylated podoplanin PUBTATOR podoplanin 10630 A platform of C-type lectin-like receptor CLEC-2 for binding O-glycosylated podoplanin and nonglycosylated rhodocytin. 28052259 0 10 gly N-glycosylation 62:76 arg1 the Wnt Antagonist Dkk1 the Wnt Antagonist Dkk1 PUBTATOR Dkk1 22943 Conformational Freedom of the LRP6 Ectodomain Is Regulated by N-glycosylation and the Binding of the Wnt Antagonist Dkk1. 26567221 3 58 gly N-glycosylation 506:520 arg1 HMGB1 HMGB1 PUBTATOR HMGB1 3146 Here, we identified the role of N-glycosylation of HMGB1 in extracellular secretion. 27653286 4 13 gly glycosylated 754:765 arg1 glycosylated Robo1 Robo1 OGER Robo1 Q9Y6N7 Here, we apply an alternative methodology, based on labeling with a single amino acid type and high structural content NMR data, to characterize a two-domain construct of glycosylated Robo1 (Robo1-Ig1-2) interacting with a synthetic HS tetramer (IdoA-GlcNS6S-IdoA2S-GlcNS6S-(CH2)5NH2). 27938679 1 23 gly glycoproteins 283:295 arg1 TM TM Cterm TM The bovine leukaemia virus (BLV) envelope protein (Env) is synthesized as a polyprotein precursor (gp72) proteolytically cleaved into the mature surface (SU) and transmembrane (TM) glycoproteins. 28167607 4 15 gly contains 491:498 arg1 Wild-type (WT) integrin α5 and N-glycosylation mutant S3-5 (sites 3 to 5) integrin α5 AND fewer N-glycans Wild-type (WT) integrin α5 and N-glycosylation mutant S3-5 (sites 3 to 5) integrin α5 fewer N-glycans PUBTATOR 5) integrin α5 Wild-type (WT) integrin α5 and N-glycosylation mutant S3-5 (sites 3 to 5) integrin α5, which contains fewer N-glycans, were stably reconstituted in α5 knockout cancer cells. 24820161 0 19 gly hyaluronidase 25:37 arg1 C-mannosylation hyaluronidase 1 C-mannosylation PUBTATOR hyaluronidase 1 3373 C-mannosylation of human hyaluronidase 1: possible roles for secretion and enzymatic activity. 24820161 0 30 gly C-mannosylation 0:14 arg1 human hyaluronidase 1 human hyaluronidase 1 PUBTATOR hyaluronidase 1 3373 C-mannosylation of human hyaluronidase 1: possible roles for secretion and enzymatic activity. 24308486 0 39 gly N-glycosylation 14:28 arg1 IgE IgE PUBTATOR IgE P01854 Site-specific N-glycosylation analysis of human immunoglobulin e. Immunoglobulin E (IgE) is a heterodimeric glycoprotein involved in antiparasitic and allergic immune reactions. 24308486 0 39 gly N-glycosylation 14:28 arg1 human immunoglobulin e. Immunoglobulin E human immunoglobulin e. Immunoglobulin E OGER Immunoglobulin E P01854 Site-specific N-glycosylation analysis of human immunoglobulin e. Immunoglobulin E (IgE) is a heterodimeric glycoprotein involved in antiparasitic and allergic immune reactions. 24308457 5 67 gly sialylation 1069:1079 arg1 transforming growth factor-beta transforming growth factor-beta PUBTATOR transforming growth factor-beta receptor type I 7046 We demonstrated the capability of this cis-membrane FRET imaging method by visualizing the sialylation of several important cell surface receptors including integrin αXβ2, epidermal growth factor receptor, and transforming growth factor-beta receptor type I. Furthermore, our imaging experiments revealed that the sialylation might be important for β2 integrin activation. 24308457 5 67 gly sialylation 1069:1079 arg1 epidermal growth factor receptor αXβ2, epidermal growth factor receptor PUBTATOR αXβ2, epidermal growth factor receptor 1956 We demonstrated the capability of this cis-membrane FRET imaging method by visualizing the sialylation of several important cell surface receptors including integrin αXβ2, epidermal growth factor receptor, and transforming growth factor-beta receptor type I. Furthermore, our imaging experiments revealed that the sialylation might be important for β2 integrin activation. 28400175 3 104 gly N-glycosylation 442:456 arg1 recombinant IgE recombinant IgE OGER IgE P01854 Here, we present the expression of recombinant IgE in wild type and glycan-engineered Nicotiana benthamiana plants and in-depth N-glycosylation analyses. 26328495 3 49 gly O-glycosylated 447:460 arg1 POMGNT1 POMGNT1 PUBTATOR POMGNT1 55624 To determine whether POMGNT1 is O-glycosylated, we prepared recombinant human POMGNT1 from HEK293T cells. 27439567 0 43 gly fucosylation 69:80 arg1 alpha-1-antitrypsin alpha-1-antitrypsin fucosylation OGER alpha-1-antitrypsin P01009 A procedure for the analysis of site-specific and structure-specific fucosylation in alpha-1-antitrypsin. 28167607 1 69 gly N-glycosylation 144:158 arg1 integrin α5β1 integrin α5β1 PUBTATOR integrin α5 The N-glycosylation of integrin α5β1 is thought to control many fundamental aspects of cell behavior, including cell adhesion and migration. 25927005 7 15 gly N-glycosylation 1040:1054 arg1 HCV protein E2 HCV protein E2 Cterm E2 In order to investigate these processes, point mutations of the N-glycosylation sites of HCV protein E2 (genotype 1b strain 274933RU) were generated and the mutant proteins were further analyzed in the baculovirus expression system. 28575723 3 2 gly linked 403:408 arg1 Cha o 3 AND N -glycans Cha o 3 N -glycans OGER Cha o 3 Q9UL49 However, the structures of N -glycans linked to Cha o 3 remain to be determined. 29273683 3 75 gly Glycosylation 205:217 arg1 human CBG human CBG PUBTATOR CBG 866 Glycosylation of human CBG influences its steroid-binding activity, and there are N-glycosylation sites in the reactive center loops (RCLs) of human and rat CBGs. 25628020 4 24 part_of Asn-76 821:826 arg1 thyroglobulin thyroglobulin Asn-76 PUBTATOR SpecificSite thyroglobulin 7038 Asn-76 Three of them, Asn-196 in adipocyte plasma membrane-associated protein (APMAP), Asn-91 in cluster of differentiation 166 (CD166/ALCAM), and Asn-76 in thyroglobulin, are human-specific. 25628020 4 33 part_of Asn-91 761:766 arg1 thyroglobulin thyroglobulin Asn-91 PUBTATOR SpecificSite thyroglobulin 7038 Asn-91 Three of them, Asn-196 in adipocyte plasma membrane-associated protein (APMAP), Asn-91 in cluster of differentiation 166 (CD166/ALCAM), and Asn-76 in thyroglobulin, are human-specific. 25628020 4 73 part_of Asn-196 696:702 arg1 adipocyte plasma membrane-associated protein adipocyte plasma membrane-associated protein Asn-196 PUBTATOR SpecificSite adipocyte plasma membrane-associated protein 57136 Asn-196 Three of them, Asn-196 in adipocyte plasma membrane-associated protein (APMAP), Asn-91 in cluster of differentiation 166 (CD166/ALCAM), and Asn-76 in thyroglobulin, are human-specific. 25628020 4 73 part_of Asn-196 696:702 arg1 APMAP APMAP Asn-196 PUBTATOR SpecificSite APMAP 57136 Asn-196 Three of them, Asn-196 in adipocyte plasma membrane-associated protein (APMAP), Asn-91 in cluster of differentiation 166 (CD166/ALCAM), and Asn-76 in thyroglobulin, are human-specific. 28880909 6 56 gly had 1127:1129 arg1 Bemfola AND greater sialylation Bemfola greater sialylation Cterm Overall, Bemfola Overall, Bemfola had bulkier glycan structures and greater sialylation than GONAL-f. 28880909 6 56 gly had 1127:1129 arg1 Bemfola AND bulkier glycan structures Bemfola bulkier glycan structures Cterm Overall, Bemfola Overall, Bemfola had bulkier glycan structures and greater sialylation than GONAL-f. 27206480 1 28 gly glycosylation 142:154 arg1 the flagellin protein the flagellin protein PUBTATOR flagellin protein 29373638 BACKGROUND Post-translational glycosylation of the flagellin protein is relatively common among Gram-negative bacteria, and has been linked to several phenotypes, including flagellar biosynthesis and motility, biofilm formation, host immune evasion and manipulation and virulence. 25230686 0 30 gly -acetylglucosaminyltransferase 30:59 arg1 the key determinant N -acetylglucosaminyltransferase I the key determinant OGER N -acetylglucosaminyltransferase I Q8N0V5 The transmembrane domain of N -acetylglucosaminyltransferase I is the key determinant for its Golgi subcompartmentation. 28122822 8 33 gly O-glycosylated 1076:1089 arg1 Muc2 Muc2 PUBTATOR Muc2 Q02817 As Muc2 is the main O-glycosylated product in mucus, we made the simplified assumption that most of the glycosyltransferases found in the epithelial cells are involved in Muc2 O-glycan biosynthesis. 27493216 6 16 gly POMGnT1 1452:1458 arg1 O-mannosyl glycan POMGnT1 O-mannosyl glycan PUBTATOR POMGnT1 55624 Unexpectedly, we found that the stem domain recognizes the β-linked GlcNAc of O-mannosyl glycan, an enzymatic product of POMGnT1. 24828077 1 59 gly glycan 224:229 arg1 HIV Env HIV Env glycan PUBTATOR HIV Env 100616444 Broadly neutralizing monoclonal antibodies (bnmAbs) that target the high-mannose patch centered around the glycan at position 332 on HIV Env are promising vaccine leads and therapeutic candidates because they effectively protect against mucosal SHIV challenge and strongly suppress SHIV viremia in established infection in macaque models. 26993603 3 7 part_of GP73 560:563 arg1 Asn144 GP73 Asn109, Asn144 and Asn398 PUBTATOR AminoAcid GP73 51280 Asn109, Asn144 and Asn398 We identified three GP73 N-glycosylation sites: Asn109, Asn144 and Asn398. 26993603 3 7 part_of GP73 560:563 arg1 Asn109 GP73 Asn109, Asn144 and Asn398 PUBTATOR AminoAcid GP73 51280 Asn109, Asn144 and Asn398 We identified three GP73 N-glycosylation sites: Asn109, Asn144 and Asn398. 26993603 3 7 part_of GP73 560:563 arg1 Asn109 GP73 Asn109, Asn144 and Asn398 PUBTATOR AminoAcid GP73 51280 Asn109, Asn144 and Asn398 We identified three GP73 N-glycosylation sites: Asn109, Asn144 and Asn398. 26631508 4 18 gly glycosylated 677:688 arg1 MUC7 MUC7 PUBTATOR MUC7 4589 Saliva is a complicated biological fluid with major constituents, including heavily glycosylated mucins MUC5B and MUC7, important for its viscoelastic and hydrating and lubricating properties. 26631508 4 18 gly glycosylated 677:688 arg1 MUC5B MUC5B PUBTATOR MUC5B 727897 Saliva is a complicated biological fluid with major constituents, including heavily glycosylated mucins MUC5B and MUC7, important for its viscoelastic and hydrating and lubricating properties. 27705835 1 20 gly glycosylated 279:290 arg1 Cry Cry OGER Cry Q9Y2S2 The Japanese cedar pollen allergen (Cry j1) and the mountain cedar pollen allergen (Jun a1) are glycosylated with plant complex type N-glycans bearing Lewis a epitope(s) (Galβ1-3[Fucα1-4]GlcNAc-). 28955811 4 67 gly non-glycosylated 708:723 arg1 a secreted form a secreted form PUBTATOR form of hCES2 8824 Partial or non-glycosylated forms of a secreted form of hCES2 have been obtained by three approaches: (i) enzymatic deglycosylation with peptide N-glycosidase F; (ii) incubation with the inhibitor tunicamycin; ii) site directed mutagenesis of each or both N-glycosylation sites. 27604319 4 0 gly glycosylation 713:725 arg1 gp120 gp120 PUBTATOR gp120 Q14624 Knowing the site-specific glycosylation of gp120 can facilitate the rational design of glycopeptide antigens for HIV vaccine development. 29268168 6 43 gly IgG 965:967 arg1 increased galactose IgG increased galactose PUBTATOR IgG 16059 However, unlike hFcγRIIIa, mFcγRIV did not bind more avidly to IgG with increased galactose and reduced fucose. 29268168 6 43 gly IgG 965:967 arg1 reduced fucose IgG reduced fucose PUBTATOR IgG 16059 However, unlike hFcγRIIIa, mFcγRIV did not bind more avidly to IgG with increased galactose and reduced fucose. 29268168 5 10 gly N162-glycan 777:787 arg1 mFcγRIV FcγRIV N162-glycan PUBTATOR FcγRIV 246256 The N162-glycan in mFcγRIV was also responsible for enhancing the binding to mouse IgG with reduced fucose similar to hFcγRIIIa. 25369125 9 10 gly Galectin-3 1199:1208 arg1 the glycan-dependent self-association Galectin-3 the glycan-dependent self-association PUBTATOR Galectin-3 3958 We propose that LNnT induces a release of the N-terminal domain resulting in the glycan-dependent self-association of Galectin-3 through N-terminal domain interactions. 27641064 0 32 gly N-Glycosylation 0:14 arg1 integrin α5 integrin α5 PUBTATOR integrin α5 3678 N-Glycosylation of integrin α5 acts as a switch for EGFR-mediated complex formation of integrin α5β1 to α6β4. 26812091 6 10 gly predominant 1025:1035 arg1 the uhFSH AND macro-heterogeneity glycans the uhFSH macro-heterogeneity glycans OGER hFSH Results showed that highly sialylated, branched, and macro-heterogeneity glycans are predominant in the uhFSH compared with those in rhFSH. 24327294 5 42 gly glycosylated 844:855 arg1 glycosylated human BChE glycosylated human BChE PUBTATOR BChE 590 In this study, we built a three-dimensional (3D) model of glycosylated human BChE to investigate the influence of glycans on the PEGylation modification. 26576925 6 8 gly desialylated 858:869 arg1 C C Cterm C 19122 However, when partially desialylated PrP(C) was used as a substrate, recruitment of three glycoforms into PrP(Sc) was found to be proportional to their respective populations in the substrate. 26576925 6 8 gly desialylated 858:869 arg1 partially desialylated PrP partially desialylated PrP PUBTATOR PrP 19122 However, when partially desialylated PrP(C) was used as a substrate, recruitment of three glycoforms into PrP(Sc) was found to be proportional to their respective populations in the substrate. 27641064 1 36 gly N-Glycosylation 110:124 arg1 integrin α5β1 integrin α5β1 PUBTATOR integrin α5 3678 N-Glycosylation of integrin α5β1 is involved in multiple cell behaviors. 26563299 6 2 part_of IL-15 881:885 arg1 IL-15 Asn79 IL-15 IL-15 Asn79 PUBTATOR AminoAcid IL-15 P40933 Asn79 IL-15 Asn79 and sIL-15Rα Asn107 carried the same repertoire of biosynthetically-related N-glycans covering mostly α1-6-core-fucosylated and β-GlcNAc-terminating complex-type structures. 26563299 6 93 part_of sIL-15Rα 897:904 arg1 sIL-15Rα Asn107 sIL sIL-15Rα Asn107 OGER AminoAcid sIL Q15468 Asn107 IL-15 Asn79 and sIL-15Rα Asn107 carried the same repertoire of biosynthetically-related N-glycans covering mostly α1-6-core-fucosylated and β-GlcNAc-terminating complex-type structures. 26959529 3 45 gly N-glycans 414:422 arg1 milk milk N-glycans PUBTATOR milk 100532204 Since the proteins in milk are highly glycosylated, N-glycans in milk also play an import role. 28630087 10 54 gly glycosylation 1662:1674 arg1 HNE HNE PUBTATOR HNE 1991 The three glycosylation sites of HNE were located distal to the active site indicating glycan functions other than interference with HNE enzyme activity. 24931470 1 11 gly glycoprotein 71:82 arg1 Env Env PUBTATOR Env 100616444 The HIV envelope glycoprotein (Env) trimer undergoes receptor-induced conformational changes that drive fusion of the viral and cellular membranes. 24931470 1 11 gly glycoprotein 71:82 arg1 HIV envelope glycoprotein HIV envelope glycoprotein PUBTATOR HIV envelope glycoprotein 155971 The HIV envelope glycoprotein (Env) trimer undergoes receptor-induced conformational changes that drive fusion of the viral and cellular membranes. 26747427 1 11 gly attached 182:189 arg2 AT AND the N-linked oligosaccharides AT the N-linked oligosaccharides PUBTATOR AT 462 The structure of the N-linked oligosaccharides attached to antithrombin (AT) has been shown to affect its anticoagulant activity and pharmacokinetics. 26747427 1 11 gly attached 182:189 arg1 antithrombin AND the N-linked oligosaccharides antithrombin the N-linked oligosaccharides PUBTATOR antithrombin 462 The structure of the N-linked oligosaccharides attached to antithrombin (AT) has been shown to affect its anticoagulant activity and pharmacokinetics. 27223297 0 5 gly N-Glycans 0:8 arg1 Gn Gn N-Glycans Cterm Gn N-Glycans on the Rift Valley Fever Virus Envelope Glycoproteins Gn and Gc Redundantly Support Viral Infection via DC-SIGN. 28994411 2 11 gly glycoprotein 403:414 arg1 Env Env PUBTATOR Env 100616444 While these studies have revealed critical mechanisms by which bNAbs recognize and/or accommodate N-glycans on the trimeric envelope glycoprotein (Env), they have been limited to the visualization of high-mannose glycan forms only, since heterogeneity introduced from the presence of complex glycans makes it difficult to obtain high-resolution structures. 28994411 2 11 gly glycoprotein 403:414 arg1 the trimeric envelope glycoprotein the trimeric envelope glycoprotein PUBTATOR envelope glycoprotein 100616444 While these studies have revealed critical mechanisms by which bNAbs recognize and/or accommodate N-glycans on the trimeric envelope glycoprotein (Env), they have been limited to the visualization of high-mannose glycan forms only, since heterogeneity introduced from the presence of complex glycans makes it difficult to obtain high-resolution structures. 28994411 2 21 gly N-glycans 368:376 arg1 Env Env N-glycans PUBTATOR Env 100616444 While these studies have revealed critical mechanisms by which bNAbs recognize and/or accommodate N-glycans on the trimeric envelope glycoprotein (Env), they have been limited to the visualization of high-mannose glycan forms only, since heterogeneity introduced from the presence of complex glycans makes it difficult to obtain high-resolution structures. 28994411 2 21 gly N-glycans 368:376 arg1 the trimeric envelope glycoprotein envelope glycoprotein N-glycans PUBTATOR envelope glycoprotein 100616444 While these studies have revealed critical mechanisms by which bNAbs recognize and/or accommodate N-glycans on the trimeric envelope glycoprotein (Env), they have been limited to the visualization of high-mannose glycan forms only, since heterogeneity introduced from the presence of complex glycans makes it difficult to obtain high-resolution structures. 28630087 0 55 gly N-glycosylation 18:32 arg1 Spatiotemporally Regulated Human Neutrophil Elastase Spatiotemporally Regulated Human Neutrophil Elastase PUBTATOR Human Neutrophil Elastase 1991 Paucimannose-Rich N-glycosylation of Spatiotemporally Regulated Human Neutrophil Elastase Modulates Its Immune Functions. 28630087 0 122 gly Elastase 81:88 arg1 Paucimannose-Rich N-glycosylation Human Neutrophil Elastase Paucimannose-Rich N-glycosylation PUBTATOR Human Neutrophil Elastase 1991 Paucimannose-Rich N-glycosylation of Spatiotemporally Regulated Human Neutrophil Elastase Modulates Its Immune Functions. 26489654 5 66 gly hexosaminidase 718:731 arg1 HexB hexosaminidase B HexB PUBTATOR hexosaminidase B 3074 Endogenous glycosidases, including neuraminidase 1 (Neu1), neuraminidase 3 (Neu3), beta-galactosidase 1 (Glb1), and hexosaminidase B (HexB), possess hydrolytic activities that temporally remodel N-glycan structures, progressively exposing different saccharides with increased protein age. 28575723 4 25 gly glycoform 488:496 arg1 Cha o 3 Cha o 3 OGER Cha o 3 Q9UL49 In this study, therefore, we analyzed the glycoform of Cha o 3 and found that this glycoallergen carries exclusively plant complex-type N-glycans; major structures were GlcNAc2Man3Xyl1Fuc1GlcNAc2 (39%), Gal1Fuc1GlcNAc2Man3Xyl1Fuc1GlcNAc2 (14%), and Gal2Fuc2GlcNAc2Man3Xyl1Fuc1GlcNAc2 (25%). 24012618 5 7 gly attached 837:844 arg1 IgG AND N-glycans IgG N-glycans Cterm IgG A hydrophilic interaction chromatography on Waters BEH Glycan chromatography column was used to analyze N-glycans attached to IgG in plasma samples from a total of 3515 individuals. 25907685 10 61 gly N-glycosylation 1562:1576 arg1 mAbs mAbs Cterm mAbs BIOLOGICAL SIGNIFICANCE The characterization of the N-glycosylation sites of therapeutic recombinant monoclonal antibodies (mAbs) is usually one of the most critical and time consuming steps in the developing process of biosimilars or any other glycosylated drug. 29029079 5 40 gly EC-SOD 792:797 arg1 the N-glycans EC-SOD the N-glycans PUBTATOR EC-SOD 6649 Using glycan maturation-defective CHO mutant cells, we further revealed that the presence of terminal sialic acids in the N-glycans of EC-SOD enhanced both the secretion and furin-mediated C-terminal cleavage of EC-SOD. 28928219 6 3 gly glycosylated 1244:1255 arg1 glycosylated Skp1 glycosylated Skp1 PUBTATOR Skp1 6500 Molecular dynamics trajectories of glycosylated Skp1 whose calculated monosaccharide relaxation kinetics and rotational correlation times agreed with the NMR data indicated that the glycan interacts with the loop connecting two α-helices of the F-box-combining site. 26255982 7 52 gly glycoproteins 1094:1106 arg1 MUC1 MUC1 PUBTATOR MUC1 4582 In addition, there were significant correlations between the abundance of the O-glycans and glycoproteins (MUC1, CEA) in the serum of GC. 26492619 0 8 part_of Podoplanin 113:122 arg1 Thr34 Human Podoplanin Thr34 PUBTATOR AminoAcid Human Podoplanin 10630 Thr34 Development of Monoclonal Antibody LpMab-10 Recognizing Non-glycosylated PLAG1/2 Domain Including Thr34 of Human Podoplanin. 28109443 5 91 gly IgA1 1095:1098 arg1 the O-glycans IgA1 the O-glycans PUBTATOR IgA1 P01876 To address these questions, we conducted a systematic study on the O-glycans of plasma IgA1 from both IgAN patients and healthy controls using serial HPA and PNA lectin chromatography followed by western blotting and further analysis of O-glycans from HPA-bound and PNA-bound IgA1 fractions by mass spectrometry. 29268168 2 0 gly afucosylated 383:394 arg1 the afucosylated IgG the afucosylated IgG PUBTATOR IgG 16059 Particularly, afucosylation increases the binding affinity of human IgG1 to human FcγRIIIa up to ∼20 fold, and additional galactosylation of the afucosylated IgG increases the affinity up to ∼40 fold. 26256339 3 33 gly RCP-II 447:452 arg1 The carbohydrate RCP The carbohydrate OGER RCP P04000 The carbohydrate of RCP-II was composed with galacturonic acid, rhamnose, arabinose, xylose, glucose and galactose in a molar ratio of 1.00:0.55:1.19:0.52:0.44:1.90 and the average molecular weight was estimated to be 4013 Da, based on dextran standards. 28745859 4 10 gly derived 756:762 arg2 the Trichoderma reesei cellulase TrCel7A AND a carbohydrate binding module the Trichoderma reesei cellulase TrCel7A a carbohydrate binding module Cterm TrCel7A Here, we took advantage of synthetic, homogeneous O-glycopeptides to show that certain glycosylation patterns have an intrinsic effect, independent of any cellular folding machinery, on the folding pathway of a model O-glycoprotein, a carbohydrate binding module (CBM) derived from the Trichoderma reesei cellulase TrCel7A. 24417605 10 50 gly sialylated 1518:1527 arg1 HDL HDL OGER HDL Q9UNE0 This report describes for the first time a glycomic approach for analyzing HDL, highlighting that HDL are highly sialylated particles. 28323417 1 2 gly glycoproteins 317:329 arg1 human α1-acid glycoprotein human α1-acid glycoprotein Cterm α1-acid An ion mobility quadrupole time-of-flight mass spectrometer was used to examine the gas-phase structures of a set of glycopeptides resulting from proteolytic digestion of the well-characterized glycoproteins bovine ribonuclease B, human transferrin, bovine fetuin and human α1-acid glycoprotein, the corresponding deglycosylated peptides, and the glycans released by the endoglycosidase PNGase F. 28323417 1 2 gly glycoproteins 317:329 arg1 bovine ribonuclease B bovine ribonuclease B Cterm bovine ribonuclease B An ion mobility quadrupole time-of-flight mass spectrometer was used to examine the gas-phase structures of a set of glycopeptides resulting from proteolytic digestion of the well-characterized glycoproteins bovine ribonuclease B, human transferrin, bovine fetuin and human α1-acid glycoprotein, the corresponding deglycosylated peptides, and the glycans released by the endoglycosidase PNGase F. 28323417 1 2 gly glycoproteins 317:329 arg1 human transferrin human transferrin PUBTATOR transferrin 7018 An ion mobility quadrupole time-of-flight mass spectrometer was used to examine the gas-phase structures of a set of glycopeptides resulting from proteolytic digestion of the well-characterized glycoproteins bovine ribonuclease B, human transferrin, bovine fetuin and human α1-acid glycoprotein, the corresponding deglycosylated peptides, and the glycans released by the endoglycosidase PNGase F. 28323417 1 71 gly glycoprotein 405:416 arg1 human α1-acid glycoprotein human α1-acid glycoprotein Cterm α1-acid An ion mobility quadrupole time-of-flight mass spectrometer was used to examine the gas-phase structures of a set of glycopeptides resulting from proteolytic digestion of the well-characterized glycoproteins bovine ribonuclease B, human transferrin, bovine fetuin and human α1-acid glycoprotein, the corresponding deglycosylated peptides, and the glycans released by the endoglycosidase PNGase F. 29268168 0 47 gly fucosylated 45:55 arg1 fucosylated and afucosylated IgG fucosylated and afucosylated IgG PUBTATOR IgG 16059 Conserved FcγR- glycan discriminates between fucosylated and afucosylated IgG in humans and mice. 29268168 0 53 gly afucosylated 61:72 arg1 fucosylated and afucosylated IgG fucosylated and afucosylated IgG PUBTATOR IgG 16059 Conserved FcγR- glycan discriminates between fucosylated and afucosylated IgG in humans and mice. 27629418 7 79 gly glycoproteins 1296:1308 arg1 human lactoferrin glycoproteins human lactoferrin glycoproteins OGER lactoferrin glycoproteins P02788 W251N mutants could act on the immunoglobulin G-derived core-fucosylated glycopeptides and human lactoferrin glycoproteins. 28543513 3 8 gly glycoprotein 586:597 arg1 haptoglobin glycoprotein haptoglobin glycoprotein PUBTATOR haptoglobin glycoprotein 3240 Herein, an LC-MS/MS-based analysis was conducted to define the glycosylation patterns of haptoglobin glycoprotein derived from sera collected from cirrhotic and hepatocellular carcinoma (HCC) patients. 28543513 3 12 gly glycosylation 548:560 arg1 haptoglobin glycoprotein haptoglobin glycoprotein PUBTATOR haptoglobin glycoprotein 3240 Herein, an LC-MS/MS-based analysis was conducted to define the glycosylation patterns of haptoglobin glycoprotein derived from sera collected from cirrhotic and hepatocellular carcinoma (HCC) patients. 25658763 6 12 gly Glycosylation 1274:1286 arg1 EMMPRIN EMMPRIN PUBTATOR EMMPRIN 682 2) Glycosylation of EMMPRIN in monocytes/macrophages led to N-linked-glycans being added to the protein, with the HG form containing complex-type glycans and the less-glycosylated form (LG) the simple type. 28803068 6 34 gly N-glycosylation 1097:1111 arg1 hIFNγ-HEK hIFNγ-HEK OGER HEK P29320 Complex-type oligosaccharides dominated the N-glycosylation pattern of hIFNγ-HEK with some terminal sialylation and core fucosylation. 26869352 2 61 gly N-glycans 365:373 arg1 haptoglobin haptoglobin N-glycans PUBTATOR haptoglobin 3240 Previously, we reported that fucosylated N-glycans on haptoglobin in the sera of patients with pancreatic cancer were increased by lectin-ELISA and mass spectrometry analyses. 24417605 5 59 gly glycoproteins 648:660 arg1 the N-glycans HDL glycoproteins the N-glycans OGER HDL glycoproteins Q9UNE0 Most of the N-glycans (∼90%) from HDL glycoproteins were sialylated with one or two neuraminic acids (Neu5Ac). 26869421 1 29 gly glycoforms 208:217 arg1 4 well-defined IgG1-Fc glycoforms 4 well-defined IgG1-Fc glycoforms OGER IgG1 P01857 As part of a series of articles in this special issue describing 4 well-defined IgG1-Fc glycoforms as a model system for biosimilarity analysis (high mannose-Fc, Man5-Fc, GlcNAc-Fc and N297Q-Fc aglycosylated), the focus of this work is comparisons of their physical properties. 26869421 1 74 gly aglycosylated 314:326 arg1 N297Q-Fc aglycosylated N297Q-Fc aglycosylated Cterm Fc As part of a series of articles in this special issue describing 4 well-defined IgG1-Fc glycoforms as a model system for biosimilarity analysis (high mannose-Fc, Man5-Fc, GlcNAc-Fc and N297Q-Fc aglycosylated), the focus of this work is comparisons of their physical properties. 25355867 8 53 gly carrying 1321:1328 arg1 secreted A1AT AND sialylated N-glycan structures secreted A1AT sialylated N-glycan structures PUBTATOR A1AT 5265 Notwithstanding, an intensive glycoengineering approach led to secreted A1AT carrying sialylated N-glycan structures largely resembling its serum-derived counterpart. 25554420 2 12 gly N-glycosylation 407:421 arg1 CR3 CR3 OGER CR3 To investigate the relative importance of the individual N-glycans of CR3 for toxin activity, the asparagine residues of the consensus N-glycosylation sites of CR3 were substituted with glutamine residues that cannot be glycosylated. 25554420 2 41 gly CR3 342:344 arg1 the individual N-glycans CR3 the individual N-glycans OGER CR3 To investigate the relative importance of the individual N-glycans of CR3 for toxin activity, the asparagine residues of the consensus N-glycosylation sites of CR3 were substituted with glutamine residues that cannot be glycosylated. 26457517 2 41 gly S 344:344 arg1 Three complex crystal structures the glycosyl hydrolase 48 (GH48) cellobiohydrolase S (ExgS Three complex crystal structures Cterm the glycosyl hydrolase 48 (GH48) cellobiohydrolase S (ExgS Three complex crystal structures of the glycosyl hydrolase 48 (GH48) cellobiohydrolase S (ExgS) from Clostridium cellulovorans with cellobiose, cellotetraose and triethylene glycol molecules were solved. 24680513 4 60 gly glycosylation 540:552 arg1 feline IgG feline IgG Cterm IgG We evaluated the variation of N-linked glycosylation of human, bovine, ovine, equine, canine and feline IgG using three orthogonal glycan separation techniques: hydrophilic interaction liquid chromatography (HILIC)-UPLC, reversed phase (RP)-UPLC and capillary electrophoresis with laser induced fluorescence detection (CE-LIF). 24519758 4 33 gly glycosylation 471:483 arg1 goat milk lactoferrin goat milk lactoferrin OGER lactoferrin P02788 The aim of this study was to characterize the glycosylation pattern of goat milk lactoferrin. 28322444 5 16 gly N220-glycosylated 946:962 arg1 N220-glycosylated Kv3.1b. N220-glycosylated Kv3.1b. Cterm Kv3.1b Mass spectrometry analysis revealed a complex type Hex3 HexNAc4 Fuc1 glycan as the major glycan component of the N229-glycosylated Kv3.1b protein, as opposed to a high-mannose type Man8 GlcNAc2 glycan for N220-glycosylated Kv3.1b. Taken together, these results suggest that trafficking-dependent roles of the Kv3.1b potassium channel are dependent on N229 site-specific glycosylation and N-glycan structure, and operate through a mechanism whereby specific N-glycan structures regulate cell surface expression. 25265424 3 25 gly glycoforms 356:365 arg1 hemopexin hemopexin PUBTATOR hemopexin 3263 We present a case study that compares site specific glycoforms of four proteins including haptoglobin, complement factor H, kininogen-1, and hemopexin isolated from the same patient. 25265424 3 25 gly glycoforms 356:365 arg1 kininogen-1 kininogen-1 PUBTATOR kininogen-1 3827 We present a case study that compares site specific glycoforms of four proteins including haptoglobin, complement factor H, kininogen-1, and hemopexin isolated from the same patient. 25265424 3 25 gly glycoforms 356:365 arg1 complement factor H haptoglobin, complement factor H PUBTATOR haptoglobin, complement factor H 3240 We present a case study that compares site specific glycoforms of four proteins including haptoglobin, complement factor H, kininogen-1, and hemopexin isolated from the same patient. 26503433 4 13 gly haptoglobin 626:636 arg1 eight glycans haptoglobin eight glycans PUBTATOR haptoglobin 3240 The separation of the derivatized glycans in a HILIC column shows that eight glycans from haptoglobin can be detected using less than 1 μL of a serum sample, with excellent reproducibility and quantitation, where without derivatization the glycans could not be detected. 27333379 4 21 gly O-glycans 605:613 arg1 IgA1 IgA1 O-glycans PUBTATOR IgA1 P01876 Even though the disease is associated with the overproduction of aberrant O-glycans on IgA1, specific structure-function-studies of mucin-type O-glycans are limited. 27547921 1 35 gly N-glycosylated 124:137 arg1 Glucose transporter 4 N-glycosylated Glucose transporter 4 Cterm N-glycosylated Glucose transporter 4 (GLUT4) is an N-glycosylated protein that maintains glucose homeostasis by regulating the protein translocation. 28336547 2 90 gly glycosylated 361:372 arg1 the proton-coupled oligopeptide transporter 1 the proton-coupled oligopeptide transporter 1 PUBTATOR proton-coupled oligopeptide transporter 1 56643 We recently demonstrated that the proton-coupled oligopeptide transporter 1 (PEPT1) in the intestine is glycosylated at six asparagine residues (N50, N406, N439, N510, N515, and N532). 28336547 2 90 gly glycosylated 361:372 arg1 PEPT1 PEPT1 PUBTATOR PEPT1 56643 We recently demonstrated that the proton-coupled oligopeptide transporter 1 (PEPT1) in the intestine is glycosylated at six asparagine residues (N50, N406, N439, N510, N515, and N532). 29274340 2 60 gly glycosylation 453:465 arg1 rhGAA rhGAA glycosylation OGER rhGAA Q6P7A9 Mannose-6-phosphate (M6P) glycosylation on rhGAA is a key factor influencing lysosomal enzyme targeting and the efficacy of enzyme replacement therapy (ERT); however, its complex structure and relatively small quantity still remain to be characterized. 28445724 3 15 gly trimers 398:404 arg1 select glycans Env trimers select glycans PUBTATOR Env trimers 100616444 We engineered diverse Env trimers with select glycans removed proximal to the CD4 supersite, characterized their structures and glycosylation, and immunized guinea pigs and rhesus macaques. 26797772 1 46 gly glycoprotein 220:231 arg1 Tissue-nonspecific alkaline phosphatase Tissue-nonspecific alkaline phosphatase PUBTATOR Tissue-nonspecific alkaline phosphatase 249 Tissue-nonspecific alkaline phosphatase (TNSALP) is a membrane glycoprotein with a proposed role in bone mineralization. 25355867 7 2 gly carried 1110:1116 arg1 Secreted A1AT AND vacuolar-type paucimannosidic N-glycans Secreted A1AT vacuolar-type paucimannosidic N-glycans PUBTATOR Secreted A1AT 5265 Secreted A1AT carried vacuolar-type paucimannosidic N-glycans generated by the activity of hexosaminidases located in the apoplast/plasma membrane. 27956708 2 25 gly ACPA-IgG 454:461 arg1 the Fab-glycans ACPA the Fab-glycans PUBTATOR ACPA 5657 As N-linked glycans can mediate a variety of biological functions, we now aimed at investigating the structural composition of the Fab-glycans of ACPA-IgG to better understand their mediated biological effects. 26101185 1 7 gly glycoproteins 116:128 arg1 Milk glycoproteins Milk glycoproteins PUBTATOR Milk glycoproteins 100532204 Milk glycoproteins are involved in different functions and contribute to different cellular processes, including adhesion and signaling, and shape the development of the infant microbiome. 25641685 6 60 gly monosialylated 1023:1036 arg1 monosialylated apoC-III monosialylated apoC-III PUBTATOR apoC-III 345 Furthermore, in CDG samples, comparison study between 2DE and MALDI-TOF showed a particular behavior of monosialylated apoC-III in the mass spectrometer that could be related to an abnormal O-glycan structure. 29031045 9 4 gly glycoforms 1574:1583 arg1 IgG3 Fc glycoforms IgG3 Fc glycoforms PUBTATOR IgG3 P01860 Additionally, protein-glycan contacts observed in the crystal structure appear to correlate with IgG3 affinity for Fcγ receptors as shown by binding studies with IgG3 Fc glycoforms. 25479762 6 0 gly hGGT1 1101:1105 arg1 N-glycan content hGGT1 N-glycan content PUBTATOR hGGT1 2678 Herein, we investigated a new antibody-lectin sandwich array (ALSA) platform to determine whether this microanalytical technique could be applied to the characterization of N-glycan content of hGGT1 in complex biological samples. 28630087 11 16 gly sialoglycoforms 1940:1954 arg1 the HNE sialoglycoforms the HNE sialoglycoforms PUBTATOR HNE 1991 Functionally, the paucimannosidic HNE glycoforms displayed preferential binding to human mannose binding lectin compared with the HNE sialoglycoforms, suggesting a glycoform-dependent involvement of HNE in complement activation. 28630087 11 30 gly glycoforms 1844:1853 arg1 the paucimannosidic HNE glycoforms the paucimannosidic HNE glycoforms PUBTATOR HNE 1991 Functionally, the paucimannosidic HNE glycoforms displayed preferential binding to human mannose binding lectin compared with the HNE sialoglycoforms, suggesting a glycoform-dependent involvement of HNE in complement activation. 28905148 3 26 gly released 579:586 arg2 Immunoglobulin A AND previously reported N-glycan structures Immunoglobulin A previously reported N-glycan structures PUBTATOR Immunoglobulin A 973 We used previously reported N-glycan structures released from the purified glycoproteins Immunoglobulin G (IgG), Immunoglobulin A (IgA), lactoferrin, α1-acid glycoprotein, Ribonuclease B (RNase B), fetuin and ovalbumin to profile their behaviour on capillary PGC-LC-MS. 28905148 3 26 gly released 579:586 arg1 lactoferrin AND previously reported N-glycan structures lactoferrin previously reported N-glycan structures OGER lactoferrin P02788 We used previously reported N-glycan structures released from the purified glycoproteins Immunoglobulin G (IgG), Immunoglobulin A (IgA), lactoferrin, α1-acid glycoprotein, Ribonuclease B (RNase B), fetuin and ovalbumin to profile their behaviour on capillary PGC-LC-MS. 28905148 3 26 gly released 579:586 arg1 Ribonuclease B AND previously reported N-glycan structures Ribonuclease B previously reported N-glycan structures Cterm Ribonuclease B We used previously reported N-glycan structures released from the purified glycoproteins Immunoglobulin G (IgG), Immunoglobulin A (IgA), lactoferrin, α1-acid glycoprotein, Ribonuclease B (RNase B), fetuin and ovalbumin to profile their behaviour on capillary PGC-LC-MS. 28905148 3 45 gly glycoproteins 606:618 arg1 Immunoglobulin A Immunoglobulin A PUBTATOR Immunoglobulin A 973 We used previously reported N-glycan structures released from the purified glycoproteins Immunoglobulin G (IgG), Immunoglobulin A (IgA), lactoferrin, α1-acid glycoprotein, Ribonuclease B (RNase B), fetuin and ovalbumin to profile their behaviour on capillary PGC-LC-MS. 28905148 3 45 gly glycoproteins 606:618 arg1 lactoferrin lactoferrin OGER lactoferrin P02788 We used previously reported N-glycan structures released from the purified glycoproteins Immunoglobulin G (IgG), Immunoglobulin A (IgA), lactoferrin, α1-acid glycoprotein, Ribonuclease B (RNase B), fetuin and ovalbumin to profile their behaviour on capillary PGC-LC-MS. 28905148 3 45 gly glycoproteins 606:618 arg1 Ribonuclease B Ribonuclease B Cterm Ribonuclease B We used previously reported N-glycan structures released from the purified glycoproteins Immunoglobulin G (IgG), Immunoglobulin A (IgA), lactoferrin, α1-acid glycoprotein, Ribonuclease B (RNase B), fetuin and ovalbumin to profile their behaviour on capillary PGC-LC-MS. 27748959 6 3 gly -glycoprotein 928:940 arg1 Golgi-associated mannosyl (α-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase Golgi-associated mannosyl (α-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase OGER α-1,3-)-glycoprotein beta Q6XFR6 Characterization of Golgi-associated mannosyl (α-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase (MGAT1), α-1,2-mannosidase (Man-I), and α-mannosidase II (Man-II) were performed in VA-13 cells and rat hepatocytes followed by three-dimensional structured illumination microscopy (3D SIM). 27384922 1 9 gly N-glycosylated 181:194 arg1 cellular prion protein cellular prion protein PUBTATOR prion protein 5621 Prions are formed of misfolded assemblies (PrP(Sc)) of the variably N-glycosylated cellular prion protein (PrP(C)). 26959529 7 70 gly had 843:845 arg1 Human milk AND more complex free oligosaccharides structures Human milk more complex free oligosaccharides structures PUBTATOR Human milk 100532204 Human milk had more complex free oligosaccharides structures than the other two milk samples. 26840264 5 67 gly glycosylation 1041:1053 arg1 IgG IgG Cterm IgG In cohorts of individuals ranging from infancy to centenarians we determined the activity of plasmatic β4 galactosyltransferase(s) (B4GALTs) and of α2,6-sialyltransferase ST6GAL1, the glycosylation of IgG, the GlycoAge test (a glycosylation-based marker of aging) and the plasma level of inflammatory and liver damage markers. 26840264 5 67 gly glycosylation 1041:1053 arg1 α2,6-sialyltransferase ST6GAL1 α2,6-sialyltransferase ST6GAL1 PUBTATOR sialyltransferase ST6GAL1 84620 In cohorts of individuals ranging from infancy to centenarians we determined the activity of plasmatic β4 galactosyltransferase(s) (B4GALTs) and of α2,6-sialyltransferase ST6GAL1, the glycosylation of IgG, the GlycoAge test (a glycosylation-based marker of aging) and the plasma level of inflammatory and liver damage markers. 27223297 3 49 part_of RVFV 405:408 arg1 N794 RVFV N794, N829, N1035, and N1077 Cterm SpecificSite RVFV N794, N829, N1035, and N1077 The Rift Valley fever virus (RVFV) glycoproteins (Gn/Gc) encode five putative N-glycan sequons (asparagine (N)-any amino acid (X)-serine (S)/threonine (T)) at positions: N438 (Gn), and N794, N829, N1035, and N1077 (Gc). 27223297 3 49 part_of RVFV 405:408 arg1 N829 RVFV N794, N829, N1035, and N1077 Cterm SpecificSite RVFV N794, N829, N1035, and N1077 The Rift Valley fever virus (RVFV) glycoproteins (Gn/Gc) encode five putative N-glycan sequons (asparagine (N)-any amino acid (X)-serine (S)/threonine (T)) at positions: N438 (Gn), and N794, N829, N1035, and N1077 (Gc). 27223297 3 49 part_of RVFV 405:408 arg1 N1077 RVFV N794, N829, N1035, and N1077 Cterm SpecificSite RVFV N794, N829, N1035, and N1077 The Rift Valley fever virus (RVFV) glycoproteins (Gn/Gc) encode five putative N-glycan sequons (asparagine (N)-any amino acid (X)-serine (S)/threonine (T)) at positions: N438 (Gn), and N794, N829, N1035, and N1077 (Gc). 27223297 3 49 part_of RVFV 405:408 arg1 N829 RVFV N794, N829, N1035, and N1077 Cterm SpecificSite RVFV N794, N829, N1035, and N1077 The Rift Valley fever virus (RVFV) glycoproteins (Gn/Gc) encode five putative N-glycan sequons (asparagine (N)-any amino acid (X)-serine (S)/threonine (T)) at positions: N438 (Gn), and N794, N829, N1035, and N1077 (Gc). 27223297 3 49 part_of RVFV 405:408 arg1 N1077 RVFV N794, N829, N1035, and N1077 Cterm SpecificSite RVFV N794, N829, N1035, and N1077 The Rift Valley fever virus (RVFV) glycoproteins (Gn/Gc) encode five putative N-glycan sequons (asparagine (N)-any amino acid (X)-serine (S)/threonine (T)) at positions: N438 (Gn), and N794, N829, N1035, and N1077 (Gc). 27223297 3 49 part_of RVFV 405:408 arg1 N1077 RVFV N794, N829, N1035, and N1077 Cterm SpecificSite RVFV N794, N829, N1035, and N1077 The Rift Valley fever virus (RVFV) glycoproteins (Gn/Gc) encode five putative N-glycan sequons (asparagine (N)-any amino acid (X)-serine (S)/threonine (T)) at positions: N438 (Gn), and N794, N829, N1035, and N1077 (Gc). 27649061 2 102 gly glycoforms 353:362 arg1 IgG IgG Cterm IgG Multiple analytical methods have been designed for the determination of the IgG N-glycan microheterogeneity, including MS methods for the analysis of site specific glycoforms of IgG. 27529638 0 23 gly Glycosylation 14:26 arg1 Peptide/Protein Peptide/Protein OGER Peptide Site-Directed Glycosylation of Peptide/Protein with Homogeneous O-Linked Eukaryotic N-Glycans. 26797772 9 4 gly mutants 1670:1676 arg1 TNSALP TNSALP mutants PUBTATOR TNSALP 249 A comprehensive analysis of a series of multiple N-glycan depletion mutants in TNSALP revealed that three N-glycans on N230, N271 and N303 were the minimal requirement for the structure and function of TNSALP and a prerequisite for its stable expression in a cell. 26797772 9 52 gly N-glycans 1708:1716 arg1 N271 N271 N271 SpecificSite N230, N271 and N303 A comprehensive analysis of a series of multiple N-glycan depletion mutants in TNSALP revealed that three N-glycans on N230, N271 and N303 were the minimal requirement for the structure and function of TNSALP and a prerequisite for its stable expression in a cell. 26797772 9 52 gly N-glycans 1708:1716 arg1 N230 N230 N230 SpecificSite N230, N271 and N303 A comprehensive analysis of a series of multiple N-glycan depletion mutants in TNSALP revealed that three N-glycans on N230, N271 and N303 were the minimal requirement for the structure and function of TNSALP and a prerequisite for its stable expression in a cell. 26797772 9 52 gly N-glycans 1708:1716 arg1 N303 N303 N303 SpecificSite N230, N271 and N303 A comprehensive analysis of a series of multiple N-glycan depletion mutants in TNSALP revealed that three N-glycans on N230, N271 and N303 were the minimal requirement for the structure and function of TNSALP and a prerequisite for its stable expression in a cell. 29069609 12 35 gly glycoforms 2012:2021 arg1 two IgG1 glycoforms two IgG1 glycoforms OGER IgG1 P01857 This is demonstrated through the analysis of immunoglobulins in human plasma where we detected two IgG1 glycoforms that are rarely observed. 24780636 5 84 gly sTf 845:847 arg1 the N-glycans sTf the N-glycans Cterm sTf P02787 Mass spectrometric analyses confirmed that Tf-2 is modified with disialylated biantennary glycans at both of the two N-glycosylation sites, which are similar to the N-glycans of sTf. 26059044 0 0 gly interleukin-22 82:95 arg1 the atypical N-glycan composition interleukin-22 the atypical N-glycan composition PUBTATOR interleukin-22 50616 The N-glycan on Asn54 affects the atypical N-glycan composition of plant-produced interleukin-22, but does not influence its activity. 26059044 0 4 gly N-glycan 4:11 arg1 Asn54 Asn54 Asn54 AminoAcid Asn54 The N-glycan on Asn54 affects the atypical N-glycan composition of plant-produced interleukin-22, but does not influence its activity. 27574189 0 25 gly glycans 18:24 arg1 plasma-derived ADAMTS13 ADAMTS13 glycans PUBTATOR ADAMTS13 11093 Identification of glycans on plasma-derived ADAMTS13. 27653286 3 40 gly glycosylated 396:407 arg1 Robo1 Robo1 OGER Robo1 Q9Y6N7 However, the fact that Robo1 is a glycosylated protein prevents employment of commonly used bacterial hosts for expression of properly glycosylated forms with the uniform 15N, 13C, and 2H labeling needed for NMR studies. 26132640 6 5 gly glycoproteins 984:996 arg1 PSM PSM OGER PSM Following optimization of the reaction conditions, the MW-assisted BEP reaction substantially improved the recovery of total O-glycans from model glycoproteins (PSM) and the reaction time was reduced from 16 to 2 h. Combined with sequential solid-phase extractions, this MW-assisted BEP procedure enabled O-glycomic analyses of various biological samples. 25527317 3 8 gly have 553:556 arg1 bovine BNC AND a typical ruminant glycan composition bovine BNC a typical ruminant glycan composition OGER BNC Q01954 We have used lectin histochemistry to examine the glycosylation of these cells in these species and compare them with bovine BNC which have a typical ruminant glycan composition. 26211613 1 10 gly glycosylation 98:110 arg1 immunoglobulin G immunoglobulin G Cterm immunoglobulin G Asparagine(N)297-linked glycosylation of immunoglobulin G (IgG) Fc is required for binding to FcγRIIa, IIb, and IIIa, although it is unclear how it contributes. 26211613 1 10 gly glycosylation 98:110 arg1 IgG IgG Cterm IgG Asparagine(N)297-linked glycosylation of immunoglobulin G (IgG) Fc is required for binding to FcγRIIa, IIb, and IIIa, although it is unclear how it contributes. 25799047 8 82 gly glycosylated 1607:1618 arg1 the extracellular CelA protein the extracellular CelA protein PUBTATOR CelA protein 2693958 Analysis of protein in culture supernatants revealed that the extracellular CelA protein is glycosylated whereas the intracellular CelA is not, suggesting that either protein transport is required for this post-translational modification or that glycosylation is required for protein export. 26171609 2 64 gly N-glycans 466:474 arg1 Asn-57 Asn-57 Asn-57 SpecificSite Asn-57 Here, we show that SPINT 2 is expressed as two species of different size (30-40- versus 25-kDa) due to different N-glycans on Asn-57. 26488311 0 48 gly Glycosylation 0:12 arg1 Human Plasma Clusterin Human Plasma Clusterin OGER Clusterin P10909 Glycosylation of Human Plasma Clusterin Yields a Novel Candidate Biomarker of Alzheimer's Disease. 26812091 9 4 gly hFSH 1404:1407 arg1 the critical glycan structures hFSH the critical glycan structures OGER hFSH The differences in glycosylation provide useful information in elucidating and in further investigation the critical glycan structures of hFSH. 24797265 2 32 gly glycosylated 391:402 arg1 Srr proteins Srr proteins OGER Srr proteins Q9GZT4 Lectin-binding experiments have previously shown that Srr proteins are heavily glycosylated. 28104755 6 59 gly non-glycosylated 963:978 arg1 non-glycosylated SMPDL3A non-glycosylated SMPDL3A PUBTATOR SMPDL3A 10924 Tunicamycin (TM) treatment resulted in expression of non-glycosylated SMPDL3A that was not secreted, and was largely degraded by the proteasome. 27956708 5 57 gly Fc-glycosylation 864:879 arg1 ACPA-IgG ACPA-IgG PUBTATOR ACPA 5657 The Fc-glycosylation of ACPA-IgG and IgG was analyzed at the glycopeptide level using LC-MS. 27956708 5 57 gly Fc-glycosylation 864:879 arg1 IgG IgG Cterm IgG The Fc-glycosylation of ACPA-IgG and IgG was analyzed at the glycopeptide level using LC-MS. 26512079 3 42 gly site 531:534 arg1 the surface antigen gp120 gp120 site Cterm gp120 3700 Previous work has shown that removal of a highly conserved potential N-linked glycan (PNLG) site at amino acid residue 197 (N7) on the surface antigen gp120 of HIV-1 increases neutralization sensitivity of the mutant virus to CD4 binding site (CD4bs)-directed antibodies compared to its wild-type (WT) counterpart. 25305020 4 88 gly glycosylated 890:901 arg1 the CaSR ECD the CaSR ECD OGER CaSR ECD P41180 Both glycosylated forms of the CaSR ECD were purified as dimers and exhibit similar secondary structures with ∼ 50% α-helix, ∼ 20% β-sheet content, and a well buried Trp environment. 26863921 3 24 part_of N-glycosylation 633:647 arg1 Asn-279 N-glycosylation Asn-13, Asn-83, Asn-274 and Asn-279 Cterm SpecificSite N-glycosylation Asn-13, Asn-83, Asn-274 and Asn-279 In the present study, mass spectrometry (MS) and nuclear magnetic resonance spectroscopy were used to define the structure of this glycan attached to at least four of the seven putative S-layer glycoprotein N-glycosylation sites, namely Asn-13, Asn-83, Asn-274 and Asn-279. 26863921 3 24 part_of N-glycosylation 633:647 arg1 Asn-274 N-glycosylation Asn-13, Asn-83, Asn-274 and Asn-279 Cterm SpecificSite N-glycosylation Asn-13, Asn-83, Asn-274 and Asn-279 In the present study, mass spectrometry (MS) and nuclear magnetic resonance spectroscopy were used to define the structure of this glycan attached to at least four of the seven putative S-layer glycoprotein N-glycosylation sites, namely Asn-13, Asn-83, Asn-274 and Asn-279. 26863921 3 24 part_of N-glycosylation 633:647 arg1 Asn-83 N-glycosylation Asn-13, Asn-83, Asn-274 and Asn-279 Cterm SpecificSite N-glycosylation Asn-13, Asn-83, Asn-274 and Asn-279 In the present study, mass spectrometry (MS) and nuclear magnetic resonance spectroscopy were used to define the structure of this glycan attached to at least four of the seven putative S-layer glycoprotein N-glycosylation sites, namely Asn-13, Asn-83, Asn-274 and Asn-279. 26863921 3 24 part_of N-glycosylation 633:647 arg1 Asn-274 N-glycosylation Asn-13, Asn-83, Asn-274 and Asn-279 Cterm SpecificSite N-glycosylation Asn-13, Asn-83, Asn-274 and Asn-279 In the present study, mass spectrometry (MS) and nuclear magnetic resonance spectroscopy were used to define the structure of this glycan attached to at least four of the seven putative S-layer glycoprotein N-glycosylation sites, namely Asn-13, Asn-83, Asn-274 and Asn-279. 26863921 3 24 part_of N-glycosylation 633:647 arg1 Asn-83 N-glycosylation Asn-13, Asn-83, Asn-274 and Asn-279 Cterm SpecificSite N-glycosylation Asn-13, Asn-83, Asn-274 and Asn-279 In the present study, mass spectrometry (MS) and nuclear magnetic resonance spectroscopy were used to define the structure of this glycan attached to at least four of the seven putative S-layer glycoprotein N-glycosylation sites, namely Asn-13, Asn-83, Asn-274 and Asn-279. 26863921 3 24 part_of N-glycosylation 633:647 arg1 Asn-83 N-glycosylation Asn-13, Asn-83, Asn-274 and Asn-279 Cterm SpecificSite N-glycosylation Asn-13, Asn-83, Asn-274 and Asn-279 In the present study, mass spectrometry (MS) and nuclear magnetic resonance spectroscopy were used to define the structure of this glycan attached to at least four of the seven putative S-layer glycoprotein N-glycosylation sites, namely Asn-13, Asn-83, Asn-274 and Asn-279. 26863921 3 57 part_of S-layer 612:618 arg1 Asn-279 S-layer Asn-13, Asn-83, Asn-274 and Asn-279 Cterm SpecificSite S-layer Asn-13, Asn-83, Asn-274 and Asn-279 In the present study, mass spectrometry (MS) and nuclear magnetic resonance spectroscopy were used to define the structure of this glycan attached to at least four of the seven putative S-layer glycoprotein N-glycosylation sites, namely Asn-13, Asn-83, Asn-274 and Asn-279. 26863921 3 57 part_of S-layer 612:618 arg1 Asn-274 S-layer Asn-13, Asn-83, Asn-274 and Asn-279 Cterm SpecificSite S-layer Asn-13, Asn-83, Asn-274 and Asn-279 In the present study, mass spectrometry (MS) and nuclear magnetic resonance spectroscopy were used to define the structure of this glycan attached to at least four of the seven putative S-layer glycoprotein N-glycosylation sites, namely Asn-13, Asn-83, Asn-274 and Asn-279. 26863921 3 57 part_of S-layer 612:618 arg1 Asn-83 S-layer Asn-13, Asn-83, Asn-274 and Asn-279 Cterm SpecificSite S-layer Asn-13, Asn-83, Asn-274 and Asn-279 In the present study, mass spectrometry (MS) and nuclear magnetic resonance spectroscopy were used to define the structure of this glycan attached to at least four of the seven putative S-layer glycoprotein N-glycosylation sites, namely Asn-13, Asn-83, Asn-274 and Asn-279. 26863921 3 57 part_of S-layer 612:618 arg1 Asn-274 S-layer Asn-13, Asn-83, Asn-274 and Asn-279 Cterm SpecificSite S-layer Asn-13, Asn-83, Asn-274 and Asn-279 In the present study, mass spectrometry (MS) and nuclear magnetic resonance spectroscopy were used to define the structure of this glycan attached to at least four of the seven putative S-layer glycoprotein N-glycosylation sites, namely Asn-13, Asn-83, Asn-274 and Asn-279. 26863921 3 57 part_of S-layer 612:618 arg1 Asn-83 S-layer Asn-13, Asn-83, Asn-274 and Asn-279 Cterm SpecificSite S-layer Asn-13, Asn-83, Asn-274 and Asn-279 In the present study, mass spectrometry (MS) and nuclear magnetic resonance spectroscopy were used to define the structure of this glycan attached to at least four of the seven putative S-layer glycoprotein N-glycosylation sites, namely Asn-13, Asn-83, Asn-274 and Asn-279. 26863921 3 57 part_of S-layer 612:618 arg1 Asn-83 S-layer Asn-13, Asn-83, Asn-274 and Asn-279 Cterm SpecificSite S-layer Asn-13, Asn-83, Asn-274 and Asn-279 In the present study, mass spectrometry (MS) and nuclear magnetic resonance spectroscopy were used to define the structure of this glycan attached to at least four of the seven putative S-layer glycoprotein N-glycosylation sites, namely Asn-13, Asn-83, Asn-274 and Asn-279. 26576925 2 1 gly has 258:260 arg1 PrP AND two sialylated N-linked carbohydrates PrP two sialylated N-linked carbohydrates PUBTATOR PrP 19122 PrP(C) has two sialylated N-linked carbohydrates. 26576925 2 1 gly has 258:260 arg1 C AND two sialylated N-linked carbohydrates C two sialylated N-linked carbohydrates Cterm C 19122 PrP(C) has two sialylated N-linked carbohydrates. 24575722 8 94 gly fucosylated 1477:1487 arg1 fucosylated haptoglobin fucosylated haptoglobin PUBTATOR haptoglobin 3240 The combination of CA125 and fucosylated haptoglobin resulted in an AUC of 0.855, which outperforms CA125 to distinguish early-stage cancer from noncases. 28230186 0 29 gly IgM 56:58 arg1 Glycan-independent binding IgM Glycan-independent binding PUBTATOR IgM P01871 Glycan-independent binding and internalization of human IgM to FCMR, its cognate cellular receptor. 26618856 4 66 gly glycosylation 729:741 arg1 IDP structure IDP structure OGER IDP P48735 An important open question is, does glycosylation affect IDP structure or binding characteristics or both? 26488311 8 4 gly glycoforms 1402:1411 arg1 specific clusterin glycoforms specific clusterin glycoforms OGER clusterin P10909 These results provide a novel and robust workflow suitable for rapid verification of specific clusterin glycoforms with utility as AD biomarkers. 25142936 3 55 gly possesses 551:559 arg1 eNPP 6 AND four N-glycans eNPP 6 four N-glycans PUBTATOR eNPP 6 537431 eNPP 6 consists of two identical monomers of 55 kDa joined by a disulfide bridge, and possesses four N-glycans in each monomer. 24352591 7 75 gly glycoform 1671:1679 arg1 a unique phosphacan glycoform a unique phosphacan glycoform PUBTATOR phosphacan 19283 Furthermore, we characterized the as-yet-unknown epitope of the 6B4 monoclonal antibody (mAb), which was thought to recognize a unique phosphacan glycoform. 28452462 0 34 gly Erythropoietin 27:40 arg1 Glycan Remodeling Human Erythropoietin Glycan Remodeling PUBTATOR Human Erythropoietin 2056 Glycan Remodeling of Human Erythropoietin (EPO) Through Combined Mammalian Cell Engineering and Chemoenzymatic Transglycosylation. 26576925 8 2 gly desialylation 1264:1276 arg1 C C Cterm C 19122 Moreover, as predicted by the hypothesis, partial desialylation of PrP(C) significantly increased the replication rate. 26576925 8 2 gly desialylation 1264:1276 arg1 PrP PrP PUBTATOR PrP 19122 Moreover, as predicted by the hypothesis, partial desialylation of PrP(C) significantly increased the replication rate. 26576925 8 58 gly PrP 1281:1283 arg1 partial desialylation PrP partial desialylation PUBTATOR PrP 19122 Moreover, as predicted by the hypothesis, partial desialylation of PrP(C) significantly increased the replication rate. 29029079 0 27 gly dismutase 40:48 arg1 Sialylation extracellular superoxide dismutase Sialylation PUBTATOR extracellular superoxide dismutase 6649 Sialylation of extracellular superoxide dismutase (EC-SOD) enhances furin-mediated cleavage and secretion. 24028868 6 91 gly Glycans 758:764 arg1 EEQYNSTYR (IgG1) EEQYNSTYR (IgG1 Glycans OGER EEQYNSTYR (IgG1 P01857 Glycans on peptides EEQYNSTYR (IgG1) and EEQFNSTFR (IgG2) were quantified, and their abundances were normalized to total IgGn glycoform abundance. 24028868 6 91 gly Glycans 758:764 arg1 EEQFNSTFR (IgG2) EEQFNSTFR (IgG2 Glycans OGER EEQFNSTFR (IgG2 P01859 Glycans on peptides EEQYNSTYR (IgG1) and EEQFNSTFR (IgG2) were quantified, and their abundances were normalized to total IgGn glycoform abundance. 25142936 7 56 gly eNPP6 1358:1362 arg1 an alternative Golgi glycan-processing pathway eNPP6 an alternative Golgi glycan-processing pathway PUBTATOR eNPP6 537431 Thus, the non-classical glycan processing pathway of brain eNPP 6 is not due to mannose-6-phosphorylation, suggesting that there is an alternative Golgi glycan-processing pathway of eNPP6 in brain. 25142936 7 71 gly eNPP 1235:1238 arg1 the non-classical glycan processing pathway eNPP 6 the non-classical glycan processing pathway PUBTATOR eNPP 6 537431 Thus, the non-classical glycan processing pathway of brain eNPP 6 is not due to mannose-6-phosphorylation, suggesting that there is an alternative Golgi glycan-processing pathway of eNPP6 in brain. 25499076 5 45 gly present 859:865 arg1 native, pituitary G-hPRL AND the N-glycan structures native, pituitary G-hPRL the N-glycan structures PUBTATOR hPRL P01236 The main objective of this study was to determine the N-glycan structures present in native, pituitary G-hPRL and compare them with those present in the recombinant hormone. 27638310 0 44 gly GM-CSF 57:62 arg1 O-glycans GM-CSF O-glycans PUBTATOR GM-CSF 1437 O-glycans and O-glycosylation sites of recombinant human GM-CSF derived from suspension-cultured rice cells, and their structural role. 27638310 0 46 gly O-glycosylation 14:28 arg1 recombinant human GM-CSF recombinant human GM-CSF PUBTATOR GM-CSF 1437 O-glycans and O-glycosylation sites of recombinant human GM-CSF derived from suspension-cultured rice cells, and their structural role. 27614258 0 13 gly IgGs 125:128 arg1 Fc N-glycans IgGs Fc N-glycans Cterm IgGs Applying mini-bore HPAEC-MS/MS for the characterization and quantification of Fc N-glycans from heterogeneously glycosylated IgGs. 27614258 0 32 gly glycosylated 112:123 arg1 heterogeneously glycosylated IgGs heterogeneously glycosylated IgGs Cterm IgGs Applying mini-bore HPAEC-MS/MS for the characterization and quantification of Fc N-glycans from heterogeneously glycosylated IgGs. 27649061 9 111 gly glycoforms 1678:1687 arg1 IgG glycoforms IgG glycoforms Cterm IgG Our results show that optimized CID fragmentation enables DIA of IgG glycoforms and suggest that such workflow may enable quantitative analyses of the glycoproteome in complex matrixes. 25142936 0 63 gly phosphodiesterase/pyrophosphatase 78:110 arg1 The non-classical N-glycan processing pathway ecto-nucleotide phosphodiesterase/pyrophosphatase 6 The non-classical N-glycan processing pathway PUBTATOR ecto-nucleotide phosphodiesterase/pyrophosphatase 6 537431 The non-classical N-glycan processing pathway of bovine brain ecto-nucleotide phosphodiesterase/pyrophosphatase 6 (eNPP6) is brain specific and not due to mannose-6-phosphorylation. 28920453 4 19 gly O-glycans 623:631 arg1 rhEPOs rhEPOs O-glycans Cterm rhEPOs We developed selective and sensitive method to profile native O-glycans on rhEPOs. 25462875 5 17 part_of had 836:838 arg1 the B4GALT1 AND a leucine the B4GALT1 a leucine PUBTATOR SpecificSite B4GALT1 2683 leucine at position 282 We also noted that the B4GALT1 used in our study had a leucine at position 282, whereas all other animal B4GALT1 sequences have an aromatic amino acid at this position. 29273683 5 11 part_of N230 549:552 arg1 rat CBG CBG N230 PUBTATOR SpecificSite CBG 299270 N230 We now show that mutations of conserved N-glycosylation sites at N238 in human CBG and N230 in rat CBG disrupt steroid binding. 29273683 5 58 part_of N238 527:530 arg1 human CBG CBG N238 PUBTATOR SpecificSite CBG 866 N238 We now show that mutations of conserved N-glycosylation sites at N238 in human CBG and N230 in rat CBG disrupt steroid binding. 29190644 5 34 gly glycoforms 888:897 arg1 monomeric human BChE glycoforms monomeric human BChE glycoforms PUBTATOR BChE 590 To investigate the effects of populating glycosylation site ASN241, monomeric human BChE glycoforms were simulated with and without site ASN241 glycosylated. 26908049 7 9 gly nonglycosylated 1160:1174 arg1 glycosylated and nonglycosylated ART glycosylated and nonglycosylated ART PUBTATOR ART 9048 RESULTS No difference in pharmacokinetics or relative potency was revealed between glycosylated and nonglycosylated ART. 26908049 7 20 gly glycosylated 1143:1154 arg1 glycosylated and nonglycosylated ART glycosylated and nonglycosylated ART PUBTATOR ART 9048 RESULTS No difference in pharmacokinetics or relative potency was revealed between glycosylated and nonglycosylated ART. 25546301 1 1 gly gp120 281:285 arg1 the 15 N-linked glycans gp120 the 15 N-linked glycans PUBTATOR gp120 155971 The crystal structure of a fully glycosylated HIV-1 gp120 core in complex with CD4 receptor and Fab 17b at 4.5-Å resolution reveals 9 of the 15 N-linked glycans of core gp120 to be partially ordered. 28322444 1 13 gly glycosylated 198:209 arg1 The potassium ion channel Kv3.1b The potassium ion channel Kv3.1b Cterm Kv3.1b The potassium ion channel Kv3.1b is a member of a family of voltage-gated ion channels that are glycosylated in their mature form. 24824609 3 41 gly glycosylation 647:659 arg1 antithrombin antithrombin PUBTATOR antithrombin 462 OBJECTIVES: To evaluate the effects of different natural pleiotropic mutations on the glycosylation of antithrombin and their functional effects. 26059044 9 20 gly IL-22 1367:1371 arg1 the atypical N-glycan composition IL-22 the atypical N-glycan composition PUBTATOR IL-22 50929 However, we do show that the presence of a N-glycan on Asn54 contributes to the atypical N-glycan composition of plant-produced IL-22 and influences the N-glycan composition of N-glycans on other positions. 27718394 8 9 gly glycosylation 1510:1522 arg1 alpha-1-antitrypsin alpha-1-antitrypsin PUBTATOR alpha-1-antitrypsin 5265 The developed method was evaluated concerning its specificity, and thereafter implemented for studying the glycosylation pattern of two different proteins, alpha-1-antitrypsin and transferrin, in human serum and cerebrospinal fluid. 27718394 8 9 gly glycosylation 1510:1522 arg1 transferrin transferrin PUBTATOR transferrin 7018 The developed method was evaluated concerning its specificity, and thereafter implemented for studying the glycosylation pattern of two different proteins, alpha-1-antitrypsin and transferrin, in human serum and cerebrospinal fluid. 28277614 9 123 gly present 1839:1845 arg2 cellobiohydrolase I AND this novel O-glycan composition cellobiohydrolase I domain this novel O-glycan composition Cterm cellobiohydrolase I domain Using glycopeptide analysis, this novel O-glycan composition was found to be present on the catalytic domain of cellobiohydrolase I, the most abundant secreted protein by T. reesei. 24997456 3 68 gly glycosylations 509:522 arg1 full-length rhPRG4 full-length rhPRG4 OGER rhPRG4 Q92954 The objectives of this study were to 1) biochemically characterize the gross structure and glycosylations of full-length rhPRG4, and 2) assess the ocular surface boundary lubricating ability of rhPRG4 at both human cornea-eyelid and human cornea-polydimethylsiloxane (PDMS) biointerfaces. 29119347 2 37 gly Man5 1003:1006 arg1 high-mannose N-glycans IDUA high-mannose N-glycans PUBTATOR IDUA 3425 Both strategies effectively prevented N-glycan maturation and the resultant N-glycan structures on the consensus sites for N-glycosylation of the human enzyme revealed high-mannose N-glycans of predominantly Man5 (cgl-IDUA) or Man6-8 (gm1-IDUA) structures. 27038031 4 20 gly N-glycosylation 476:490 arg1 recombinant pentameric and hexameric IgM recombinant pentameric and hexameric IgM OGER IgM P01871 In this study, the N-glycosylation of recombinant pentameric and hexameric IgM produced by the same human cell type and culture conditions was site-specifically profiled by RP-LC-CID/ETD-MS/MS using HILIC-enriched tryptic and GluC glycopeptides. 29106908 3 23 gly glycosylated 369:380 arg1 IgMs IgMs Cterm IgMs IgMs are large, complex and highly glycosylated proteins that are only stable in a limited range of conditions. 25658763 5 83 gly highly-glycosylated 1147:1165 arg1 HG-EMMPRIN HG-EMMPRIN PUBTATOR HG-EMMPRIN 682 RESULTS 1) It was mainly the highly-glycosylated form of EMMPRIN (HG-EMMPRIN) that increased after being exposed to inflammatory signals (PMA and H2O2). 25658763 5 83 gly highly-glycosylated 1147:1165 arg1 the highly-glycosylated form form of EMMPRIN PUBTATOR form of EMMPRIN 682 RESULTS 1) It was mainly the highly-glycosylated form of EMMPRIN (HG-EMMPRIN) that increased after being exposed to inflammatory signals (PMA and H2O2). 28803068 3 45 gly glycosylated/de-glycosylated 468:495 arg1 hIFNγ-CHO hIFNγ-CHO PUBTATOR hIFNγ (hIFNγ 3458 The efficacy of E. coli- and mammalian-expressed hIFNγ (hIFNγ-CHO and HEK293, glycosylated/de-glycosylated) on cytostasis, cell death (MTT, and Guava-ViaCount® flow-cytometry) and apoptotic signalling (Western blot of Cdk2, histone H3, procaspase-3, FADD, cleaved PARP, and caspase-3) was examined. 26567221 6 1 gly Non-glycosylated 917:932 arg1 N→Q N→Q PUBTATOR N→Q) HMGB1 proteins 3146 Non-glycosylated double mutant (N→Q) HMGB1 proteins (HMGB1(N37Q/N134Q) and HMGB1(N37Q/N135Q)) showed localization to the nuclei, strong binding to DNA, weak binding to the nuclear export protein CRM1 and rapid degradation by ubiquitylation. 29268168 1 40 part_of position 199:206 arg1 IgG IgG position PUBTATOR SpecificSite IgG 16059 position N297 The binding strength between IgG and FcγR is influenced by the composition of the N-linked glycan at position N297 in the Fc-domain of IgG. 27649061 4 73 gly glycoforms 566:575 arg1 IgG IgG Cterm IgG We present a workflow for quantitative analysis of site specific glycoforms of IgG based on data independent acquisition (DIA) of Y-ions generated under "minimal" fragmentation conditions. 24780636 2 18 gly glycoforms 191:200 arg1 Transferrin glycoforms Transferrin glycoforms PUBTATOR Transferrin 7018 Transferrin glycoforms Tf-1 and Tf-2, previously identified in human cerebrospinal fluid, are defined as the lower and upper bands in gel electrophoresis, respectively. 27161092 6 26 gly O-glycosylation 987:1001 arg1 Muc5ac Muc5ac PUBTATOR Muc5ac P98088 Our results demonstrated that the FUT2 determines the O-glycosylation pattern of Muc5ac, with Fut2 knock-out leading to a marked decrease in α1,2-fucosylated structures and increased expression of the terminal type 1 glycan structure Lewis-a. 27984785 4 21 gly present 477:483 arg2 GP1,2 AND approximately 50 different N-glycan structures GP1 approximately 50 different N-glycan structures PUBTATOR GP1 9567 Here we demonstrate that approximately 50 different N-glycan structures are present in GP1,2 derived from the four pathogenic ebolaviruses, including high mannose, hybrid, and bi-, tri-, and tetra-antennary complex glycans with and without fucose and sialic acid. 26182462 8 74 gly albumin 1225:1231 arg1 the N-glycans albumin the N-glycans OGER albumin P02768 Secondly, maltoheptaose and the N-glycans from chicken egg albumin were used as standard samples to optimize the enrichment conditions and evaluate the enrichment efficiency of pGMAG-SiO2. 25071157 5 38 gly present 1133:1139 arg2 IgA1 AND Tn antigen IgA1 Tn antigen PUBTATOR IgA1 P01876 Importantly, Tn antigen present on IgA1 from IgAN patients and controls was convertible into the core 1 structure in vitro by recombinant T-synthase. 25094044 3 8 gly attached 576:583 arg1 UGGT1 AND glycan UGGT1 glycan PUBTATOR UGGT1 56886 The structure of glycan attached to UGGT1, however, has not been investigated. 29187599 3 84 part_of sites 367:371 arg1 rhDAO rhDAO sites OGER SpecificSite rhDAO O35078 sites Asn-168, Asn-538, and Asn-745 We recently reported that the N-glycosylation sites Asn-168, Asn-538, and Asn-745 in recombinant hDAO (rhDAO) carry complex-type glycans, whereas Asn-110 carries only mammalian-atypical oligomannosidic glycans. 29187599 3 84 part_of sites 367:371 arg1 recombinant hDAO hDAO sites PUBTATOR SpecificSite hDAO 1610 sites Asn-168, Asn-538, and Asn-745 We recently reported that the N-glycosylation sites Asn-168, Asn-538, and Asn-745 in recombinant hDAO (rhDAO) carry complex-type glycans, whereas Asn-110 carries only mammalian-atypical oligomannosidic glycans. 26701617 0 41 gly Glycosylation 50:62 arg1 Recombinant Human Platelet-Derived Growth Factor-BB Recombinant Human Platelet-Derived Growth Factor-BB OGER Platelet-Derived Growth Factor Identification and Functional Characterization of Glycosylation of Recombinant Human Platelet-Derived Growth Factor-BB in Pichia pastoris. 29062024 6 8 gly IgG1-Fc 1152:1158 arg1 core fucosylation IgG1 core fucosylation OGER IgG1 P01857 Moreover, our simulation demonstrates that core fucosylation of IgG1-Fc affects conformational dynamics and rearrangements of surrounding amino acid residues, typified by Tyr296 of IgG1-Fc, which was more extensively involved in the interaction with sFcγRIIIa without Fc core fucosylation. 29062024 6 58 gly fucosylation 1136:1147 arg1 IgG1-Fc IgG1-Fc OGER IgG1 P01857 Moreover, our simulation demonstrates that core fucosylation of IgG1-Fc affects conformational dynamics and rearrangements of surrounding amino acid residues, typified by Tyr296 of IgG1-Fc, which was more extensively involved in the interaction with sFcγRIIIa without Fc core fucosylation. 28318221 1 45 gly N-glycosylation 137:151 arg1 IgG IgG Cterm IgG N-glycosylation on IgG modulates Fc conformation and effector functions. 27604319 1 35 gly glycoprotein 148:159 arg1 SU SU Cterm SU Q14624 The surface envelope glycoprotein (SU) of Human immunodeficiency virus type 1 (HIV-1), gp120(SU) plays an essential role in virus binding to target CD4+ T-cells and is a major vaccine target. 27604319 1 35 gly glycoprotein 148:159 arg1 The surface envelope glycoprotein The surface envelope glycoprotein PUBTATOR envelope glycoprotein 155971 The surface envelope glycoprotein (SU) of Human immunodeficiency virus type 1 (HIV-1), gp120(SU) plays an essential role in virus binding to target CD4+ T-cells and is a major vaccine target. 28170415 9 52 gly contain 1087:1093 arg1 hLF AND mostly neutral complex/hybrid N-glycans hLF mostly neutral complex/hybrid N-glycans PUBTATOR hLF 3131 Based on the relative abundances of N-glycan types, rhLF and hLF appeared to contain mostly neutral complex/hybrid N-glycans (81% and 52% of the total respectively) whereas bLF was characterized by high mannose glycans (65%). 28170415 9 52 gly contain 1087:1093 arg1 rhLF AND mostly neutral complex/hybrid N-glycans rhLF mostly neutral complex/hybrid N-glycans OGER rhLF P02788 Based on the relative abundances of N-glycan types, rhLF and hLF appeared to contain mostly neutral complex/hybrid N-glycans (81% and 52% of the total respectively) whereas bLF was characterized by high mannose glycans (65%). 27638310 9 18 gly rrhGM-CSF 1338:1346 arg1 O-glycans CSF O-glycans OGER CSF These findings indicate that O-glycans of rrhGM-CSF are essential for maintaining its structural stability and result in an extended in vivo half-life, but without affecting its biological function. 27038031 0 36 gly N-Glycosylation 14:28 arg1 Hexameric Human IgM Hexameric Human IgM OGER IgM P01871 Site-Specific N-Glycosylation of Recombinant Pentameric and Hexameric Human IgM. 28630087 12 18 gly N-glycosylated 2047:2060 arg1 α1-antitrypsin α1-antitrypsin PUBTATOR 1-antitrypsin 5265 The heavily N-glycosylated HNE protease inhibitor, α1-antitrypsin, displayed concentration-dependent complex formation and preferred glycoform-glycoform interactions with HNE. 28397166 7 78 gly glycosylation 1328:1340 arg1 IgG IgG Cterm IgG The results indicate that CE coupled with MSn can identify abnormal glycosylation of IgG in RA patients compared with healthy people, and that the present work is useful for RA mechanism studies and RA diagnosis. 28955811 5 73 gly Deglycosylated 976:989 arg1 Deglycosylated protein Deglycosylated protein Cterm Deglycosylated protein 8824 Deglycosylated protein did not show a detectable decrease in enzyme activity. 28170415 7 49 gly had 838:840 arg1 hLF AND 23, 27 and 18 N-glycans hLF 23, 27 and 18 N-glycans PUBTATOR hLF 3131 rhLF, bLF and hLF had 23, 27 and 18 N-glycans respectively with 8 N-glycan in common overall. 28170415 7 49 gly had 838:840 arg1 bLF AND 23, 27 and 18 N-glycans bLF 23, 27 and 18 N-glycans Cterm bLF 280846 rhLF, bLF and hLF had 23, 27 and 18 N-glycans respectively with 8 N-glycan in common overall. 28170415 7 49 gly had 838:840 arg1 rhLF AND 23, 27 and 18 N-glycans rhLF 23, 27 and 18 N-glycans OGER rhLF P02788 rhLF, bLF and hLF had 23, 27 and 18 N-glycans respectively with 8 N-glycan in common overall. 26059044 6 12 gly N-glycans 861:869 arg1 IL-22 IL-22 N-glycans PUBTATOR IL-22 50616 Surprisingly, upon engineering of human-like N-glycans on IL-22 by co-expressing mouse FUT8 in ΔXT/FT plants a strong reduction in Lewis A was observed. 27818199 6 56 part_of tACE 845:848 arg1 tACE residues tACE tACE residues PUBTATOR SiteSequence tACE 6868 residues H610-L614 In the proximal ectodomain of tACE residues H610-L614 were mutated to alanines and this resulted in a decrease in ACE shedding. 28378791 5 33 gly glycan 590:595 arg1 GluN2B-N688 GluN2B glycan PUBTATOR GluN2B 2904 The glycan on GluN2B-N688 shows a similar, though weaker, effect. 27614258 3 34 gly derived 799:805 arg1 immunoglobulin G AND N-glycans immunoglobulin G N-glycans Cterm immunoglobulin G Here we applied HPAEC coupled on-line with electrospray ion trap mass spectrometry (HPAEC-MS) using a prototype mini-bore (1mm I.D.) CarboPac PA200 column and challenged the analytical separation based method for the structural assignment of heterogeneous mixtures of N-glycans derived from immunoglobulin G from human plasma, glyco-engineered CHO cells, and Sp2/0 mouse myeloma cells. 26492619 1 45 gly sialoglycoprotein 169:185 arg1 Podoplanin Podoplanin PUBTATOR Podoplanin 10630 Podoplanin (PDPN) is a type-I transmembrane sialoglycoprotein that possesses a platelet aggregation-stimulating (PLAG) domain in the N-terminus. 27547921 2 5 gly GLUT4 276:280 arg1 the N-glycan GLUT4 the N-glycan PUBTATOR GLUT4 6517 To date, it has been unclear whether the N-glycan of GLUT4 contributes to its intracellular trafficking. 28104755 12 0 gly N-glycosylation 1946:1960 arg1 human SMPDL3A human SMPDL3A PUBTATOR SMPDL3A Q92484 In conclusion, site-specific N-glycosylation is essential for the intracellular stability, secretion and activity of human SMPDL3A. 28509333 8 57 gly residues 1327:1334 arg1 native complexed IgG IgG residues Cterm IgG We also observed a significantly higher accessibility to sialic acid residues and galactose/GalNAc glyco-epitopes in native complexed IgG of patients with RA at baseline. 28509333 8 100 gly glyco-epitopes 1357:1370 arg1 native complexed IgG IgG glyco-epitopes Cterm IgG We also observed a significantly higher accessibility to sialic acid residues and galactose/GalNAc glyco-epitopes in native complexed IgG of patients with RA at baseline. 28516782 5 68 gly carry 887:891 arg1 plant-produced IgAs AND mainly complex-type biantennary N-glycans plant-produced IgAs mainly complex-type biantennary N-glycans Cterm IgAs P11912 Mass-spectrometric analysis of site-specific glycosylation revealed that plant-produced IgAs carry mainly complex-type biantennary N-glycans. 25451932 8 69 gly N-glycosylation 978:992 arg1 corin cell surface targeting corin cell surface targeting PUBTATOR corin 10699 Moreover, N-glycosylation at Asn-697 in the scavenger receptor domain and at Asn-1022 in the protease domain is important for corin cell surface targeting and zymogen activation. 26959529 1 72 gly Oligosaccharides 122:137 arg1 milk milk Oligosaccharides PUBTATOR milk 100532204 Oligosaccharides in milk not only provide nutrition to the infants but also have significant immune biofunctions such as inhibition of pathogen binding to the host cell. 28301166 8 46 gly O-glycans 1264:1272 arg1 noninfected pigs pigs O-glycans OGER pigs Q96S52 The dominating structures shifted from core-4-type O-glycans in noninfected pigs toward core-2-type O-glycans in infected animals, which correlated with increased levels of the C2GnT glycosyl transferase. 25554420 3 30 gly N-glycosylation 579:593 arg1 CR3 CR3 OGER CR3 Examination of CR3 mutant variants and mass spectrometry analysis of the N-glycosylation pattern of CR3 revealed that N-glycans located in the C-terminal part of the CD11b subunit are involved in binding and cytotoxic activity of CyaA. 26657071 8 68 gly N-glycosylation 1386:1400 arg1 hCES1 hCES1 PUBTATOR hCES1 1066 Overall the results indicate that preventing N-glycosylation of hCES1 does not significantly affect the structure or activity of the enzyme. 28630087 1 25 gly N-glycosylated 170:183 arg1 Human neutrophil elastase Human neutrophil elastase PUBTATOR Human neutrophil elastase 1991 Human neutrophil elastase (HNE) is an important N-glycosylated serine protease in the innate immune system, but the structure and immune-modulating functions of HNE N-glycosylation remain undescribed. 25402728 7 8 gly glycan 824:829 arg1 ANXA2 ANXA2 glycan PUBTATOR ANXA2 302 N-linked mannose-rich glycan on ANXA2 may mediate the interaction. 25940448 7 1 gly glycans 1220:1226 arg1 Notch Notch glycans PUBTATOR Notch 31293 The clustered phenotypes reflected the biosynthetic pathways of GAGs, Fringe-dependent glycan on Notch, and glycans placed at or near nonreducing ends (herein termed terminal domains of glycans). 25940448 7 48 gly glycan 1199:1204 arg1 Notch Notch glycan PUBTATOR Notch 31293 The clustered phenotypes reflected the biosynthetic pathways of GAGs, Fringe-dependent glycan on Notch, and glycans placed at or near nonreducing ends (herein termed terminal domains of glycans). 26056814 3 1 gly A/California/07/09 679:696 arg1 The glycan-binding selectivity A/California/07/09 HAs The glycan-binding selectivity OGER A/California/07/09 HAs Q92839 The glycan-binding selectivity of three A/California/07/09 vaccine production strains, and purified recombinant A/California/07/09 HAs harboring these mutations was examined via a solid-phase ELISA assay. 25261856 5 20 gly acid 894:897 arg1 α2,3- 2,3- acid PUBTATOR 2,3- 28923 The N-glycans found in the CSF were predominantly complex diantennary with sialic acid in α2,3- and α2,6-linkage, and bisecting N-acetylglucosamine-containing structures as well as peripherally fucosylated structures were found. 25261856 5 39 gly found 826:830 arg1 the CSF AND The N-glycans the CSF The N-glycans OGER CSF The N-glycans found in the CSF were predominantly complex diantennary with sialic acid in α2,3- and α2,6-linkage, and bisecting N-acetylglucosamine-containing structures as well as peripherally fucosylated structures were found. 26701617 5 64 gly O-glycosylated 780:793 arg1 PDGF-BB PDGF-BB OGER PDGF We demonstrated that PDGF-BB was O-glycosylated during the secretion process and detected putative O-glycosylation sites using glycosylation staining and immunoblotting. 25261856 3 61 gly N-glycosylation 532:546 arg1 the CSF the CSF OGER CSF Furthermore, we compared protein N-glycosylation of the CSF in ALS patients and controls, by applying a glycomics approach based on liquid chromatography and mass spectrometry. 29255015 1 19 gly Vp54 192:195 arg1 The glycans Vp54 The glycans Cterm Vp54 The glycans of the major capsid protein (Vp54) of Paramecium bursaria chlorella virus (PBCV-1) were recently described and found to be unusual. 26328495 6 20 gly O-glycans 840:848 arg1 POMGNT1 POMGNT1 O-glycans PUBTATOR POMGNT1 55624 Next, we analyzed the structures of the O-glycans on POMGNT1 by β-elimination and pyrazolone-labeling methods in combination with mass spectrometry. 29062024 6 36 part_of IgG1-Fc 1269:1275 arg1 Tyr296 IgG1 Tyr296 OGER AminoAcid IgG1 P01857 Tyr296 Moreover, our simulation demonstrates that core fucosylation of IgG1-Fc affects conformational dynamics and rearrangements of surrounding amino acid residues, typified by Tyr296 of IgG1-Fc, which was more extensively involved in the interaction with sFcγRIIIa without Fc core fucosylation. 25305020 3 70 part_of calcium-sensing 697:711 arg1 residues 20-612 calcium-sensing receptor residues 20-612 PUBTATOR SpecificSite calcium-sensing receptor 846 residues 20-612 In the present study, we purified the glycosylated extracellular domain of calcium-sensing receptor (CaSR) (ECD) (residues 20-612), containing either complex or high mannose N-glycan structures depending on the host cell line employed for recombinant expression. 24719303 0 46 gly B 36:36 arg1 the glycan moiety RNase B the glycan moiety OGER RNase B P07998 Studying the glycan moiety of RNase B by means of Raman and Raman optical activity. 24473128 3 51 gly glycan 323:328 arg1 The glycan cap MLD The glycan cap OGER MLD O09005 The glycan cap contains only N-linked glycans, whereas the MLD contains both N- and O-linked glycans. 28696719 0 58 gly Glyco-Microheterogeneity 16:39 arg1 Plasma von Willebrand Factor Plasma von Willebrand Factor PUBTATOR Plasma von Willebrand Factor 7450 An Insight into Glyco-Microheterogeneity of Plasma von Willebrand Factor by Mass Spectrometry. 28575723 5 21 gly glycoform 741:749 arg1 Cha o 3 Cha o 3 OGER Cha o 3 Q9UL49 The glycoform of Cha o 3 bearing the Lea epitope is similar to those of Cry j1, Jun a 1, or Cup a 1, major glycoallergens in cedar or cypress pollens, and the predominant occurrence of GlcNAc2Man3Xyl1Fuc1GlcNAc2 is a common structural feature of glycoallergens from Cupressaceae pollens. 25071157 3 5 gly glycoforms 760:769 arg1 IgA1 IgA1 PUBTATOR IgA1 P01876 Here we have used serial lectin separation technologies, Western blot, enzymatic modifications, and mass spectrometry to explore whether there are different glycoforms of IgA1 in plasma from patients with IgAN and healthy individuals. 28039139 12 20 gly N-glycosylation 2602:2616 arg1 S-layer integrity S-layer integrity Cterm S-layer Here, insight into the purpose of archaeal N-glycosylation was gained by addressing the surface layer (S-layer) surrounding cells of the halophilic species Haloferax volcanii Relying on mutant strains defective in N-glycosylation, such efforts revealed that compromised N-glycosylation affected S-layer integrity and the transfer of a secreted reporter protein across the S-layer into the growth medium, as well as the conformation of the S-layer glycoprotein, the sole component of the S-layer. 27649061 7 18 gly glycoforms 1134:1143 arg1 IgG IgG Cterm IgG Under optimized conditions, we achieve label-free quantification of the majority of previously reported glycoforms of IgG (26 glycoforms of IgG1, 22 glycoforms of IgG 2/3, and 19 glycoforms of IgG4) directly in unfractionated samples of human plasma and we detect traces of previously unreported glycoforms of IgG1, including doubly fucosylated glycoforms. 27649061 7 47 gly glycoforms 1179:1188 arg1 IgG4 IgG4 OGER IgG4 P01861 Under optimized conditions, we achieve label-free quantification of the majority of previously reported glycoforms of IgG (26 glycoforms of IgG1, 22 glycoforms of IgG 2/3, and 19 glycoforms of IgG4) directly in unfractionated samples of human plasma and we detect traces of previously unreported glycoforms of IgG1, including doubly fucosylated glycoforms. 27649061 7 47 gly glycoforms 1179:1188 arg1 IgG 2/3 IgG 2/3 OGER IgG 2 P01859 Under optimized conditions, we achieve label-free quantification of the majority of previously reported glycoforms of IgG (26 glycoforms of IgG1, 22 glycoforms of IgG 2/3, and 19 glycoforms of IgG4) directly in unfractionated samples of human plasma and we detect traces of previously unreported glycoforms of IgG1, including doubly fucosylated glycoforms. 27649061 7 47 gly glycoforms 1179:1188 arg1 IgG1 IgG1 OGER IgG1 P01857 Under optimized conditions, we achieve label-free quantification of the majority of previously reported glycoforms of IgG (26 glycoforms of IgG1, 22 glycoforms of IgG 2/3, and 19 glycoforms of IgG4) directly in unfractionated samples of human plasma and we detect traces of previously unreported glycoforms of IgG1, including doubly fucosylated glycoforms. 27649061 7 66 gly glycoforms 1326:1335 arg1 IgG1 IgG1 OGER IgG1 P01857 Under optimized conditions, we achieve label-free quantification of the majority of previously reported glycoforms of IgG (26 glycoforms of IgG1, 22 glycoforms of IgG 2/3, and 19 glycoforms of IgG4) directly in unfractionated samples of human plasma and we detect traces of previously unreported glycoforms of IgG1, including doubly fucosylated glycoforms. 27649061 7 91 gly glycoforms 1209:1218 arg1 IgG4 IgG4 OGER IgG4 P01861 Under optimized conditions, we achieve label-free quantification of the majority of previously reported glycoforms of IgG (26 glycoforms of IgG1, 22 glycoforms of IgG 2/3, and 19 glycoforms of IgG4) directly in unfractionated samples of human plasma and we detect traces of previously unreported glycoforms of IgG1, including doubly fucosylated glycoforms. 27649061 7 91 gly glycoforms 1209:1218 arg1 IgG 2/3 IgG 2/3 OGER IgG 2 P01859 Under optimized conditions, we achieve label-free quantification of the majority of previously reported glycoforms of IgG (26 glycoforms of IgG1, 22 glycoforms of IgG 2/3, and 19 glycoforms of IgG4) directly in unfractionated samples of human plasma and we detect traces of previously unreported glycoforms of IgG1, including doubly fucosylated glycoforms. 27649061 7 91 gly glycoforms 1209:1218 arg1 IgG1 IgG1 OGER IgG1 P01857 Under optimized conditions, we achieve label-free quantification of the majority of previously reported glycoforms of IgG (26 glycoforms of IgG1, 22 glycoforms of IgG 2/3, and 19 glycoforms of IgG4) directly in unfractionated samples of human plasma and we detect traces of previously unreported glycoforms of IgG1, including doubly fucosylated glycoforms. 27649061 7 99 gly glycoforms 1156:1165 arg1 IgG4 IgG4 OGER IgG4 P01861 Under optimized conditions, we achieve label-free quantification of the majority of previously reported glycoforms of IgG (26 glycoforms of IgG1, 22 glycoforms of IgG 2/3, and 19 glycoforms of IgG4) directly in unfractionated samples of human plasma and we detect traces of previously unreported glycoforms of IgG1, including doubly fucosylated glycoforms. 27649061 7 99 gly glycoforms 1156:1165 arg1 IgG 2/3 IgG 2/3 OGER IgG 2 P01859 Under optimized conditions, we achieve label-free quantification of the majority of previously reported glycoforms of IgG (26 glycoforms of IgG1, 22 glycoforms of IgG 2/3, and 19 glycoforms of IgG4) directly in unfractionated samples of human plasma and we detect traces of previously unreported glycoforms of IgG1, including doubly fucosylated glycoforms. 27649061 7 99 gly glycoforms 1156:1165 arg1 IgG1 IgG1 OGER IgG1 P01857 Under optimized conditions, we achieve label-free quantification of the majority of previously reported glycoforms of IgG (26 glycoforms of IgG1, 22 glycoforms of IgG 2/3, and 19 glycoforms of IgG4) directly in unfractionated samples of human plasma and we detect traces of previously unreported glycoforms of IgG1, including doubly fucosylated glycoforms. 29217182 0 45 gly N-glycosylation 39:53 arg1 immunoglobulin Y immunoglobulin Y Cterm immunoglobulin Y Mass spectrometry characterization for N-glycosylation of immunoglobulin Y from hen egg yolk. 27235585 0 36 gly glycosylation 14:26 arg1 the transferrin structure the transferrin structure PUBTATOR transferrin 7018 The effect of glycosylation on the transferrin structure: A molecular dynamic simulation analysis. 26563299 12 17 gly glycosylation 1741:1753 arg1 IL-15 IL-15 PUBTATOR IL-15 P40933 Highly reproducible glycosylation of IL-15 and sIL-15Rα of two batches of hetIL-15 demonstrated consistent manufacturing and purification. 24854630 0 107 gly O-glycosylation 57:71 arg1 PSA PSA PUBTATOR PSA 354 Increased expression of GCNT1 is associated with altered O-glycosylation of PSA, PAP, and MUC1 in human prostate cancers. 24854630 0 107 gly O-glycosylation 57:71 arg1 PAP PAP PUBTATOR PAP 55 Increased expression of GCNT1 is associated with altered O-glycosylation of PSA, PAP, and MUC1 in human prostate cancers. 24854630 0 107 gly O-glycosylation 57:71 arg1 MUC1 MUC1 PUBTATOR MUC1 4582 Increased expression of GCNT1 is associated with altered O-glycosylation of PSA, PAP, and MUC1 in human prostate cancers. 24692304 1 7 gly glycosylated 198:209 arg1 the glycosylated chemokine Ser-CCL1 the glycosylated chemokine Ser-CCL1 PUBTATOR AminoAcid CCL1 6346 Our goal was to obtain the X-ray crystal structure of the glycosylated chemokine Ser-CCL1. 25036289 7 72 gly disialylated 1124:1135 arg1 fully disialylated IgG Fc fully disialylated IgG Fc Cterm Fc We used chemoenzymatic glycoengineering to prepare fully disialylated IgG Fc and solved its crystal structure. 25402728 12 45 gly glycosylation 1380:1392 arg1 NPC NPC PUBTATOR NPC 4864 This report suggests that suppression of ANXA2 at its expression or glycosylation on NPC may improve DC-mediated immunotherapy for the tumor. 26972002 1 34 gly glycoprotein 123:134 arg1 The HIV-1 envelope glycoprotein The HIV-1 envelope glycoprotein PUBTATOR HIV-1 envelope glycoprotein trimer 155971 The HIV-1 envelope glycoprotein trimer is covered by an array of N-linked glycans that shield it from immune surveillance. 25094044 4 22 gly glycosylation 668:680 arg1 UGGT1 UGGT1 PUBTATOR UGGT1 171129 In this study, we reveal the site of glycosylation (N269) and the glycan structures (Hex5-8HexNAc2) in UGGT1 obtained from rat (Rattus norvegicus), pig (Sus scrofa), cow (Bos taurus), and human (Homo sapiens). 24910992 6 80 gly glycosylated 957:968 arg1 the glycosylated SHH the glycosylated SHH PUBTATOR SHH 6469 Efficient ERAD of N278A requires the core processing complex of HRD1, SEL1L and p97, similar to the glycosylated SHH. 27223297 3 49 gly RVFV 405:408 arg1 five putative N-glycan sequons RVFV five putative N-glycan sequons Cterm RVFV The Rift Valley fever virus (RVFV) glycoproteins (Gn/Gc) encode five putative N-glycan sequons (asparagine (N)-any amino acid (X)-serine (S)/threonine (T)) at positions: N438 (Gn), and N794, N829, N1035, and N1077 (Gc). 25641685 0 51 gly glycoforms 33:42 arg1 apoC-III glycoforms apoC-III glycoforms PUBTATOR apoC-III 345 MALDI-TOF MS applied to apoC-III glycoforms of patients with congenital disorders affecting O-glycosylation. 27145274 1 33 gly IgG 335:337 arg1 no glycan IgG no glycan Cterm IgG Concanavalin A (ConA) chromatography has been extensively used to separate asymmetric Immunoglobulin G (IgG), which possesses oligosaccharide attached to one of the two F(ab')2 arms, from symmetric IgG with no glycan attached to Fab fragments. 27145274 1 57 gly possesses 253:261 arg1 IgG AND oligosaccharide IgG oligosaccharide Cterm IgG Concanavalin A (ConA) chromatography has been extensively used to separate asymmetric Immunoglobulin G (IgG), which possesses oligosaccharide attached to one of the two F(ab')2 arms, from symmetric IgG with no glycan attached to Fab fragments. 27145274 1 57 gly possesses 253:261 arg1 separate asymmetric Immunoglobulin G AND oligosaccharide separate asymmetric Immunoglobulin G oligosaccharide Cterm separate asymmetric Immunoglobulin G Concanavalin A (ConA) chromatography has been extensively used to separate asymmetric Immunoglobulin G (IgG), which possesses oligosaccharide attached to one of the two F(ab')2 arms, from symmetric IgG with no glycan attached to Fab fragments. 28902916 10 20 gly glycosylated 1595:1606 arg1 fully glycosylated Env fully glycosylated Env PUBTATOR Env 100616444 The first was to delete 4 PNGS sites and then boost with fully glycosylated Env; the second was to delete 4 sites and gradually re-introduce these N-glycans in subsequent boosts. 25092234 0 34 gly N-glycosylation 14:28 arg1 human factor XI human factor XI OGER factor XI P03951 Site-specific N-glycosylation analysis of human factor XI: Identification of a noncanonical NXC glycosite. 28935113 9 64 gly oligosaccharides 1532:1547 arg1 the HIV envelope glycoprotein gp120 gp120 oligosaccharides PUBTATOR gp120 155971 The target described here is the HIV broadly neutralizing monoclonal antibody 2G12; 2G12 binds to cluster of high-mannose oligosaccharides on the HIV envelope glycoprotein gp120; and glycopeptides that mimic this epitope may be useful in HIV vaccine applications. 28529241 7 24 gly Sp1-binding 1278:1288 arg1 the β4GalT1 gene promoter Sp1 the β4GalT1 gene promoter OGER Sp1 P08047 The analysis of underlying mechanism for decreased β4-galactosylation of N-glycans showed that the gene expression level of β4-galactosyltransferase (β4GalT) 1 decreases dramatically by downregulation of Sp1 without changes in those of β4GalT2 and N-acetylglucosaminyltransferase V. Mutations in the Sp1-binding sites of the β4GalT1 gene promoter showed that the promoter activity decreases significantly, indicating that the gene expression is regulated by Sp1. 26687240 2 50 gly glycosylated 188:199 arg1 IgE IgE PUBTATOR IgE P01854 IgE is the most heavily glycosylated antibody, but in comparison to other antibodies little is known about its glycan structure function relationships. 28920453 5 31 gly O-glycosylation 653:667 arg1 rhEPO rhEPO OGER rhEPO P11678 RESULTS: O-glycosylation on rhEPO including O-acetylation on a sialic acid was comprehensively characterized. 28920453 5 34 gly rhEPO 672:676 arg1 a sialic acid rhEPO a sialic acid OGER rhEPO P11678 RESULTS: O-glycosylation on rhEPO including O-acetylation on a sialic acid was comprehensively characterized. 25036289 8 4 gly sialylated 1226:1235 arg1 sialylated Fc sialylated Fc Cterm Fc Comparison of the structures of asialylated Fc, sialylated Fc, and F241A Fc, a mutant that displays increased glycan sialylation, suggests that increased conformational flexibility of the CH2 domain is associated with the switch from pro-inflammatory to anti-inflammatory activity of the Fc. 25036289 8 10 gly asialylated 1210:1220 arg1 asialylated Fc asialylated Fc Cterm Fc Comparison of the structures of asialylated Fc, sialylated Fc, and F241A Fc, a mutant that displays increased glycan sialylation, suggests that increased conformational flexibility of the CH2 domain is associated with the switch from pro-inflammatory to anti-inflammatory activity of the Fc. 26512077 6 81 gly present 1455:1461 arg1 the domestic dog TfR TfR present PUBTATOR TfR 403703 Analysis of the TfRs of carnivore hosts used in the experimental evolution studies demonstrated that their glycosylation patterns varied, including a glycan present only on the domestic dog TfR that dictates susceptibility to parvoviruses. 24828077 0 69 gly gp120 79:83 arg1 the high-mannose patch gp120 the high-mannose patch PUBTATOR gp120 3700 Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. 28443077 1 38 gly N-glycosylation 452:466 arg1 HA HA Cterm (HA) Increasing evidence suggests that the antigenic change occasionally occurred concomitant with the alterations of the N-glycosylation site profile and hemagglutination activity of the virion surface protein hemagglutinin (HA). 25275130 8 32 gly structures 1488:1497 arg1 Env Env structures PUBTATOR Env 64006 Thus, N-linked Env glycans display discordant effects on the major events of HIV-1 transmission, with mature oligosaccharide structures on Env playing a crucial role in HIV-1 infection. 28301166 9 30 gly pigs 1455:1458 arg1 glycan chains pigs glycan chains OGER pigs Q96S52 Overall, glycan chains from infected pigs were shorter and had a higher abundance of structures that were neutral or predominantly contained NeuGc instead of NeuAc, whereas they had a lower abundance of structures that were fucosylated, acidic, or sulfated than those from noninfected pigs. 24575722 4 17 gly AAL 730:732 arg1 sugars AAL sugars Cterm AAL In the presence of competing sugars of lectin AAL or with sialic acid removed from the glycoproteins, we confirmed that this method specifically detects glycosylation changes of proteins rather than protein abundance variation. 28680094 6 69 gly β3-I-EGF3 800:808 arg1 the β3-N654 N-glycan 3 the β3-N654 N-glycan PUBTATOR 3 1934 The β3-N559 N-glycan at the β3-I-EGF3 and αIIb-calf-1 domain interface, and the β3-N654 N-glycan at the β3-β-tail and αIIb-calf-2 domain interface positively regulate the activation of both αIIbβ3 and αVβ3 integrins. 28680094 6 69 gly β3-I-EGF3 800:808 arg1 The β3-N559 N-glycan 3 The β3-N559 N-glycan PUBTATOR 3 1934 The β3-N559 N-glycan at the β3-I-EGF3 and αIIb-calf-1 domain interface, and the β3-N654 N-glycan at the β3-β-tail and αIIb-calf-2 domain interface positively regulate the activation of both αIIbβ3 and αVβ3 integrins. 25230686 5 13 gly GnTI 895:898 arg1 the major determinant GnTI the major determinant OGER GnTI P26572 Using co-localization analysis and N-glycan profiling, we show that the transmembrane domain of GnTI is the major determinant for its cis/medial-Golgi localization. 29212317 5 5 gly heterogeneity 859:871 arg1 Apo CIII Apo CIII PUBTATOR form of Apo CIII 345 Here, we profile the O- and N-linked glycosylation of HDL associated-proteins including the truncated form of Apo CIII and their glycan heterogeneity in a site-specific manner. 29212317 5 22 gly glycosylation 760:772 arg1 HDL associated-proteins HDL associated-proteins OGER HDL associated-proteins Q9UNE0 Here, we profile the O- and N-linked glycosylation of HDL associated-proteins including the truncated form of Apo CIII and their glycan heterogeneity in a site-specific manner. 29212317 5 68 gly CIII 837:840 arg1 their glycan heterogeneity form of Apo CIII their glycan heterogeneity PUBTATOR form of Apo CIII 345 Here, we profile the O- and N-linked glycosylation of HDL associated-proteins including the truncated form of Apo CIII and their glycan heterogeneity in a site-specific manner. 25479762 3 8 gly N-glycans 468:476 arg1 hGGT1 hGGT1 N-glycans PUBTATOR hGGT1 2678 The structures of the N-glycans on human GGT1 (hGGT1) have been shown to be tissue-specific. 25479762 3 8 gly N-glycans 468:476 arg1 human GGT1 GGT1 N-glycans PUBTATOR GGT1 2678 The structures of the N-glycans on human GGT1 (hGGT1) have been shown to be tissue-specific. 27161092 5 78 gly O-glycosylation 786:800 arg1 Muc5ac Muc5ac PUBTATOR Muc5ac P98088 In this study we unraveled the O-glycosylation profile of Muc5ac from glycoengineered mice models lacking the FUT2 enzyme and therefore mimicking a non-secretor human phenotype. 27732771 2 22 gly glycoforms 202:211 arg1 VWF glycoforms VWF glycoforms PUBTATOR VWF 22371 VWF glycoforms were used to examine the role of specific glycan moieties in regulating clearance. 24719303 1 23 gly B 232:232 arg1 the glycan moiety the protein ribonuclease B the glycan moiety Cterm the protein ribonuclease B Raman and Raman optical activity (ROA) spectroscopy are used to study the solution-phase structure of the glycan moiety of the protein ribonuclease B (RNase B). 26075384 5 35 gly O-glycosylation 727:741 arg1 the MUC5AC the MUC5AC PUBTATOR MUC5AC 4586 METHODS In this study, we analyzed the expression of the MUC5AC and the O-glycosylation of acidic glycoproteins secreted into ovarian cyst fluids. 24417605 7 21 gly apolipoprotein 1058:1071 arg1 fetuin A. GM3 apolipoprotein CIII fetuin A. GM3 PUBTATOR apolipoprotein CIII 345 The observed O-glycans were all sialylated, and most contained a core 1 structure with two Neu5Acs, including those that were associated with apolipoprotein CIII (ApoC-III) and fetuin A. GM3 (monosialoganglioside, NeuAc2-3Gal1-4Glc-Cer) and GD3 (disialoganglioside, NeuAc2-8NeuAc2-3Gal1-4Glc-Cer) were the major gangliosides in HDL. 28973586 0 54 gly N-glycosylation 35:49 arg1 Auxin-Binding Protein 1 Auxin-Binding Protein 1 PUBTATOR Auxin-Binding Protein 1 542232 The role of Zn2+, dimerization and N-glycosylation in the interaction of Auxin-Binding Protein 1 (ABP1) with different auxins. 28973586 0 54 gly N-glycosylation 35:49 arg1 ABP1 ABP1 PUBTATOR ABP1 P19801 The role of Zn2+, dimerization and N-glycosylation in the interaction of Auxin-Binding Protein 1 (ABP1) with different auxins. 24820161 5 11 gly C-mannosylated 778:791 arg1 intracellular HYAL1 intracellular HYAL1 PUBTATOR HYAL1 3373 Using mass spectrometry, we first demonstrated that intracellular HYAL1 is C-mannosylated at Trp¹³⁰ but not at Trp³²¹. 26154505 2 23 gly N-glycosylation 397:411 arg1 recombinant erythropoietin recombinant erythropoietin PUBTATOR erythropoietin P01588 In order to examine the impact of glycosyltransferase expression on the N-glycosylation of recombinant erythropoietin (rEPO), a human α2,6-sialyltransferase (ST6Gal1) was expressed in Chinese hamster ovary (CHO-K1) cells. 26154505 2 23 gly N-glycosylation 397:411 arg1 rEPO rEPO PUBTATOR rEPO 24335 In order to examine the impact of glycosyltransferase expression on the N-glycosylation of recombinant erythropoietin (rEPO), a human α2,6-sialyltransferase (ST6Gal1) was expressed in Chinese hamster ovary (CHO-K1) cells. 26699903 0 58 gly SCUBE1 59:64 arg1 N-glycan-mediated membrane tethering SCUBE1 N-glycan-mediated membrane tethering PUBTATOR SCUBE1 Q8IWY4 Electrostatics and N-glycan-mediated membrane tethering of SCUBE1 is critical for promoting bone morphogenetic protein signalling. 25628020 6 43 part_of thyroglobulin 1002:1014 arg1 the Asn-76 thyroglobulin the Asn-76 PUBTATOR SpecificSite thyroglobulin 7038 Asn-76 Notably, the Asn-76 of thyroglobulin might be involved in the increased production of thyroid hormones in humans, especially thyroxine (T4), because the removal of the glycan moiety from this site was reported to result in a significant decrease in T4 production. 24692304 0 9 gly non-glycosylated 53:68 arg1 the chemokine Ser-CCL1 the chemokine Ser-CCL1 PUBTATOR AminoAcid CCL1 6346 (Quasi-)racemic X-ray structures of glycosylated and non-glycosylated forms of the chemokine Ser-CCL1 prepared by total chemical synthesis. 24692304 0 67 gly glycosylated 36:47 arg1 the chemokine Ser-CCL1 the chemokine Ser-CCL1 PUBTATOR AminoAcid CCL1 6346 (Quasi-)racemic X-ray structures of glycosylated and non-glycosylated forms of the chemokine Ser-CCL1 prepared by total chemical synthesis. 27617431 1 47 gly N-glycans 265:273 arg1 the trimeric envelope glycoprotein envelope glycoprotein N-glycans PUBTATOR envelope glycoprotein 100616444 HIV-1 vaccine design is informed by structural studies elucidating mechanisms by which broadly neutralizing antibodies (bNAbs) recognize and/or accommodate N-glycans on the trimeric envelope glycoprotein (Env). 27617431 1 47 gly N-glycans 265:273 arg1 Env Env N-glycans PUBTATOR Env 100616444 HIV-1 vaccine design is informed by structural studies elucidating mechanisms by which broadly neutralizing antibodies (bNAbs) recognize and/or accommodate N-glycans on the trimeric envelope glycoprotein (Env). 27617431 1 53 gly glycoprotein 300:311 arg1 the trimeric envelope glycoprotein the trimeric envelope glycoprotein PUBTATOR envelope glycoprotein 100616444 HIV-1 vaccine design is informed by structural studies elucidating mechanisms by which broadly neutralizing antibodies (bNAbs) recognize and/or accommodate N-glycans on the trimeric envelope glycoprotein (Env). 27617431 1 53 gly glycoprotein 300:311 arg1 Env Env PUBTATOR Env 100616444 HIV-1 vaccine design is informed by structural studies elucidating mechanisms by which broadly neutralizing antibodies (bNAbs) recognize and/or accommodate N-glycans on the trimeric envelope glycoprotein (Env). 24910992 0 18 gly non-glycosylated 61:76 arg1 non-glycosylated sonic hedgehog non-glycosylated sonic hedgehog PUBTATOR sonic hedgehog 6469 EDEM2 and OS-9 are required for ER-associated degradation of non-glycosylated sonic hedgehog. 28039139 9 67 gly N-glycosylation 1707:1721 arg1 S-layer glycoprotein folding S-layer glycoprotein folding Cterm S-layer Perturbed N-glycosylation thus affects S-layer glycoprotein folding. 24726881 9 54 gly present 1156:1162 arg2 melanoma cell adhesion molecule AND beta1-6 branched N-glycans melanoma cell adhesion molecule beta1-6 branched N-glycans OGER melanoma cell adhesion molecule P43121 Increased amounts of "bisected" and beta1-6 branched N-glycans were present on melanoma cell adhesion molecule (known as MCAM/MUC18). 24799124 0 43 gly ceruloplasmin 49:61 arg1 Mass-selected site-specific core-fucosylation ceruloplasmin Mass-selected site-specific core-fucosylation PUBTATOR ceruloplasmin 1356 Mass-selected site-specific core-fucosylation of ceruloplasmin in alcohol-related hepatocellular carcinoma. 24799124 0 50 gly core-fucosylation 28:44 arg1 ceruloplasmin ceruloplasmin PUBTATOR ceruloplasmin 1356 Mass-selected site-specific core-fucosylation of ceruloplasmin in alcohol-related hepatocellular carcinoma. 24780636 1 1 gly possesses 127:135 arg1 Transferrin AND N-glycans Transferrin N-glycans PUBTATOR Transferrin 7018 Transferrin is an iron-transport protein which possesses N-glycans at Asn432 and Asn630 in humans. 27798070 4 14 gly Gal 799:801 arg1 Gal Gal Gal OGER Gal P47212 Here, we describe an evaluation of blood-borne sialyl-, galactosyl- and fucosyltransferase activities that act upon the four common terminal glycan precursor motifs, GlcNAc monomer, Gal(β3)GlcNAc, Gal(β4)GlcNAc and Gal(β3)GalNAc, to produce more complex glycan structures. 27798070 4 17 gly Gal 781:783 arg1 Gal Gal Gal OGER Gal P47212 Here, we describe an evaluation of blood-borne sialyl-, galactosyl- and fucosyltransferase activities that act upon the four common terminal glycan precursor motifs, GlcNAc monomer, Gal(β3)GlcNAc, Gal(β4)GlcNAc and Gal(β3)GalNAc, to produce more complex glycan structures. 25071157 0 61 gly glycoforms 27:36 arg1 IgA1 IgA1 PUBTATOR IgA1 P01876 Identification of distinct glycoforms of IgA1 in plasma from patients with immunoglobulin A (IgA) nephropathy and healthy individuals. 27550041 6 63 gly lactoferrin 1282:1292 arg1 the N-glycans lactoferrin the N-glycans PUBTATOR lactoferrin 280846 A comparison of the monosaccharide composition of the N-glycans of donkey milk lactoferrin with respect to that of human, bovine and goat milk lactoferrin is reported. 26956484 6 49 gly glycosylation 879:891 arg1 Orai1N223A Orai1N223A PUBTATOR Orai1N223A 84876 Ca(2+) imaging experiments and patch-clamp experiments revealed that mutation of the only glycosylation site of Orai1 (Orai1N223A) enhanced SOCE in Jurkat T cells. 26956484 6 49 gly glycosylation 879:891 arg1 Orai1 Orai1 PUBTATOR Orai1 84876 Ca(2+) imaging experiments and patch-clamp experiments revealed that mutation of the only glycosylation site of Orai1 (Orai1N223A) enhanced SOCE in Jurkat T cells. 26956484 5 37 gly glycosylation 743:755 arg1 Orai1 Orai1 PUBTATOR Orai1 84876 Using Western blot analysis and lectin-binding assays from various primary human cells and cancer cell lines, we found that glycosylation of Orai1 is cell type-specific. 25095792 0 56 gly glycosylation 9:21 arg1 cytochrome c cytochrome c PUBTATOR cytochrome c 54205 Chemical glycosylation of cytochrome c improves physical and chemical protein stability. 24233973 1 55 gly glycoprotein 176:187 arg1 P-selectin glycoprotein ligand-1/mouse IgG2b P-selectin glycoprotein ligand-1/mouse IgG2b PUBTATOR P-selectin glycoprotein ligand-1 6404 The interaction between P-selectin glycoprotein ligand-1/mouse IgG2b (PSGL-1/mIgG(2b)) fusion protein carrying multiple copies of the influenza hemagglutinin receptor Siaα2-3Gal on different O-glycan chains and recombinant human influenza H5N1 A/Vietnam/1203/04 hemagglutinin was investigated with a Biacore biosensor. 27994047 8 41 gly contain 1165:1171 arg1 Decorin AND either chondroitin or dermatan sulfate glycosaminoglycan (GAG) chains Decorin either chondroitin or dermatan sulfate glycosaminoglycan (GAG) chains OGER Decorin P07585 Decorin and biglycan contain either chondroitin or dermatan sulfate glycosaminoglycan (GAG) chains whereas fibromodulin only contains keratan sulfate and the large (>2500 kDa), highly glycosylated aggrecan contains both keratan and chondroitin sulfate. 25275130 1 22 gly glycosylated 115:126 arg1 Env Env PUBTATOR Env 64006 UNLABELLED The HIV-1 envelope protein (Env) is heavily glycosylated, with approximately 50% of the Env molecular mass being contributed by N-glycans. 25275130 1 22 gly glycosylated 115:126 arg1 The HIV-1 envelope protein The HIV-1 envelope protein PUBTATOR HIV-1 envelope protein 64006 UNLABELLED The HIV-1 envelope protein (Env) is heavily glycosylated, with approximately 50% of the Env molecular mass being contributed by N-glycans. 24028868 7 57 gly glycoforms 1048:1057 arg1 the IgG glycoforms the IgG glycoforms Cterm IgG Univariate and multivariate statistics were employed to investigate the correlations between the patients groups and the abundances of the IgG glycoforms as well as those of inflammatory mediating proteins. 26492619 4 60 part_of PLAG1 587:591 arg1 Thr34 PLAG1 Thr34 PUBTATOR AminoAcid PLAG1 5324 Thr34 In contrast, the glycosylation of Thr34 of PLAG1 of human PDPN remains to be clarified. 26059044 10 9 gly glycoproteins 1597:1609 arg1 IL-22 IL-22 PUBTATOR IL-22 50929 Altogether, our data demonstrate that plants offer an excellent tool to investigate the role of N-glycosylation on folding and activity of recombinant glycoproteins, such as IL-22.